Blueprint

0001654954-19-001367.txt : 20190212 0001654954-19-001367.hdr.sgml : 20190212 20190212161622 ACCESSION NUMBER: 0001654954-19-001367 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20181231 FILED AS OF DATE: 20190212 DATE AS OF CHANGE: 20190212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KNOW LABS, INC. CENTRAL INDEX KEY: 0001074828 STANDARD INDUSTRIAL CLASSIFICATION: MEASURING & CONTROLLING DEVICES, NEC [3829] IRS NUMBER: 900273142 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-30262 FILM NUMBER: 19590998 BUSINESS ADDRESS: STREET 1: 500 UNION STREET STREET 2: SUITE 810 CITY: SEATTLE STATE: WA ZIP: 98101 BUSINESS PHONE: 206-903-1351 MAIL ADDRESS: STREET 1: 500 UNION STREET STREET 2: SUITE 810 CITY: SEATTLE STATE: WA ZIP: 98101 FORMER COMPANY: FORMER CONFORMED NAME: VISUALANT INC DATE OF NAME CHANGE: 20070220 FORMER COMPANY: FORMER CONFORMED NAME: Visualant, INC DATE OF NAME CHANGE: 20050106 FORMER COMPANY: FORMER CONFORMED NAME: STARBERRYS CORP DATE OF NAME CHANGE: 20020918 10-Q 1 knwn_10q-17597.htm KNOW LABS, INC. 10-Q Blueprint

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2018

☐ TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT

For the transition period from _______ to ________

Commission File number 000-30262

KNOW LABS, INC.

(Exact name of registrant as specified in charter)

Nevada	90-0273142
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)


500 Union Street, Suite 810, Seattle, Washington USA	98101
(Address of principal executive offices)	(Zip Code)

	206-903-1351
	(Registrant's telephone number, including area code)



	(Former name, address, and fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer (Do not check if a smaller reporting company)	☐	Smaller reporting company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of common stock, $.001 par value, issued and outstanding as of February 12, 2019: 18,107,319 shares.

TABLE OF CONTENTS
		Page Number

PART I	FINANCIAL INFORMATION	3

ITEM 1	Financial Statements (unaudited except as noted)	3

	Consolidated Balance Sheets as of December 31, 2018 and September 30, 2018 (audited)	3

	Consolidated Statements of Operations for the three months ended December 31, 2018 and 2017	4

	Consolidated Statements of Cash Flows for the three months ended December 31, 2018 and 2017	5

	Notes to the Financial Statements	6

ITEM 2	Management's Discussion and Analysis of Financial Condition and Results of Operation	20

ITEM 3	Quantitative and Qualitative Disclosures About Market Risk	28

ITEM 4	Controls and Procedures	28

PART II	OTHER INFORMATION	29

ITEM 1A.	Risk Factors	29

ITEM 2	Unregistered Sales of Equity Securities and Use of Proceeds	39

ITEM 3	Defaults upon Senior Securities	39

ITEM 4	Mine Safety Disclosures	39

ITEM 5	Other Information	39

ITEM 6	Exhibits	39

	SIGNATURES	43

ITEM 1.

FINANCIAL STATEMENTS

KNOW LABS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	December 31, 2018	September 30, 2018
ASSETS

CURRENT ASSETS:
Cash and cash equivalents	$310,779	$934,407
Accounts receivable, net of allowance of $60,000 and $60,000, respectively	206,084	320,538
Prepaid expenses	14,691	20,140
Inventories, net	159,223	203,582
Total current assets	690,777	1,478,667

EQUIPMENT, NET	153,690	169,333

OTHER ASSETS
Intangible assets	404,445	447,778
Other assets	7,170	7,170

TOTAL ASSETS	$1,256,082	$2,102,948

LIABILITIES AND STOCKHOLDERS' (DEFICIT)

CURRENT LIABILITIES:
Accounts payable - trade	$1,412,018	$1,512,617
Accounts payable - related parties	-	12,019
Accrued expenses	71,036	72,140
Accrued expenses - related parties	676,681	657,551
Deferred revenue	-	55,959
Convertible notes payable	2,255,066	2,255,066
Notes payable - current portion of long term debt	46,576	145,186
Total current liabilities	4,461,377	4,710,538

COMMITMENTS AND CONTINGENCIES	-	-

STOCKHOLDERS' DEFICIT
Preferred stock - $0.001 par value, 5,000,000 shares authorized, 0 shares issued and
outstanding at 12/31/2018 and 9/30/2018, respectively	-	-
Series A Convertible Preferred stock - $0.001 par value, 23,334 shares authorized, 20,000
issued and outstanding at 12/31/2018 and 9/30/2018, respectively	11	11
Series C Convertible Preferred stock - $0.001 par value, 1,785,715 shares authorized,
1,785,715 shares issued and outstanding at 12/31/2018 and 9/30/2018, respectively	1,790	1,790
Series D Convertible Preferred stock - $0.001 par value, 1,016,014 shares authorized,
1,016,004 shares issued and outstanding at 12/31/2018 and 9/30/2018, respectively	1,015	1,015
Common stock - $0.001 par value, 100,000,000 shares authorized, 17,811,431 and 17,531,502 shares
issued and outstanding at 12/31/2018 and 9/30/2018, respectively	17,811	17,532
Additional paid in capital	32,334,605	32,163,386
Accumulated deficit	(35,560,527)	(34,791,324)
Total stockholders' deficit	(3,205,295)	(2,607,590)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$1,256,082	$2,102,948

The accompanying notes are an integral part of these consolidated financial statements.

KNOW LABS, INC. AND SUBSIDIARIES

STATEMENTS OF OPERATIONS

	Three Months Ended,
	December 31, 2018	December 31, 2017

REVENUE	$602,209	$1,232,857
COST OF SALES	472,286	985,023
GROSS PROFIT	129,923	247,834
RESEARCH AND DEVELOPMENT EXPENSES	206,990	87,720
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	689,446	414,365
OPERATING LOSS	(766,513)	(254,251)

OTHER INCOME (EXPENSE):
Interest expense	(9,126)	(293,202)
Other income	6,436	19,188
Total other income (expense)	(2,690)	(274,014)

(LOSS) BEFORE INCOME TAXES	(769,203)	(528,265)

Income taxes - current provision	-	-

NET (LOSS)	$(769,203)	$(528,265)

Basic and diluted loss per common share attributable to Know Labs,
Inc. and subsidiaries common shareholders-
Basic and diluted loss per share	$(0.04)	$(0.11)

Weighted average shares of common stock outstanding- basic and diluted	17,571,057	4,655,486

The accompanying notes are an integral part of these consolidated financial statements.

KNOW LABS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Three Months Ended,
	December 31, 2018	December 31, 2017

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$(769,203)	$(528,265)
Adjustments to reconcile net loss to net cash (used in)
operating activities
Depreciation and amortization	61,824	13,898
Stock based compensation- stock option grans	171,499	5,187
(Loss) on sale of assets	-	(1,710)
Amortization of debt discount	-	216,774
Provision on loss on accounts receivable	1,371	-
Changes in operating assets and liabilities:
Accounts receivable	113,083	(40,117)
Prepaid expenses	5,449	(9,499)
Inventory	44,359	64,597
Other assets	-	(2,100)
Accounts payable - trade and accrued expenses	(94,593)	(90,162)
Deferred revenue	(55,959)	-
NET CASH (USED IN) OPERATING ACTIVITIES	(522,170)	(371,397)

CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in equipment	(2,848)	-
Proceeds from sale of equipment	-	1,710
NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES:	(2,848)	1,710

CASH FLOWS FROM FINANCING ACTIVITIES:
(Repayments) proceeds from line of credit	(98,610)	58,764
Proceeds from convertible notes payable	-	300,000
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(98,610)	358,764

NET (DECREASE) IN CASH AND CASH EQUIVALENTS	(623,628)	(10,923)

CASH AND CASH EQUIVALENTS, beginning of period	934,407	103,181

CASH AND CASH EQUIVALENTS, end of period	$310,779	$92,258

Supplemental disclosures of cash flow information:
Interest paid	$9,126	$11,723
Taxes paid	$-	$-

Non-cash investing and financing activities:
Beneficial conversion feature	$-	$216,774

The accompanying notes are an integral part of these consolidated financial statements.

KNOW LABS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

The accompanying unaudited consolidated condensed financial statements have been prepared by Know Labs, Inc, formerly Visualant, Incorporated (“the Company”, “us,” “we,” or “our”) in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting and rules and regulations of the Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. In the opinion of our management, all adjustments, consisting of only normal recurring accruals, necessary for a fair presentation of the financial position, results of operations, and cash flows for the fiscal periods presented have been included.

These financial statements should be read in conjunction with the audited financial statements and related notes included in our Annual Report filed on Form 10-K for the year ended September 30, 2018, filed with the Securities and Exchange Commission (“SEC”) on December 21, 2018. The results of operations for the three months ended December 31, 2018 are not necessarily indicative of the results expected for the full fiscal year, or for any other fiscal period.

1.	ORGANIZATION

Know Labs, Inc. (the “Company”) was incorporated under the laws of the State of Nevada in 1998. The Company has authorized 105,000,000 shares of capital stock, of which 100,000,000 are shares of voting common stock, par value $0.001 per share, and 5,000,000 are shares preferred stock, par value $0.001 per share.

The Company is focused on the development, marketing and sales of a proprietary technologies which are capable of uniquely authenticating or diagnosing almost any substance or material using electromagnetic energy to create, record and detect the unique “signature” of the substance. The Company’s call these our “ChromaID™” and “Bio-RFID™” technologies.

Overview

Historically, the Company focused on the development of our proprietary ChromaID technology. Using light from low-cost LEDs (light emitting diodes) the Company’s map the color of substances, fluids and materials and with our proprietary processes we can authenticate, identify and diagnose based upon the color that is present. The color is both visible to us as humans but also outside of the humanly visible color spectrum in the near infra-red and near ultra-violet and beyond. The Company’s ChromaID scanner sees what we like to call “Nature’s Color Fingerprint.” Everything in nature has a unique color identifier and with ChromaID the Company can see it, and identify, authenticate and diagnose based upon the color that is present. The Company’s ChromaID scanner is capable of uniquely identifying and authenticating almost any substance or liquid using light to create, record and detect its unique color signature. The Company will continue to develop and enhance its ChromaID technology and extend its capacity. More recently, the Company has focused upon extensions and new inventions that are derived from and extend beyond our ChromaID technology. The Company’s call this technology Bio-RFID. The rapid advances made with our Bio-RFID technology in our laboratory have caused us to move quickly in to the commercialization phase of our Company as we work to create revenue generating products for the marketplace. The Company will also, as resources permit, pursue licensing opportunities with third parties who have ready applications for our technologies.

In 2010, the Company acquired TransTech Systems, Inc. as an adjunct to its business. TransTech is a distributor of products for employee and personnel identification. TransTech currently provides substantially all of the Company’s revenues.

The Company is in the process of commercializing its technology. To date, the Company has entered into License Agreements with Sumitomo Precision Products Co., Ltd. In addition, it has a technology license agreement with Allied Inventors, formerly Xinova and Invention Development Management Company, a subsidiary of Intellectual Ventures.

The Company believes that its commercialization success is dependent upon its ability to significantly increase the number of customers that are purchasing and using its products. To date the Company has generated minimal revenue from sales of its ChromaID and Bio-RFID products. The Company is currently not profitable. Even if the Company succeeds in introducing the ChromaID and Bio-RFID technology and related products to its target markets, the Company may not be able to generate sufficient revenue to achieve or sustain profitability.

ChromaID was invented by scientists under contract with the Company. Bio-RFID was invented by individuals working for the Company. The Company actively pursues a robust intellectual property strategy and has been granted twelve patents. The Company also has 20 patents pending. The Company possesses all right, title and interest to the issued patents. Ten of the pending patents are licensed exclusively to the Company in perpetuity by the Company’s strategic partner, Allied Inventors.

Merger with RAAI Lighting, Inc.

On April 10, 2018, the Company entered into an Agreement and Plan of Merger with 500 Union Corporation, a Delaware corporation and a wholly owned subsidiary of the Company, and RAAI Lighting, Inc., a Delaware corporation. Pursuant to the Merger Agreement, we have acquired all the outstanding shares of RAAI’s capital stock through a merger of Merger Sub with and into RAAI (the “Merger”), with RAAI surviving the Merger as a wholly owned subsidiary of the Company.

Under the terms of the Merger Agreement, each share of RAAI common stock issued and outstanding immediately before the Merger (1,000 shares) were cancelled and we issued 2,000,000 shares of our common stock. As a result, we issued 2,000,000 shares of its common stock to Phillip A. Bosua, formerly the sole stockholder of RAAI. The consideration for the Merger was determined through arms-length bargaining by the Company and RAAI. The Merger was structured to qualify as a tax-free reorganization for U.S. federal income tax purposes. As a result of the Merger, the Company received certain intellectual property, related to RAAI.

Appointment of Director

On April 10, 2018, the Board increased the size of the Board from three to four members and Phillip A. Bosua was appointed as a member of the Board. Mr. Bosua’s term of office expires at the next annual meeting of our stockholders. On May 24, 2018, the Board of Directors increased the size of the Board from four to five members and appointed (Ret.) Admiral William Owens as a member of the Board. Admiral Owen’s term of office expires at the next annual meeting of our stockholders.

Appointment of Officer

On April 10, 2018, the Company appointed Mr. Bosua as Chief Executive Officer of the Company, replacing Ronald P. Erickson, who remains Chairman of the Company. Previously, Mr. Bosua served as the Company’s Chief Product Officer since August 2017. The Company entered into a Consulting Agreement with Mr. Bosua’s company, Blaze Clinical on July 7, 2017.

On April 10, 2018, the Company entered into an Employment Agreement with Mr. Bosua reflecting Mr. Bosua’s appointment as Chief Executive Officer. The Employment Agreement is for an initial term of 12 months (subject to earlier termination) and will be automatically extended for additional 12-month terms unless either party notifies the other party of its intention to terminate the Employment Agreement. Mr. Bosua will be paid a base salary of $225,000 per year, received 500,000 shares of common stock valued at $0.33 per share and may be entitled to bonuses and equity awards at the discretion of the Board or a committee of the Board. The Employment Agreement provides for severance pay equal to 12 months of base salary if Mr. Bosua is terminated without “cause” or voluntarily terminates his employment for “good reason.”

On April 10, 2018, the Company entered into an Amended Employment Agreement for Ronald P. Erickson which amends the Employment Agreement dated July 1, 2017. The Agreement expires March 21, 2019.

Merger with Know Labs, Inc.

On May 1, 2018, Know Labs, Inc., a Nevada corporation incorporated on April 3, 2018, and our wholly-owned subsidiary, merged with and into the Company pursuant to an Agreement and Plan of Merger dated May 1, 2018. In connection with the merger, our Articles of Incorporation were effectively amended to change our name to Know Labs, Inc. by and through the filing of Articles of Merger. This parent-subsidiary merger was approved by us, the parent, in accordance with Nevada Revised Statutes Section 92A.180. Stockholder approval was not required. This amendment was filed with the Nevada Secretary of State and became effective on May 1, 2018.

Corporate Name Change and Symbol Change

On May 24, 2018, the Financial Industry Regulatory Authority (“FINRA”) announced the effectiveness of a change in our name from Visualant Incorporated to Know Labs, Inc. and a change in our ticker symbol from VSUL to the new trading symbol KNWN which became effective on the opening of trading as of May 25, 2018. In addition, in connection with the name change and symbol change, we were assigned the CUSIP number of 499238103.

Closing of Financing on June 25, 2018

On June 25, 2018, the Company closed a private placement and received gross proceeds of $1,750,000 in exchange for issuing 7,000,000 shares of common stock and warrants to purchase 3,500,000 shares of common stock in a private placement to accredited investors pursuant to a series of substantially identical subscription agreements.

The initial exercise price of the warrants described above is $0.25 per share, subject to certain adjustments, and the warrants expire five years after their issuance.

The shares and the warrants described above were issued in transactions that were not registered under the Securities Act of 1933, as amended (the “Act”) in reliance upon applicable exemptions from registration under Section 4(a)(2) of the Act and/or Rule 506 of SEC Regulation D under the Act.

2.	GOING CONCERN

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company incurred net losses of $769,203, $3,257,597 and $3,901,232 for the three months ended December 31, 2018 and the years ended September 30, 2018 and 2017, respectively. Net cash used in operating activities was $522,170, $1,117,131 and $1,264,324 for the three months ended December 31, 2018 and for the years ended September 30, 2018 and 2017, respectively.

The Company anticipates that it will record losses from operations for the foreseeable future. As of December 31, 2018, the Company’s accumulated deficit was $35,560,527. The Company has limited capital resources, and operations to date have been funded with the proceeds from private equity and debt financings and loans from Ronald P. Erickson, the Company’s Chief Executive Officer, or entities with which he is affiliated. These conditions raise substantial doubt about our ability to continue as a going concern. The audit report prepared by the Company’s independent registered public accounting firm relating to our financial statements for the year ended September 30, 2018 includes an explanatory paragraph expressing the substantial doubt about the Company’s ability to continue as a going concern.

The Company believe that its cash on hand will be sufficient to fund our operations until February 28, 2019. We need additional financing to implement our business plan and to service our ongoing operations and pay our current debts. There can be no assurance that we will be able to secure any needed funding, or that if such funding is available, the terms or conditions would be acceptable to us. If we are unable to obtain additional financing when it is needed, we will need to restructure our operations, and divest all or a portion of our business. We may seek additional capital through a combination of private and public equity offerings, debt financings and strategic collaborations. Debt financing, if obtained, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, and could increase our expenses and require that our assets secure such debt. Equity financing, if obtained, could result in dilution to the Company’s then-existing stockholders and/or require such stockholders to waive certain rights and preferences. If such financing is not available on satisfactory terms, or is not available at all, the Company may be required to delay, scale back, eliminate the development of business opportunities or file for bankruptcy and our operations and financial condition may be materially adversely affected.

3.	SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS

Basis of Presentation – The accompanying unaudited consolidated financial statements include the accounts of the Company. Intercompany accounts and transactions have been eliminated. The preparation of these unaudited condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (“GAAP”).

Principles of Consolidation – The consolidated financial statements include the accounts of the Company and its wholly owned and majority-owned subsidiaries, TransTech Systems, Inc and RAAI Lighting, Inc. Inter-Company items and transactions have been eliminated in consolidation.

Cash and Cash Equivalents – The Company classifies highly liquid temporary investments with an original maturity of three months or less when purchased as cash equivalents. The Company maintains cash balances at various financial institutions. Balances at US banks are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant risk for cash on deposit.

Accounts Receivable and Allowance for Doubtful Accounts – Accounts receivable consist primarily of amounts due to the Company from normal business activities. The Company maintains an allowance for doubtful accounts to reflect the expected non-collection of accounts receivable based on past collection history and specific risks identified within the portfolio. If the financial condition of the customers were to deteriorate resulting in an impairment of their ability to make payments, or if payments from customers are significantly delayed, additional allowances might be required.

Inventories – Inventories consist primarily of printers and consumable supplies, including ribbons and cards, badge accessories, capture devices, and access control components held for resale and are stated at the lower of cost or market on the first-in, first-out (“FIFO”) method. Inventories are considered available for resale when drop shipped and invoiced directly to a customer from a vendor, or when physically received by TransTech at a warehouse location. The Company records a provision for excess and obsolete inventory whenever an impairment has been identified. There is a $35,000 reserve for impaired inventory as of December 31, 2018 and September 30, 2018, respectively.

Equipment – Equipment consists of machinery, leasehold improvements, furniture and fixtures and software, which are stated at cost less accumulated depreciation and amortization. Depreciation is computed by the straight-line method over the estimated useful lives or lease period of the relevant asset, generally 2-10 years, except for leasehold improvements which are depreciated over 2-3 years.

Long-Lived Assets – The Company reviews its long-lived assets for impairment annually or when changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Long-lived assets under certain circumstances are reported at the lower of carrying amount or fair value. Assets to be disposed of and assets not expected to provide any future service potential to the Company are recorded at the lower of carrying amount or fair value (less the projected cost associated with selling the asset). To the extent carrying values exceed fair values, an impairment loss is recognized in operating results.

Intangible Assets – Intangible assets are capitalized and amortized on a straight-line basis over their estimated useful life, if the life is determinable. If the life is not determinable, amortization is not recorded. We regularly perform reviews to determine if facts and circumstances exist which indicate that the useful lives of our intangible assets are shorter than originally estimated or the carrying amount of these assets may not be recoverable. When an indication exists that the carrying amount of intangible assets may not be recoverable, we assess the recoverability of our assets by comparing the projected undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. Such impairment test is based on the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. Impairment, if any, is based on the excess of the carrying amount over the estimated fair value of those assets.

Research, Development and Engineering Expenses – Research, development and engineering expenses consist of the cost of employees, consultants and contractors who design, engineer and develop new products and processes as well as materials, supplies and facilities used in producing prototypes.

The Company’s research and development efforts are primarily focused improving the core foundational ChromaID technology and developing new and unique applications for the technology. As part of this effort, the Company typically conduct testing to ensure that ChromaID application methods are compatible with the customer’s requirements, and that they can be implemented in a cost effective manner. The Company is also actively involved in identifying new application methods. Know Lab’s team has considerable experience working with the application of light-based technologies and their application to various industries. The Company believes that its continued development of new and enhanced technologies relating to our core business is essential to its future success. The Company spent $206,990, $570,514 and $79,405 during the three months ended December 31, 2018 and the years ended September 30, 2018 and 2017, respectively, on research and development activities.

Fair Value Measurements and Financial Instruments – ASC Topic 820, Fair Value Measurement and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy, which requires classification based on observable and unobservable inputs when measuring fair value. The fair value hierarchy distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs). The hierarchy consists of three levels:

Level 1 – Quoted prices in active markets for identical assets and liabilities;

Level 2 – Inputs other than level one inputs that are either directly or indirectly observable; and.

Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The recorded value of other financial assets and liabilities, which consist primarily of cash and cash equivalents, accounts receivable, other current assets, and accounts payable and accrued expenses approximate the fair value of the respective assets and liabilities as of December 31, 2018 and September 30, 2018 are based upon the short-term nature of the assets and liabilities.

Derivative Financial Instruments -The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.

Revenue Recognition – Know Lab and TransTech revenue are derived from products and services. Revenue is considered realized when the products or services have been provided to the customer, the work has been accepted by the customer and collectability is reasonably assured. Furthermore, if an actual measurement of revenue cannot be determined, the Company defers all revenue recognition until such time that an actual measurement can be determined. If during the course of a contract management determines that losses are expected to be incurred, such costs are charged to operations in the period such losses are determined. Revenues are deferred when cash has been received from the customer but the revenue has not been earned.

Stock Based Compensation – The Company has share-based compensation plans under which employees, consultants, suppliers and directors may be granted restricted stock, as well as options to purchase shares of Company common stock at the fair market value at the time of grant. Stock-based compensation cost is measured by the Company at the grant date, based on the fair value of the award, over the requisite service period. For options issued to employees, the Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit. Grants of stock options and stock to non-employees and other parties are accounted for in accordance with the ASC 505.

Convertible Securities – Based upon ASC 815-15, we have adopted a sequencing approach regarding the application of ASC 815-40 to convertible securities. We will evaluate our contracts based upon the earliest issuance date. In the event partial reclassification of contracts subject to ASC 815-40-25 is necessary, due to our inability to demonstrate we have sufficient shares authorized and unissued, shares will be allocated on the basis of issuance date, with the earliest issuance date receiving first allocation of shares. If a reclassification of an instrument were required, it would result in the instrument issued latest being reclassified first.

Net Loss per Share – Under the provisions of ASC 260, “Earnings Per Share,” basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of the Company, subject to anti-dilution limitations. As of December 31, 2018, there were options outstanding for the purchase of 2,282,668 common shares, warrants for the purchase of 15,173,398 common shares, and 4,914,071 shares of the Company’s common stock issuable upon the conversion of Series A, Series C and Series D Convertible Preferred Stock. In addition, the Company has an unknown number of shares (9,020,264 common shares at the current price of $0.25 per share) are issuable upon conversion of convertible debentures of $2,255,066. All of which could potentially dilute future earnings per share.

As of December 31, 2017, there were options outstanding for the purchase of 15,404 common shares, warrants for the purchase of 7,767,416 common shares, 2,825,053 shares of the Company’s common stock issuable upon the conversion of Series A, Series C and Series D Convertible Preferred Stock and up to 332,940 shares of the Company’s common stock issuable upon the exercise of placement agent warrants. In addition, the Company has an unknown number of shares issuable upon conversion of convertible debentures of $870,000. All of which could potentially dilute future earnings per share.

Dividend Policy – The Company has never paid any cash dividends and intends, for the foreseeable future, to retain any future earnings for the development of our business. Our future dividend policy will be determined by the board of directors on the basis of various factors, including our results of operations, financial condition, capital requirements and investment opportunities.

Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, management has not determined whether implementation of such proposed standards would be material to the Company’s consolidated financial statements.

4. ACCOUNTS RECEIVABLE/CUSTOMER CONCENTRATION

Accounts receivable were $206,084 and $320,538, net of allowance, as of December 31, 2018 and September 30, 2018, respectively. The Company had one customer in excess of 10% (12.6% and 11.3%) of the Company’s consolidated revenues for the three months ended December 31, 2018. The Company had three customers in excess of 10% (21.2%, 16.1%, and 10.7%) with accounts receivable in excess of 10% as of December 31, 2018. The Company has a total allowance for bad debt in the amount of $60,000 as of December 31, 2018.

5. INVENTORIES

Inventories were and $159,223 and $203,582 as of December 31, 2018 and September 30, 2018, respectively. Inventories consist primarily of printers and consumable supplies, including ribbons and cards, badge accessories, capture devices, and access control components held for resale. There was a $35,000 reserve for impaired inventory as of September 30, 2018 and 2017, respectively.

6. FIXED ASSETS

Fixed assets, net of accumulated depreciation, was $153,690 and $169,333 as of December 31, 2018 and September 30, 2018, respectively. Accumulated depreciation was $689,157 and $670,666 as of December 31, 2018 and September 30, 2018, respectively. Total depreciation expense was $18,491 and $13,828 for the three months ended December 31, 2018 and 2017, respectively. All equipment is used for selling, general and administrative purposes and accordingly all depreciation is classified in selling, general and administrative expenses.

Property and equipment as of December 31, 2018 was comprised of the following:

	Estimated	December 31, 2018
	Useful Lives	Purchased	Capital Leases	Total
Machinery and equipment	2-10 years	$335,154	$42,681	$377,835
Leasehold improvements	2-3 years	276,112	-	276,112
Furniture and fixtures	2-3 years	58,050	95,020	153,070
Software and websites	3- 7 years	35,830	-	35,830
Less: accumulated depreciation		(551,456)	(137,701)	(689,157)
		$153,690	$-	$153,690

7. INTANGIBLE ASSETS

Intangible assets as of December 31, 2018 and September 30, 2018 consisted of the following:

	Estimated	December 31,	September 30,
	Useful Lives	2018	2018

Technology	3 years	$520,000	$520,000
Less: accumulated amortization		(115,555)	(72,222)
Intangible assets, net		$404,445	$447,778

Total amortization expense was $43,332 and $72,222 for the three months ended December 31, 2018 and the year ended December 31, 2018, respectively.

Merger with RAAI Lighting, Inc.

Under the terms of the Merger Agreement, each share of RAAI common stock issued and outstanding immediately before the Merger (1,000 shares) were cancelled and converted into the right to receive 2,000 shares of the Company’s common stock. As a result, the Company issued 2,000,000 shares of its common stock to Phillip A. Bosua, formerly the sole stockholder of RAAI. The consideration for the Merger was determined through arms-length bargaining by the Company and RAAI. The Merger was structured to qualify as a tax-free reorganization for U.S. federal income tax purposes. As a result of the Merger, the Company received certain intellectual property, related to RAAI.

Merger with Know Labs, Inc.

RAAI had no outstanding indebtedness or assets at the closing of the Merger. The 2,000,000 shares of the Company’s common stock issued for RAAI’s shares were recorded at the fair value at the date of the merger at $520,000 and the value assigned to the patent acquired with RAAI.

The fair value of the intellectual property associated with the assets acquired was $520,000 estimated by using a discounted cash flow approach based on future economic benefits. In summary, the estimate was based on a projected income approach and related discounted cash flows over five years, with applicable risk factors assigned to assumptions in the forecasted results.

8. ACCOUNTS PAYABLE

Accounts payable were $1,412,018 and $1,517,617 as of December 31, 2918 and September 30, 2018, respectively. Such liabilities consisted of amounts due to vendors for inventory purchases and technology development, external audit, legal and other expenses incurred by the Company. The Company had one vendor (19.8%) with accounts payable in excess of 10% of its accounts payable as of December 31, 2018. The Company does expect to have vendors with accounts payable balances of 10% of total accounts payable in the foreseeable future.

9. DERIVATIVE INSTRUMENTS

In April 2008, the FASB issued a pronouncement that provides guidance on determining what types of instruments or embedded features in an instrument held by a reporting entity can be considered indexed to its own stock for the purpose of evaluating the first criteria of the scope exception in the pronouncement on accounting for derivatives. This pronouncement was effective for financial statements issued for fiscal years beginning after December 15, 2008. The adoption of these requirements can affect the accounting for warrants and many convertible instruments with provisions that protect holders from a decline in the stock price (or “down-round” provisions). For example, warrants or conversion features with such provisions are no longer recorded in equity. Down-round provisions reduce the exercise price of a warrant or convertible instrument if a company either issues equity shares for a price that is lower than the exercise price of those instruments or issues new warrants or convertible instruments that have a lower exercise price.

There was no derivative liability as of December 31, 2018 and September 30, 2018. For the year ended September 30, 2017, the Company recorded non-cash loss of $217,828 related to the “change in fair value of derivative” expense related to its derivative instruments. The Company early adopted ASU 2017-11 and has reclassified its financial instrument with down round features to equity in the amount of $410,524.

10. CONVERTIBLE NOTES PAYABLE

Convertible notes payable as of December 31, 2018 and September 30, 2018 consisted of the following:

Convertible Promissory Note dated September 30, 2016

On September 30, 2016, the Company entered into a $210,000 Convertible Promissory Note with Clayton A. Struve, an accredited investor of the Company, to fund short-term working capital. The Convertible Promissory Note accrued interest at a rate of 10% per annum and was due on March 30, 2017. The Note holder can convert the Note into common stock at $0.70 per share. During the year ended September 30, 2017, the Company recorded interest of $21,000 related to the convertible note. This note was extended in the Securities Purchase Agreement, General Security Agreement and Subordination Agreement dated August 14, 2017 with a maturity date of August 13, 2018. Also, the conversion price of the Debenture was adjusted to $0.25 per share, subject to certain adjustments. The balance was increased $75,000 during the year ended September 30, 2018. On November 16, 2018, we signed Amendment 1 to Senior Secured Convertible Redeemable Notes dated September 30, 2016 extending the due dates of the Note to February 27, 2019. On September 24, 2018, Mr. Struve converted $200,000 of the Note into 800,000 shares of our common stock. The Company recorded accrued interest of $63,493 as of December 31, 2018.

Securities Purchase Agreement dated August 14, 2017

On August 14, 2017, the Company issued a senior convertible exchangeable debenture with a principal amount of $360,000 and a common stock purchase warrant to purchase 1,440,000 shares of common stock in a private placement to Clayton Struve for gross proceeds of $300,000 pursuant to a Securities Purchase Agreement dated August 14, 2017. The debenture accrues interest at 20% per annum and matures August 13, 2018. The convertible debenture contains a beneficial conversion valued at $110,629. The warrants were valued at $111,429. Because the note is immediately convertible, the warrants and beneficial conversion were expensed as interest.

On the same date, the Company entered into a General Security Agreement with the Mr. Struve, pursuant to which the Company has agreed to grant a security interest to the investor in substantially all of our assets, effective upon the filing of a UCC-3 termination statement to terminate the security interest held by Capital Source Business Finance Group in the assets of the Company. In addition, an entity affiliated with Ronald P. Erickson, out then Chief Executive Officer, entered into a Subordination Agreement with the investor pursuant to which all debt owed by us to such entity is subordinated to amounts owed by us to Mr. Struve under the Debenture (including amounts that become owing under any Debentures issued to the investor in the future).

The initial conversion price of the Debenture is $0.25 per share, subject to certain adjustments. The initial exercise price of the Warrant is $0.25 per share, also subject to certain adjustments.

As part of the Purchase Agreement, the Company granted the investor “piggyback” registration rights to register the shares of common stock issuable upon the conversion of the Debenture and the exercise of the Warrant with the Securities and Exchange Commission for resale or other disposition.

The Debenture and the Warrant were issued in a transaction that was not registered under the Securities Act of 1933, as amended in reliance upon applicable exemptions from registration under Section 4(a)(2) of the Act and Rule 506 of SEC Regulation D under the Act.

Under the terms of the Purchase Agreement, Mr. Struve may purchase up to an aggregate of $1,000,000 principal amount of Debentures (before a 20% original issue discount) (and Warrants to purchase up to an aggregate of 250,000 shares of common stock). These securities are being offered on a “best efforts” basis by the placement agent.

During the year ended September 30, 2017, $156,941 was recorded as interest expense related to debt discounts, beneficial conversions and warrants associated with Convertible Promissory Notes.

On December 12, 2017, the Company closed an additional $250,000 and issued a senior convertible exchangeable debenture with a principal amount of $300,000 and a common stock purchase warrant to purchase 1,200,000 shares of common stock in a private placement dated December 12, 2017 with Mr. Struve pursuant to a Securities Purchase Agreement dated August 14, 2017. The convertible debenture contains a beneficial conversion valued at $93,174. The warrants were valued at $123,600. Because the note is immediately convertible, the warrants and beneficial conversion were expensed as interest.

On March 2, 2018, the Company received gross proceeds of $280,000 in exchange for issuing a senior convertible redeemable debenture with a principal amount of $336,000 and a warrant to purchase 1,344,000 shares of common stock in a private placement dated February 28, 2018 with Mr. Struve pursuant to a Securities Purchase Agreement dated August 14, 2017. The convertible debenture contains a beneficial conversion valued at $252,932. The warrants were valued at $348,096. Because the note is immediately convertible, the warrants and beneficial conversion were expensed as interest.

In connection with the February 28, 2018 private placement, the placement agent for the debenture and the warrant received a cash fee of $28,000 and the Company issued warrants to purchase shares of the Company’s common stock to the placement agent or its affiliates based on 10% of proceeds.

On November 16, 2018, the Company signed Amendment 1 to Senior Secured Convertible Redeemable Notes dated August 14, 2017 and December 12, 2017, extending the due dates of the Notes to February 27, 2019.

Convertible Redeemable Promissory Notes with Ronald P. Erickson and J3E2A2Z

On March 16, 2018, the Company entered into a Note and Account Payable Conversion Agreement pursuant to which (a) all $664,233 currently owing under the J3E2A2Z Notes was converted to a Convertible Redeemable Promissory Note in the principal amount of $664,233, and (b) all $519,833 of the J3E2A2Z Account Payable was converted into a Convertible Redeemable Promissory Note in the principal amount of $519,833 together with a warrant to purchase up to 1,039,666 shares of common stock of the Company for a period of five years. The initial exercise price of the warrants described above is $0.50 per share, also subject to certain adjustments. The warrants were valued at $110,545. Because the note is immediately convertible, the warrants and beneficial conversion were expensed as interest. The Company recorded accrued interest of $32,602 as of December 31, 2018.

11.	NOTES PAYABLE, CAPITALIZED LEASES AND LONG TERM DEBT

Notes payable, capitalized leases and long-term debt as of December 31, 2018 and September 30, 2018 consisted of the following:

	December 31,	September 30,
	2018	2018

Capital Source Business Finance Group	$46,576	$145,186
Total debt	46,576	145,186
Less current portion of long term debt	(46,576)	(145,186)
Long term debt	$-	$-

Capital Source Business Finance Group

Know Labs, Inc. (the “Company”) finances its TransTech operations from operations and a Secured Credit Facility with Capital Source Business Finance Group. On June 15, 2018, TransTech entered into a Fifth Modification to the Loan and Security Agreement related to the $500,000 secured credit facility with Capital Source to fund its operations. The Modification extended the maturity to December 12, 2018. The secured credit facility provides for a prime rate interest floor for prime interest of 4.5% plus 2.5%. The eligible borrowing is based on 80% of eligible trade accounts receivable, not to exceed $500,000. The secured credit facility is collateralized by the assets of TransTech, with a guarantee by Know Labs, including a security interest in all assets of Know Labs. The remaining balance on the accounts receivable must be repaid by the time the secured credit facility expires on December 12, 2018, unless we renew by automatic extension for the next successive term. TransTech has $23,000 available as of December 31, 2018.

On December 6, 2018, Capital Source notified TransTech that the Loan and Security Agreement and Capital Source Credit Facility would be cancelled as of March 12, 2019. Effective December 12, 2018, TransTech entered into the Sixth Modification to the Loan and Security Agreement which reduced the secured credit facility to $200,000.

12. EQUITY

Authorized Capital Stock

The Company authorized 105,000,000 shares of capital stock, of which 100,000,000 are shares of voting common stock, par value $0.001 per share, and 5,000,000 are shares preferred stock, par value $0.001 per share.

The Company has authorized to issue up to 100,000,000 shares of common stock with a par value of $0.001. As of December 31, 2018, we had 17,811,431 shares of common stock issued and outstanding, held by 123 shareholders of record. The number of shareholders, including beneficial owners holding shares through nominee names, is approximately 2,300. Each share of common stock entitles its holder to one vote on each matter submitted to the shareholders for a vote, and no cumulative voting for directors is permitted. Shareholders do not have any preemptive rights to acquire additional securities issued by us. As of December 31, 2018, there were options outstanding for the purchase of 2,282,668 common shares, warrants for the purchase of 15,173,398 common shares, and 4,914,071 shares of the Company’s common stock issuable upon the conversion of Series A, Series C and Series D Convertible Preferred Stock. In addition, the Company has an unknown number of shares (9,020,264 common shares at the current price of $0.25 per share) are issuable upon conversion of convertible debentures of $2,255,066. All of which could potentially dilute future earnings per share.

Voting Preferred Stock

The Company is authorized to issue up to 5,000,000 shares of preferred stock with a par value of $0.001.

Series A Preferred Stock

In July 2015, the Company sold Series A Preferred Stock to two investors for a total of $350,000. As of December 31, 2018, the Company had 20,000 Series A Preferred Stock issued and outstanding.

Each holder of outstanding shares of Series A Preferred is entitled to the number of votes equal to the number of whole shares of common stock into which the shares of Series A Preferred held by such holder are then convertible as of the applicable record date. The Series A Preferred may not be redeemed without the consent of the holder. The Company cannot amend, alter or repeal any preferences, rights, or other terms of the Series A Preferred so as to adversely affect the Series A Preferred, without the written consent or affirmative vote of the holders of at least 66% of the then outstanding shares of Series A Preferred, voting as a separate voting group, given by written consent or by vote at a meeting called for such purpose for which notice shall have been duly given to the holders of the Series A Preferred.

In connection with the issuance of the Series A Preferred, the Company also issued (i) a Series C five-year Warrant for 2 shares of common stock and (ii) a Series D five-year Warrant for 23,334 shares of common stock. The Series A Preferred Stock and Series C and D Warrants currently have no registration rights.

On August 14, 2017, the price of the Series A Preferred Stock and Series C and D Warrants were adjusted to $0.25 per share pursuant to the documents governing such instruments.

On September 23, 2018, a holder of Series A Preferred Stock converted 3,334 shares into 3,334 shares of common stock. In addition, the holder exercised Series C and D Warrants for 6,668 shares of common stock at $0.25 per share.

Series C and D Preferred Stock and Warrants

On August 5, 2016, the Company closed a Series C Preferred Stock and Warrant Purchase Agreement with Clayton A. Struve, an accredited investor for the purchase of $1,250,000 of preferred stock with a conversion price of $0.70 per share. The preferred stock has a yield of 8% and an ownership blocker of 4.99%. In addition, Mr. Struve received a five-year warrant to acquire 1,785,714 shares of common stock at $0.70 per share.

To determine the effective conversion price, a portion of the proceeds received by the Company upon issuance of the Series C Preferred Stock was first allocated to the freestanding warrants issued as part of this transaction. Given that the warrants will not subsequently be measured at fair value, the Company determined that the warrants should receive an allocation of the proceeds based on their relative fair value. This is based on the understanding that the FASB staff and the SEC staff believe that a freestanding instrument issued in a basket transaction should be initially measured at fair value if it is required to be subsequently measured at fair value pursuant to US generally accepted accounting principles (“GAAP”), with the residual proceeds from the transaction allocated to any remaining instruments based on their relative fair values. As such, the warrants were allocated a fair value of approximately $514,706 upon issuance, with the remaining $735,294 of proceeds allocated to the Series C Preferred Stock.

Proportionately, this allocation resulted in approximately 59% of the face amount of the Series C Preferred Stock issuance remaining, which applied to the stated conversion price of $0.70 resulted in an effective conversion price of approximately $0.41.

Having determined the effective conversion price, the Company then compared this to the fair value of the underlying Common Stock as of the commitment date, which was approximately $1.06 per share, and concluded that the conversion feature did have an intrinsic value of $0.65 per share. As such, the Company concluded that the Series C Preferred Stock did contain a beneficial conversion feature and an accounting entry and additional financial statement disclosure was required.

Because our preferred stock is perpetual, with no stated maturity date, and the conversions may occur any time from inception, the dividend is recognized immediately when a beneficial conversion exists at issuance. During the year ending September 30, 2016, the Company recognized preferred stock dividends of $1.16 million on Series C preferred stock related to the beneficial conversion feature arising from a common stock effective conversion rate of $0.41 versus a current market price of $1.06 per common share.

On November 14, 2016, the Company issued 187,500 shares of Series D Convertible Preferred Stock and a warrant to purchase 187,500 shares of common stock in a private placement to certain accredited investors for gross proceeds of $150,000 pursuant to a Series D Preferred Stock and Warrant Purchase Agreement dated November 10, 2016.

The warrants associated with the November 14, 2016 issuance were allocated a fair value of approximately $56,539 upon issuance, with the remaining $63,539 of net proceeds allocated to the Series D Preferred Stock. Proportionately, this allocation resulted in approximately 53% of the amount of the Series D Preferred Stock issuance remaining, which applied to the stated conversion price of $0.80 resulted in an effective conversion price of approximately $0.34. Having determined the effective conversion price, the Company then compared this to the fair value of the underlying Common Stock as of the commitment date, which was approximately $1.14 per share, and concluded that the conversion feature did have an intrinsic value of $0.80 per share. As such, the Company concluded that the Series D Preferred Stock did contain a beneficial conversion feature of $150,211 which was recorded as a beneficial conversion in stockholders’ equity.

On December 19, 2016, the Company issued 187,500 shares of Series D Convertible Preferred Stock and a warrant to purchase 187,500 shares of common stock in a private placement to an accredited investor for gross proceeds of $150,000 pursuant to a Series D Preferred Stock and Warrant Purchase Agreement dated December 14, 2016.

The warrants associated with the December 19, 2016 issuance were allocated a fair value of approximately $60,357 upon issuance, with the remaining $69,643 of net proceeds allocated to the Series D Preferred Stock. Proportionately, this allocation resulted in approximately 54% of the amount of the Series D Preferred Stock issuance remaining, which applied to the stated conversion price of $0.80 resulted in an effective conversion price of approximately $0.37. Having determined the effective conversion price, the Company then compared this to the fair value of the underlying Common Stock as of the commitment date, which was approximately $0.81 per share, and concluded that the conversion feature did have an intrinsic value of $0.44 per share. As such, the Company concluded that the Series C Preferred Stock did contain a beneficial conversion feature of $82,232 which was recorded as a beneficial conversion in stockholders’ equity.

Because the Company’s preferred stock is perpetual, with no stated maturity date, and the conversions may occur any time from inception, the dividend is recognized immediately when a beneficial conversion exists at issuance. During the year ending September 30, 2017, the Company recognized preferred stock dividends of $2.3 million on Series D preferred stock related to the beneficial conversion feature arising from a common stock effective conversion rate of $0.34 and $0.37 versus the original market price of $1.14 and $1.06 per common share, respectively.

On May 1, 2017, the Company issued 357,143 shares of Series D Convertible Preferred Stock and a warrant to purchase 357,143 shares of common stock in a private placement to an accredited investor for gross proceeds of $250,000 pursuant to a Series D Preferred Stock and Warrant Purchase Agreement dated May 1, 2016.

The initial conversion price of the Series D Shares is $0.70 per share, subject to certain adjustments. The initial exercise price of the warrant is $0.70 per share, also subject to certain adjustments. The Company also amended and restated the Certificate of Designations, resulting in an adjustment to the conversion price of all currently outstanding Series D Shares to $0.70 per share.

On August 14, 2017, the price of the Series C and D Preferred Stock were adjusted to $0.25 per share pursuant to the documents governing such instruments. After adjustment there were 3,108,356 shares of Series D preferred stock authorized.

On July 17, 2018, the Company filed with the State of Nevada a second Amended and Restated Certificate of Designation of Preferences, Powers, and Rights of the Series D Convertible Preferred Stock. The Amended Certificate restates the prior Certificate of Designation filed on May 8, 2017 to decrease the number of authorized Series D shares from 3,906,250 shares to 1,016,014 shares. No other amendments were made to the preferences and rights of the Series D Convertible Preferred Stock. The filing of the Amended Certificate was unanimously approved by the Board of Directors and the shareholders of Series D Convertible Preferred Stock.

Series F Preferred Stock

On August 1, 2018, the Company filed with the State of Nevada a Certificate of Designation establishing the Designations, Preferences, Limitations and Relative Rights of Series F Preferred Stock (the “Designation”). The Designation authorized 500 shares of Series F Preferred Stock. The Series F Preferred Stock shall only be issued to the current Board of Directors on the date of the Designation’s filing and is not convertible into common stock. As set forth in the Designation, the Series F Preferred Stock has no rights to dividends or liquidation preference and carries rights to vote 100,000 shares of common stock per share of Series F upon a Trigger Event, as defined in the Designation. A Trigger Event includes certain unsolicited bids, tender offers, proxy contests, and significant share purchases, all as described in the Designation. Unless and until a Trigger Event, the Series F shall have no right to vote. The Series F Preferred Stock shall remain issued and outstanding until the date which is 731 days after the issuance of Series F Preferred Stock (“Explosion Date”), unless a Trigger Event occurs, in which case the Explosion Date shall be extended by 183 days.

Securities Subject to Price Adjustments

In the future, if we sell our common stock at a price below $0.25 per share, the exercise price of 20,000 outstanding shares of Series A Preferred Stock, 1,785,715 outstanding shares of Series C Preferred Stock, 1,016,004 outstanding shares Series D Preferred Stock that adjust below $0.25 per share pursuant to the documents governing such instruments. In addition, the conversion price of a Convertible Note Payable of $2,255,066 (9,020,264 common shares at the current price of $0.25 per share) and the exercise price of additional outstanding warrants to purchase 12,714,385 shares of common stock would adjust below $0.25 per share pursuant to the documents governing such instruments.

Common Stock

All of the offerings and sales described below were deemed to be exempt under Rule 506 of Regulation D and/or Section 4(a)(2) of the Securities Act. No advertising or general solicitation was employed in offering the securities, the offerings and sales were made to a limited number of persons, all of whom were accredited investors and transfer was restricted by the company in accordance with the requirements of Regulation D and the Securities Act. All issuances to accredited and non-accredited investors were structured to comply with the requirements of the safe harbor afforded by Rule 506 of Regulation D, including limiting the number of non-accredited investors to no more than 35 investors who have sufficient knowledge and experience in financial and business matters to make them capable of evaluating the merits and risks of an investment in our securities.

The following equity issuances occurred during the three months ended December 31, 2018:

The Company issued 279,929 shares of common stock and cancelled warrants to purchase 20,071 shares of common stock at $0.25 per share to a consultant and an investor related to the cashless exercise of warrants.

Warrants to Purchase Common Stock

The following warrants were issued during the three months ended December 31, 2018:

A summary of the warrants outstanding as of December 31, 2018 were as follows:

	December 31, 2018
		Weighted
		Average
		Exercise
	Shares	Price
Outstanding at beginning of period	15,473,398	$0.326
Issued	-	-
Exercised	(279,929)	(0.250)
Forfeited	-	-
Expired	(20,071)	(0.250)
Outstanding at end of period	15,173,398	$0.328
Exerciseable at end of period	15,173,398

A summary of the status of the warrants outstanding as of December 31, 2018 is presented below:

	December 31, 2018
	Weighted	Weighted		Weighted
	Average	Average		Average
Number of	Remaining	Exercise	Shares	Exercise
Warrants	Life ( In Years)	Price	Exerciseable	Price
13,570,286	3.75	$0.250	13,570,286	$0.250
714,286	2.58	0.700	714,286	0.700
882,159	2.87	1.000	882,159	1.000
6,667	0.25	30.000	6,667	30.000
15,173,398	3.34	$0.328	15,173,398	$0.328

The significant weighted average assumptions relating to the valuation of the Company’s warrants for the three months ended December 31, 2018 were as follows:

Assumptions

Dividend yield	0%
Expected life	1-2 years
Expected volatility	125%-145%
Risk free interest rate	..0202-.0214%

There were vested warrants of 14,284,572 as of December 31, 2018 with an aggregate intrinsic value of $9,249,235.

13.	STOCK OPTIONS

On March 21, 2013, an amendment to the Stock Option Plan was approved by the stockholders of the Company, increasing the number of shares reserved for issuance under the Plan to 93,333 shares. On April 10, 2018, the Board approved an amendment to its 2011 Stock Incentive Plan increasing the number of shares of common stock reserved under the Incentive Plan from 93,333 to 1,200,000. On August 7, 2018, the Board approved an amendment to its 2011 Stock Incentive Plan increasing the number of shares of common stock reserved under the Incentive Plan from 1,200,000 to 2,000,000 to common shares.

Determining Fair Value under ASC 505

The Company records compensation expense associated with stock options and other equity-based compensation using the Black-Scholes-Merton option valuation model for estimating fair value of stock options granted under our plan. The Company amortizes the fair value of stock options on a ratable basis over the requisite service periods, which are generally the vesting periods. The expected life of awards granted represents the period of time that they are expected to be outstanding. The Company estimates the volatility of our common stock based on the historical volatility of its own common stock over the most recent period corresponding with the estimated expected life of the award. The Company bases the risk-free interest rate used in the Black Scholes-Merton option valuation model on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term equal to the expected life of the award. The Company has not paid any cash dividends on our common stock and does not anticipate paying any cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield of zero in the Black-Scholes-Merton option valuation model and adjusts share-based compensation for changes to the estimate of expected equity award forfeitures based on actual forfeiture experience. The effect of adjusting the forfeiture rate is recognized in the period the forfeiture estimate is changed.

Stock Option Activity

The Company had the following stock option transactions during the three months ended December 31, 2018:

On October 31, 2018, the Board awarded stock option grants to two directors to acquire 50,000 shares each of the Company’s common stock. The grants were valued at $3.03 per share and expire on October 31, 2013. The grants vested immediately.

On October 31, 2018, the Board awarded Phillip A. Bosua a stock option grant to acquire 100,000 shares of the Company’s Common stock for each $1,000,000 raised by the Company in revenue generated in a planned Kickstarter campaign. In addition, Mr. Bosua was granted a stock option grant to acquire 1,000,000 shares of the Company’s common which vests upon approval of the Company’s blood glucose measurement technology by the U.S. Food and Drug Administration. The grants were valued at $3.03 per share and expire on October 31, 2023.

On October 31, 2018, the Board awarded Ronald P Erickson a stock option grant to acquire 1,000,000 shares of the Company’s common which vests upon the Company’s successful listing of its Common Stock on Nasdaq or the New York Stock Exchange (including the NYSE American Market). The grant was valued at $3.03 per share and expires on October 31, 2023.

There are currently 2,282,668 options to purchase common stock at an average exercise price of $1.757 per share outstanding as of December 31, 2018 under the 2011 Stock Incentive Plan. The Company recorded $171,498 and $2,147 of compensation expense, net of related tax effects, relative to stock options for the three months ended December 31, 2018 and December 31, 2017and in accordance with ASC 505. Net loss per share (basic and diluted) associated with this expense was approximately ($0.010) and ($0.00) per share, respectively. As of December 31, 2018, there is approximately $1,697,737, net of forfeitures, of total unrecognized costs related to employee granted stock options that are not vested. These costs are expected to be recognized over a period of approximately 4.94 years.

Stock option activity for the three months ended December 31, 2018 and the years ended September 30, 2018 and 2017 was as follows:

	Weighted Average
	Options	Exercise Price	$
Outstanding as of September 30, 2016	50,908	$18.04	$918,627
Granted	-	-	-
Exercised	-	-	-
Forfeitures	(35,504)	(19.507)	(692,568)
Outstanding as of September 30, 2017	15,404	14.675	226,059
Granted	2,180,000	1.683	3,668,500
Exercised	-	-	-
Forfeitures	(12,736)	14.764	(188,040)
Outstanding as of September 30, 2018	2,182,668	1.698	3,706,519
Granted	100,000	3.030	303,000
Exercised	-	-	-
Forfeitures	-	-	-
Outstanding as of December 31, 2018	2,282,668	$1.757	$4,009,519

The following table summarizes information about stock options outstanding and exercisable as of December 31, 2018:

		Weighted	Weighted		Weighted
		Average	Average		Average
Range of	Number	Remaining Life	Exercise Price	Number	Exercise Price
Exercise Prices	Outstanding	In Years	Exerciseable	Exerciseable	Exerciseable
0.25	530,000	4.86	$0.250	66,250	$0.25
1.28	1,150,000	4.96	1.28	71,875	1.28
3.03	100,000	4.96	3.03	100,000	3.03
4.08-4.20	500,000	4.98	4.08-4.20	-	-
13.500	1,334	0.44	13.50	1,334	13.50
15.000	1,334	-	15.00	-	15.00
	2,282,668	4.94	$1.757	239,459	$1.00

There were stock option grants of 530,000 shares as of December 31, 2018 with an aggregate intrinsic value of $355,100.

14.	OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES

Related Party Transactions with Ronald P. Erickson

See Notes 1, 10, 13 and 15 for related party transactions with Ronald P. Erickson.

Mr. Erickson and/or entities with which he is affiliated also have accrued compensation, travel and interest of approximately $530,102 as of December 31, 2018.

Related Party Transaction with Phillip A. Bosua

See Notes 1, 13 and 15 for related party transactions with Phillip A. Bosua.

Stock Option Grants to Directors

See Note 13 for related party transactions with Directors.

15.	COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS

Legal Proceedings

The Company may from time to time become a party to various legal proceedings arising in the ordinary course of our business. The Company is currently not a party to any pending legal proceeding that is not ordinary routine litigation incidental to our business.

Employment Agreement with Phillip A. Bosua, Chief Executive Officer

On April 10, 2018, the Company appointed Mr. Bosua as Chief Executive Officer of the Company, replacing Ronald P. Erickson, who remains Chairman of the Company. Mr. Erickson has been a director and officer of Know Labs since April 2003. He was appointed as our CEO and President in November 2009 and as Chairman of the Board in February 2015. Previously, Mr. Erickson was our President and Chief Executive Officer from September 2003 through August 2003 and was Chairman of the Board from August 2004 until May 2011.

Phillip A. Bosua was appointed the Company’s CEO on April 10, 2018. Previously, Mr. Bosua served as the Company’s Chief Product Officer since August 2017. The Company entered into a Consulting Agreement with Mr. Bosua’s company, Blaze Clinical on July 7, 2017. From September 2012 to February 2015, Mr. Bosua was the founder and Chief Executive Officer of LIFX Inc. (where he developed and marketed an innovative “smart” light bulb) and from August 2015 until February 2016 was Vice President Consumer Products at Soraa (which markets specialty LED light bulbs). From February 2016 to July 2017, Mr. Bosua was the founder and CEO of RAAI, Inc. (where he continued the development of his smart lighting technology). From May 2008 to February 2013 he was the Founder and CEO of LimeMouse Apps, a leading developer of applications for the Apple App Store.

On April 10, 2018, the Company entered into an Employment Agreement with Mr. Bosua reflecting his appointment as Chief Executive Officer. The Employment Agreement is for an initial term of 12 months (subject to earlier termination) and will be automatically extended for additional 12-month terms unless either party notifies the other party of its intention to terminate the Employment Agreement. Mr. Bosua will be paid a base salary of $225,000 per year, received 500,000 shares of common stock valued at $0.33 per share and may be entitled to bonuses and equity awards at the discretion of the Board or a committee of the Board. The Employment Agreement provides for severance pay equal to 12 months of base salary if Mr. Bosua is terminated without “cause” or voluntarily terminates his employment for “good reason.”

Employment Agreement with Ronald P. Erickson, Chairman of the Board and Interim Chief Financial Officer

On August 4, 2017, the Board of Directors approved an Employment Agreement with Ronald P. Erickson pursuant to which the Company engaged Mr. Erickson as our Chief Executive Officer through September 30, 2018.

Mr. Erickson’s annual compensation is $180,000. Mr. Erickson is also entitled to receive an annual bonus and equity awards compensation as approved by the Board. The bonus should be paid no later than 30 days following earning of the bonus.

Mr. Erickson will be entitled to participate in all group employment benefits that are offered by the Company to our senior executives and management employees from time to time, subject to the terms and conditions of such benefit plans, including any eligibility requirements.

If the Company terminates Mr. Erickson’s employment at any time prior to the expiration of the Term without Cause, as defined in the Employment Agreement, or if Mr. Erickson terminates his employment at any time for “Good Reason” or due to a “Disability”, Mr. Erickson will be entitled to receive (i) his Base Salary amount for one year; and (ii) medical benefits for eighteen months.

On April 10, 2018, the Company entered into an Amended Employment Agreement for Ronald P. Erickson which amends the Employment Agreement dated July 1, 2017. The Agreement expires March 21, 2019.

Properties and Operating Leases

The Company is obligated under the following non-cancelable operating leases for its various facilities and certain equipment.

Years Ended December 31,	Total
2019	$ 106,190
2020	72,519
2021	14,540
2022	-
2023	-
Beyond	-
Total	$ 193,249

Corporate Offices

On April 13, 2017, the Company leased its executive office located at 500 Union Street, Suite 810, Seattle, Washington, USA, 98101. The Company leases 943 square feet and the net monthly payment is $2,672. The monthly payment increases approximately 3% each year and the lease expires on May 31, 2022.

Lab Facilities and Executive Offices

On May 1, 2018, the Company leased its lab facilities and executive offices located at 304 Alaskan Way South, Suite 102, Seattle, Washington, USA, 98101. The Company leases 2,800 square feet and the net monthly payment is $4,000. The lease expires on April 30, 2019.

TransTech Facilities

TransTech is located at 12142 NE Sky Lane, Suite 130, Aurora, OR 97002. TransTech leases a total of approximately 6,340 square feet of office and warehouse space for its administrative offices, product inventory and shipping operations. Effective December 1, 2017, TransTech leases this office from December 1, 2017 at $4,465 per month. The monthly payment increases approximately 3% each year and the lease expires on January 31, 2020. Until December 1, 2017, TransTech leased this office on a month to month basis at $6,942 per month.

16. SUBSEQUENT EVENTS

The Company evaluates subsequent events, for the purpose of adjustment or disclosure, up through the date the financial statements are available. Subsequent to December 31, 2018, there were the following material transactions that require disclosure:

On January 2, 2019, the Company issued 170,000 shares of restricted common stock to a Names Executive Officer and a consultant and for services during 2018.

On January 16, 2019, the Company leased replacement lab facilities and executive offices located at 1517 12th Ave Suite 203 Seattle, WA 98122. The lease commences February 1, 2019 and expires June 30, 2021. The Company leases 2,642 square feet and the net monthly payment is $8,256. The monthly payment increases approximately 3% on June 30, 2019 and 2020.

On January 29, 2019, the Company issued 45,888 shares of common stock and cancelled warrants to purchase 4,112 shares of common stock at $0.25 per share to an investor related to the exercise of warrants.

On January 29, 2019, the Company issued 80,000 shares of common stock and cancelled 20,000 shares of Series A Convertible Preferred Stock at $0.25 per share to an investor related to the conversion of the preferred stock.

ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-looking statements in this report reflect the good-faith judgment of our management and the statements are based on facts and factors as we currently know them. Forward-looking statements are subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, but are not limited to, those discussed below as well as those discussed elsewhere in this report (including in Part II, Item 1A (Risk Factors)). Readers are urged not to place undue reliance on these forward-looking statements because they speak only as of the date of this report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this report.

BACKGROUND AND CAPITAL STRUCTURE

Know Labs, Inc., formerly Visualant, Incorporated, was incorporated under the laws of the State of Nevada in 1998. Since 2007, we have been focused primarily on research and development of proprietary technologies which can be used to authenticate and diagnose a wide variety of organic and non-organic substances and materials. Our Common Stock trades on the OTCQB Exchange under the symbol “KNWN.”

BUSINESS

We are focused on the development, marketing and sales of a proprietary technologies which are capable of uniquely authenticating or diagnosing almost any substance or material using electromagnetic energy to create, record and detect the unique “signature” of the substance. We call these our “ChromaID™” and “Bio-RFID™” technologies.

Overview

Historically, the Company focused on the development of our proprietary ChromaID technology. Using light from low-cost LEDs (light emitting diodes) we map the color of substances, fluids and materials and with our proprietary processes we can authenticate, identify and diagnose based upon the color that is present. The color is both visible to us as humans but also outside of the humanly visible color spectrum in the near infra-red and near ultra-violet and beyond. Our ChromaID scanner sees what we like to call “Nature’s Color Fingerprint.” Everything in nature has a unique color identifier and with ChromaID we can see it, and identify, authenticate and diagnose based upon the color that is present. Our ChromaID scanner is capable of uniquely identifying and authenticating almost any substance or liquid using light to create, record and detect its unique color signature. We will continue to develop and enhance our ChromaID technology and extend its capacity. More recently, we have focused upon extensions and new inventions that are derived from and extend beyond our ChromaID technology. We call this technology Bio-RFID. The rapid advances made with our Bio-RFID technology in our laboratory have caused us to move quickly in to the commercialization phase of our Company as we work to create revenue generating products for the marketplace. We will also, as resources permit, pursue licensing opportunities with third parties who have ready applications for our technologies.

In 2010, we acquired TransTech Systems, Inc. as an adjunct to our business. TransTech is a distributor of products for employee and personnel identification and authentication. TransTech has historically provided substantially all of the Company’s revenues. The financial results from our TransTech subsidiary have been diminishing as vendors of their products increasingly move to the Internet and direct sales to their customers. While it does provide our current revenues it is not central to our current focus as a Company. Moreover, we have written down any goodwill associated with its historic acquisition. We continue to closely monitor this subsidiary.

The Know Labs Technology

We have internally and under contract with third parties developed proprietary platform technologies to uniquely authenticate or diagnose almost any material and substance. Our technology utilizes electromagnetic energy at various points along the electromagnetic spectrum to perform analytics which allow the user to identify, authenticate and diagnose depending upon the application and the unique field of use. The Company’s proprietary platform technologies are called ChromaID and Bio-RFID.

The ChromaID patented technology utilizes light at the photon (elementary particle of light) level through a series of emitters and detectors to generate a unique signature or “fingerprint” from a scan of almost any solid, liquid or gaseous material. This signature of reflected or transmitted light is digitized, creating a unique ChromaID signature. Each ChromaID signature is comprised of from hundreds to thousands of specific data points.

The ChromaID technology looks beyond visible light frequencies to areas of near infra-red and ultraviolet light and beyond that are outside the humanly visible light spectrum. The data obtained allows us to create a very specific and unique ChromaID signature of the substance for a myriad of authentication, verification and diagnostic applications.

Traditional light-based identification technology, called spectrophotometry, has relied upon a complex system of prisms, mirrors and visible light. Spectrophotometers typically have a higher cost and utilize a form factor (shape and size) more suited to a laboratory setting and require trained laboratory personnel to interpret the information. The ChromaID technology uses lower cost LEDs and photodiodes and specific electromagnetic frequencies resulting in a more accurate, portable and easy-to-use solution for a wide variety of applications. The ChromaID technology not only has significant cost advantages as compared to spectrophotometry, it is also completely flexible is size, shape and configuration. The ChromaID scan head can range in size from endoscopic to a scale that could be the size of a large ceiling-mounted florescent light fixture.

In normal operation, a ChromaID master or reference scan is generated and stored in a database. We call this the ChromaID Reference Library. The scan head can then scan similar materials to identify, authenticate or diagnose them by comparing the new ChromaID digital signature scan to that of the original or reference ChromaID signature or scan result. Over time, we believe the ChromaID Reference Libraries can become a significant asset of the Company, providing valuable information in numerous fields of use. The Reference Libraries for Bio-RFID will have a similar promise regarding their utility and value.

The Company’s latest technology platform is called Bio-RFID. Working in our lab over the past year, we have developed extensions and new inventions derived in part from our ChromaID technology which we refer to as Bio-RFID technology. While we are in the early stages of the development of this technology, we have recently announced that we have successfully been able to non-invasively ascertain blood glucose levels. We are building the internal and external development team necessary to commercialize this newly discovered technology as well as make additional patent filings covering the intellectual property created with these new inventions. The first applications of our Bio-RFID technology will be in a product we call the UBAND™. The first UBAND product will be marketed as a real time calorie counter. It is a wearable product which will be worn on the wrist and communicate with a smart phone device via Bluetooth connectivity. It will provide the user with real time information on their caloric consumption from carbohydrates.

We have recently announced the results of laboratory-based comparison testing between our Bio-RFID technology and the leading continuous glucose monitors from Abbott Labs (Freestyle Libre®) and DexCom (G5®). These results provide evidence of a high degree of correlation between our Bio-RFID based technology and the current industry leaders. Our technology is fundamentally differentiated from these industry leaders as it is completely non-invasive.

We expect to begin the process of obtaining US Food and Drug Administration approval of our non-invasive continuous blood glucose monitoring device during calendar year 2019. We are unable to estimate the time necessary for such approval nor the likelihood of success in that endeavor.

ChromaID and Bio-RFID: Foundational Platform Technologies

Our ChromaID and Bio-RFID technologies provide a platform upon which a myriad of applications can be developed. As platform technologies, they are analogous to a smartphone, upon which an enormous number of previously unforeseen applications have been developed. ChromaID and Bio-RFID technologies are “enabling” technologies that bring the science of electromagnetic energy to low-cost, real-world commercialization opportunities across multiple industries. The technologies are foundational and, as such, the basis upon which the Company believes a significant business can be built.

As with other foundational technologies, a single application may reach across multiple industries. The ChromaID technology can, for example effectively differentiate and identify different brands of clear vodkas that appear identical to the human eye. By extension, this same technology can identify pure water from water with contaminants present. It can provide real time detection of liquid medicines such as morphine that have been adulterated or compromised. It can detect if jet fuel has water contamination present. It could determine when it is time to change oil in a deep fat fryer. These are but a few of the potential applications of the ChromaID technology based upon extensions of its ability to identify different clear liquids.

Similarly, the Bio-RFID technology can non-invasively identity the presence and quantity of glucose in the human body. By extension, there may be other molecular structures which this same technology can identity in the human body which, over time, the Company will focus upon. They may include the monitoring of drug usage or the presence of illicit drugs. They may also involve identifying hormones and various markers of disease.

The cornerstone of a company with a foundational platform technology is its intellectual property. We have pursued an active intellectual property strategy and have been granted 12 patents. We currently have 20 patents pending. We possess all right, title and interest to the issued patents. Ten of the pending patents are licensed exclusively to us in perpetuity by our strategic partner, Allied Inventors.

Our Patents and Intellectual Property

We believe that our 12 patents, 20 patent applications, three registered trademarks, and our trade secrets, copyrights and other intellectual property rights are important assets. Our issued patents will expire at various times between 2027 and 2033. The duration of our trademark registrations varies from country to country. However, trademarks are generally valid and may be renewed indefinitely as long as they are in use and/or their registrations are properly maintained.

The issued patents cover the fundamental aspects of the Know Labs ChromaID technology and a growing number of unique applications ranging, to date, from invisible bar codes to tissue and liquid analysis. We have filed patents on Bio-RFID technology and will continue to expand the Company’s patent portfolio over time through internal development efforts as well as through licensing opportunities with third parties.

Additionally, significant aspects of our technology are trade secrets which may not be disclosed through the patent filing process. We intend to be diligent in maintaining our trade secrets.

The patents that have been issued to Know Labs and their dates of issuance are:

On August 9, 2011, we were issued US Patent No. 7,996,173 B2 entitled “Method, Apparatus and Article to Facilitate Distributed Evaluation of Objects Using Electromagnetic Energy,” by the United States Office of Patents and Trademarks. The patent expires August 24, 2029.

On December 13, 2011, we were issued US Patent No. 8,076,630 B2 entitled “System and Method of Evaluating an Object Using Electromagnetic Energy” by the United States Office of Patents and Trademarks. The patent expires November 7, 2028.

On December 20, 2011, we were issued US Patent No. 8,081,304 B2 entitled “Method, Apparatus and Article to Facilitate Evaluation of Objects Using Electromagnetic Energy” by the United States Office of Patents and Trademarks. The patent expires July 28, 2030.

On October 9, 2012, we were issued US Patent No. 8,285,510 B2 entitled “Method, Apparatus, and Article to Facilitate Distributed Evaluation of Objects Using Electromagnetic Energy” by the United States Office of Patents and Trademarks. The patent expires July 31, 2027.

On February 5, 2013, we were issued US Patent No. 8,368,878 B2 entitled “Method, Apparatus and Article to Facilitate Evaluation of Objects Using Electromagnetic Energy by the United States Office of Patents and Trademarks. The patent expires July 31, 2027.

On November 12, 2013, we were issued US Patent No. 8,583,394 B2 entitled “Method, Apparatus and Article to Facilitate Distributed Evaluation of Objects Using Electromagnetic Energy by the United States Office of Patents and Trademarks. The patent expires July 31, 2027.

On November 21, 2014, we were issued US Patent No. 8,888,207 B2 entitled “Systems, Methods, and Articles Related to Machine-Readable Indicia and Symbols” by the United States Office of Patents and Trademarks. The patent expires February 7, 2033. This patent describes using ChromaID to see what we call invisible bar codes and other identifiers.

On March 23, 2015, we were issued US Patent No. 8,988,666 B2 entitled “Method, Apparatus, and Article to Facilitate Evaluation of Objects Using Electromagnetic Energy” by the United States Office of Patents and Trademarks. The patent expires July 31, 2027.

On May 26, 2015, we were issued US Patent No. 9,041,920 B2 entitled “Device for Evaluation of Fluids using Electromagnetic Energy” by the United States Office of Patents and Trademarks. The patent expires March 12, 2033. This patent describes a ChromaID fluid sampling devices.

On April 19, 2016, we were issued US Patent No. 9,316,581 B2 entitled “Method, Apparatus, and Article to Facilitate Evaluation of Substances Using Electromagnetic Energy” by the United States Office of Patents and Trademarks. The patent expires March 12, 2033. This patent describes an enhancement to the foundational ChromaID technology.

On April 18, 2017, we were issued US Patent No. 9,625,371 B2 entitled “Method, Apparatus, and Article to Facilitate Evaluation of Substances Using Electromagnetic Energy.” The patent expires July 2027. This patent pertains to the use of ChromaID technology for the identification and analysis of biological tissue. It has many potential applications in medical, industrial and consumer markets.

On April 4, 2018, we were issued US Patent No. 9,869,636 B2, entitled “Device for Evaluation of Fluids Using Electromagnetic Energy.” The patent expires approximately April 2033. This patent pertains to the use of ChromaID technology for evaluating and analyzing fluids such as those following through an IV drip in a hospital or water, for example.

We continue to pursue a patent strategy to expand our unique intellectual property in the United States and other countries.

Joint Development Agreements and Product Strategy

We are currently undertaking internal development work on potential products for the consumer marketplace. This development work was being performed through our Consulting Agreement with Blaze Clinical, and Phillip A. Bosua, who served as our Chief Product Officer. In his current role as Chief Executive Officer, Mr. Bosua continues to lead these efforts. As these products take form over the coming months, we will make appropriate product announcements.

We also will continue to engage with partners through licensing our technology in various fields of use, entering in to joint venture agreements to develop specific applications of our technology, and in certain specific instances develop our own products for the marketplace.

We have deployed our ChromaID development kit to a number of potential joint venture partners and customers around the world. There are strong indications of interest in deploying our technology in a wide variety of applications involving identification, authentication and diagnostics. Currently we are focusing our current efforts on productizing our Bio-RFID technology as we move it out of the research laboratory and in to the marketplace.

Research and Development

Our current research and development efforts are primarily focused improving our Bio-RFID technology, extending its capacity and developing new and unique applications for the technology. As part of this effort, we conduct on-going laboratory testing to ensure that application methods are compatible with the end-user and regulatory requirements, and that they can be implemented in a cost-effective manner. We are also actively involved in identifying new applications. Our current internal team along with outside consultants have considerable experience working with the application of our technologies and their application. We engage third party experts as required to supplement our internal team. We believe that continued development of new and enhanced technologies is essential to our future success. We incurred expenses of $570,514 and $79,405 for the year ended September 30, 2018 and 2017, respectively, on development activities. On July 6, 2017, we entered into a Consulting Agreement with Phillip A. Bosua, our Chief Product Officer to lead our development efforts. He has continued in that role with expanded responsibilities upon his appointment as Chief Executive Officer on April 19, 2018.

RECENT DEVELOPMENTS

We have the following recent developments:

Merger with RAAI Lighting, Inc.

On April 10, 2018, we entered into an Agreement and Plan of Merger with 500 Union Corporation, a Delaware corporation and a wholly owned subsidiary of the Company, and RAAI Lighting, Inc., a Delaware corporation. Pursuant to the Merger Agreement, we have acquired all the outstanding shares of RAAI’s capital stock through a merger of Merger Sub with and into RAAI (the “Merger”), with RAAI surviving the Merger as a wholly owned subsidiary of the Company.

Appointment of Director

On April 10, 2018, the Board increased the size of the Board from three to four members and Phillip A. Bosua was appointed as a member of the Board. Mr. Bosua’s term of office expire at the next annual meeting of our stockholders. On May 24, 2018, the Board of Directors increased the size of the Board from four to five members and appointed (Ret.) Admiral William Owens as a member of the Board. Admiral Owen’s term of office expires at the next annual meeting of our stockholders.

Appointment of Officer

On April 10, 2018, we appointed Mr. Bosua as Chief Executive Officer of the Company, replacing Ronald P. Erickson, who remains Chairman of the Company. Mr. Erickson has been a director and officer of Know Labs since April 2003. He was appointed as our CEO and President in November 2009 and as Chairman of the Board in February 2015. Previously, Mr. Erickson was our President and Chief Executive Officer from September 2003 through August 2003 and was Chairman of the Board from August 2004 until May 2011.

Phillip A. Bosua was appointed the Company’s CEO on April 10, 2018. Previously, Mr. Bosua served as our Chief Product Officer since August 2017. We entered into a Consulting Agreement with Mr. Bosua’s company, Blaze Clinical on July 7, 2017. From September 2012 to February 2015, Mr. Bosua was the founder and Chief Executive Officer of LIFX Inc. (where he developed and marketed an innovative “smart” light bulb) and from August 2015 until February 2016 was Vice President Consumer Products at Soraa (which markets specialty LED light bulbs). From February 2016 to July 2017, Mr. Bosua was the founder and CEO of RAAI, Inc. (where he continued the development of his smart lighting technology). From May 2008 to February 2013 he was the Founder and CEO of LimeMouse Apps, a leading developer of applications for the Apple App Store.

On April 10, 2018, we entered into an Employment Agreement with Mr. Bosua reflecting his appointment as Chief Executive Officer. The Employment Agreement is for an initial term of 12 months (subject to earlier termination) and will be automatically extended for additional 12-month terms unless either party notifies the other party of its intention to terminate the Employment Agreement. Mr. Bosua will be paid a base salary of $225,000 per year, received 500,000 shares of common stock valued at $0.33 per share and may be entitled to bonuses and equity awards at the discretion of the Board or a committee of the Board. The Employment Agreement provides for severance pay equal to 12 months of base salary if Mr. Bosua is terminated without “cause” or voluntarily terminates his employment for “good reason.”

On April 10, 2018, we entered into an Amended Employment Agreement for Ronald P. Erickson which amends the Employment Agreement dated July 1, 2017. The Agreement expires March 21, 2019.

Amendment of Equity Incentive Plan

On April 10, 2018, the Board approved an amendment to its 2011 Stock Incentive Plan increasing the number of shares of common stock reserved under the Incentive Plan from 93,333 to 1,200,000. On August 1, 2018, the Board approved an amendment to its 2011 Stock Incentive Plan increasing the number of shares of common stock reserved under the Incentive Plan 1,200,000 to 2,000,000.

Merger with Know Labs, Inc.

Corporate Name Change and Symbol Change

On May 24, 2018, the Financial Industry Regulatory Authority (“FINRA”) announced the effectiveness of a change in our name from Know Labs Incorporated to Know Labs, Inc. and a change in our ticker symbol from VSUL to the new trading symbol KNWN which became effective on the opening of trading as of May 25, 2018. In addition, in connection with the name change and symbol change, we were assigned the CUSIP number of 499238103.

Closing of Financing on June 25, 2018

On June 25, 2018, we closed a private placement and received gross proceeds of $1,750,000 in exchange for issuing 7,000,000 shares of common stock and warrants to purchase 3,500,000 shares of common stock in a private placement to accredited investors pursuant to a series of substantially identical subscription agreements.

The initial exercise price of the warrants described above is $0.25 per share, subject to certain adjustments, and they expired five years after their issuance.

Conversion of Certain Debt to Equity

On June 25, 2018, we closed debt conversions and issued 605,000 shares of common stock in exchange for the conversion of $199,935 in preexisting debt owed by the Company to certain service providers, all of whom are accredited investors. These shares were issued in transactions that were not registered under the Act in reliance upon applicable exemptions from registration under Section 4(a)(2) of the Act and/or Rule 506 of SEC Regulation D under the Act.

On July 9, 2018, we repaid a $199,935 Business Loan Agreement with Umpqua Bank from funds previously provided by an entity affiliated with Ronald P. Erickson, our Chairman of the Board. The Company paid $27,041 and issued 800,000 shares of common stock in exchange for the conversion of this debt. Mr. Erickson is an accredited investor. These shares were issued in transactions that were not registered under the Act in reliance upon applicable exemptions from registration under Section 4(a)(2) of the Act and/or Rule 506 of SEC Regulation D under the Act.

THE COMPANY’S COMMON STOCK

Our common stock trades on the OTCQB Exchange under the symbol “KNWN.” On May 1, 2018, we filed a corporate action with FINRA to effectively change the Company’s OTC trading symbol and change our name to “Know Labs, Inc.” Our name change from Know Labs, Incorporated to Know Labs, Inc. and symbol change from VSUL to KNWN was announced by FINRA declared effective on the opening of trading as of May 25, 2018.

EMPLOYEES

As of December 31, 2018, we had thirteen full-time employees and two consultants or consulting groups. Our senior management is located in the Seattle, Washington office.

WEBSITE ACCESS TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION REPORTS

We file annual and quarterly reports, proxy statements and other information with the Securities and Exchange Commission ("SEC"). You may read and copy any document we file at the SEC's Public Reference Room at 100 F Street, N.E., Washington D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. The SEC maintains a website at http://www.sec.gov that contains reports, proxy and information statements and other information concerning filers. We also maintain a web site at http://www.knowlabs.co that provides additional information about our Company and links to documents we file with the SEC. The Company's charters for the Audit Committee, the Compensation Committee, and the Nominating Committee; and the Code of Conduct & Ethics are also available on our website. The information on our website is not part of this Form 10-K.

PRIMARY RISKS AND UNCERTAINTIES

We are exposed to various risks related to our need for additional financing, the sale of significant numbers of our shares and a volatile market price for our common stock. These risks and uncertainties are discussed in more detail below in Part II, Item 1A.

RESULTS OF OPERATIONS

The following table presents certain consolidated statement of operations information and presentation of that data as a percentage of change from period-to-period.

(dollars in thousands)

	Three Months Ended December 31,
	2018	2017	$ Variance	% Variance

Revenue	$602	$1,233	$(631)	-51.2%
Cost of sales	472	985	(513)	52.1%
Gross profit	130	248	(118)	-47.6%
Research and development expenses	207	88	119	-135.2%
Selling, general and administrative expenses	689	414	275	-66.4%
Operating loss	(766)	(254)	(512)	2
Other (expense) income:
Interest expense	(9)	(293)	284	96.9%
Other income (expense)	6	19	(13)	68.4%
Total other income (expense)	(3)	(274)	271	98.9%
(Loss) before income taxes	(769)	(528)	(241)	-45.6%
Income taxes - current (benefit)	-	-	-	0.0%
Net (loss)	$(769)	$(528)	$(241)	-45.6%

THREE MONTHS ENDED DECEMBER 31, 2018 COMPARED TO THE THREE MONTHS ENDED DECEMBER 31, 2017

Sales

Net revenue for the three months ended December 31, 2018 decreased $631,000 to $602,000 as compared to $1,233,000 for the three months ended December 31, 2017. The decrease was due to lower sales by TransTech. We have focused TransTech on maximizing profits at the lower sales level.

Cost of Sales

Cost of sales for the three months ended December 31, 2018 decreased $513,000 to $472,000 as compared to $985,000 for the three months ended December 31, 2017. The decrease was due to lower sales by TransTech. We have focused TransTech on maximizing profits at the lower sales level.

Gross profit was $130,000 for the three months ended December 31, 2018 as compared to $248,000 for the three months ended December 31, 2017. Gross profit was 21.6% for the three months ended December 31, 2018 as compared to 20.1% for the three months ended December 31, 2017. We have focused TransTech on maximizing profits at the current sales level.

Research and Development Expenses

Research and development expenses for the three months ended December 31, 2018 increased $119,000 to $207,000 as compared to $88,000 for the three months ended December 31, 2017. The increase was due to expenditures related to the Consulting and Services Agreement with Phillip A. Bosua, our Chief Product Officer for product development, including the development of our Bio-RFID™ technology.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the three months ended December 31, 2018 increased $275,000 to $689,000 as compared to $414,000 for the three months ended December 31, 2017.

The increase primarily was due to (i) increased corporate development expense of $30,000; (ii) increased stock based compensation of $166,000; (iii) increased other expenses of $94,000; offset by (iv) decreased TransTech expenses of $68,000. As part of the selling, general and administrative expenses for the three months ended December 31, 2018, we recorded $61,000 of investor relation expenses and business development expenses.

Other Income (Expense)

Other expense for the three months ended December 31, 2018 was $3,000 as compared to other expense of $274,000 for the three months ended December 31, 2017. The other expense for the three months ended December 31, 2018 included (i) interest expense of $9,000; offset by other income of $6,000.

The other expense for the three months ended December 31, 2017 included (i) interest expense of $293,000; offset by (ii) other expense of $19,000. The interest expense related a senior convertible exchangeable debenture issued on December 12, 2017 in conjunction with a Securities Purchase Agreement dated August 14, 2017.

Net (Loss) Profit

Net loss for the three months ended December 31, 2018 was $769,000 as compared to a net loss of $528,000 for the three months ended December 31, 2017. The net loss for the three months ended December 31, 2018, included non-cash expenses of $235,000. The non-cash items include (i) depreciation and amortization of $62,000; (ii) stock based compensation of $172,000; and (iii) other of $1,000. TransTech’s net loss from operations was $32,000 for the three months ended December 31, 2018 as compared to a net income from operations of 21,000 for the three months ended December 31, 2017.

We expect losses to continue as we commercialize our ChromaID™ and Bio-RFID™technology.

LIQUIDITY AND CAPITAL RESOURCES

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures.

On June 25, 2018, we closed a private placement and received gross proceeds of $1,750,000 ($1,710,000 as of September 30, 2018) in exchange for issuing 7,000,000 (6,840,000 as of September 30, 2018) shares of common stock and warrants to purchase 3,500,000 (3,420,000 as of September 30, 2018) shares of common stock in a private placement to accredited investors pursuant to a series of substantially identical subscription agreements. The initial exercise price of the warrants described above is $0.25 per share, subject to certain adjustments, and they expired five years after their issuance. The shares and the warrants described above were issued in transactions that were not registered under the Securities Act of 1933, as amended (the “Act”) in reliance upon applicable exemptions from registration under Section 4(a)(2) of the Act and/or Rule 506 of SEC Regulation D under the Act.

We had cash of approximately $311,000 and a net working capital deficit of approximately $1,469,000 (net of convertible notes payable and notes payable) as of December 31, 2018. We have experienced net losses since inception and we expect losses to continue as we commercialize our ChromaID™ technology. As of December 31, 2018, we had an accumulated deficit of $35,561,000 and net losses in the amount of 769,000, $3,258,000 and $3,901,000 for the three months ended December 31, 2018 and years ended September 30, 2018 and 2017, respectively. We believe that our cash on hand will be sufficient to fund our operations through February 28, 2019.

The opinion of our independent registered public accounting firm on our audited financial statements as of and for the year ended September 30, 2018 contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is dependent upon raising capital from financing transactions.

We need additional financing to implement our business plan and to service our ongoing operations and pay our current debts. There can be no assurance that we will be able to secure any needed funding, or that if such funding is available, the terms or conditions would be acceptable to us. If we are unable to obtain additional financing when it is needed, we will need to restructure our operations, and divest all or a portion of our business. We may seek additional capital through a combination of private and public equity offerings, debt financings and strategic collaborations. Debt financing, if obtained, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, and could increase our expenses and require that our assets secure such debt. Equity financing, if obtained, could result in dilution to our then-existing stockholders and/or require such stockholders to waive certain rights and preferences. If such financing is not available on satisfactory terms, or is not available at all, we may be required to delay, scale back, eliminate the development of business opportunities or file for bankruptcy and our operations and financial condition may be materially adversely affected.

We have financed our corporate operations and our technology development through the issuance of convertible debentures, the issuance of preferred stock, the sale common stock, issuance of common stock in conjunction with an equity line of credit, loans by our Chairman and the exercise of warrants.

We finance our TransTech operations from operations and a Secured Credit Facility with Capital Source Business Finance Group. On June 15, 2018, TransTech entered into a Fifth Modification to the Loan and Security Agreement related to the $500,000 secured credit facility with Capital Source to fund its operations. The Modification extended the maturity to December 12, 2018. The secured credit facility provides for a prime rate interest floor for prime interest of 4.5% plus 2.5%. The eligible borrowing is based on 80% of eligible trade accounts receivable, not to exceed $500,000. The secured credit facility is collateralized by the assets of TransTech, with a guarantee by Know Labs, including a security interest in all assets of Know Labs. The remaining balance on the accounts receivable must be repaid by the time the secured credit facility expires on December 12, 2018, unless we renew by automatic extension for the next successive term. TransTech has $23,000 available as of December 31, 2018.

Operating Activities

Net cash used in operating activities for the three months ended December 31, 2018 was $522,000. This amount was primarily related to (i) a net loss of $769,000; (ii) a decrease in deferred revenue of $56,000; and (iii) a decrease in accounts payable and accrued expenses of $95,000 offset by (iv) a decrease in accounts receivable of $113,000; (v) other of $49,000; and (vi) non-cash expenses of $235,000. The non-cash items include (vii) depreciation and amortization of $62,000; (viii) stock based compensation of $172,000; and (ix) other of $1,000.

Investing Activities

Net cash used in investing activities for the three months ended December 31, 2018 was $3,000. This amount was primarily related to the investment in equipment for the lab.

Financing Activities

Net cash used in financing activities for the three months ended December 31, 2018 was $99,000. This amount was primarily related to repayments of line of credit of $99,000.

Our contractual cash obligations as of December 31, 2018 are summarized in the table below:

		Less Than			Greater Than
Contractual Cash Obligations	Total	1 Year	1-3 Years	3-5 Years	5 Years
Operating leases	$193,249	$106,190	$72,519	$14,540	$-
Convertible notes payable	2,255,066	2,255,066	-	-	-
Notes payable	46,576	46,576	-	-	-
Capital expenditures	280,000	60,000	110,000	110,000	-
	$2,774,891	$2,467,832	$182,519	$124,540	$-

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements (as that term is defined in Item 303 of Regulation S-K) that are reasonably likely to have a current or future material effect on our financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

This item is not applicable.

ITEM 4.

CONTROLS AND PROCEDURES

a) Evaluation of Disclosure Controls and Procedures

We conducted an evaluation, under the supervision and with the participation of our management, of the effectiveness of the design and operation of our disclosure controls and procedures. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures also include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our principal executive and principal financial officers concluded as of December 31, 2018 that our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses in our internal controls over financial reporting discussed immediately below.

Identified Material Weakness

A material weakness in our internal control over financial reporting is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the financial statements will not be prevented or detected.

Management identified the following material weakness during its assessment of internal controls over financial reporting:

Personnel: We do not employ a full time Chief Financial Officer. Our Chairman serves as interim Chief Financial Officer. We utilize a consultant to assist with our financial reporting.

Audit Committee: While we have an audit committee, we lack a financial expert. During 2019, the Board expects to appoint an additional independent Director to serve as Audit Committee Chairman who is an “audit committee financial expert” as defined by the Securities and Exchange Commission (“SEC”) and as adopted under the Sarbanes-Oxley Act of 2002.

(b) Management's Report on Internal Control Over Financial Reporting.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is a process designed by, or under the supervision of, our CEO and CFO, or persons performing similar functions, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America (GAAP). Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and disposition of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP and that receipts and expenditures of the Company are being made only in accordance with authorization of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.

Management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2018. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in the 2013 Internal Control-Integrated Framework. Based on its evaluation, management has concluded that the Company’s internal control over financial reporting was not effective as of December 31, 2018.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. A control system, no matter how well designed and operated can provide only reasonable, but not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their cost.

c) Changes in Internal Control over Financial Reporting

During the three months ended December 31, 2018, there were no changes in our internal controls over financial reporting during this fiscal quarter that materially affected, or is reasonably likely to have a materially affect, on our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

We may from time to time become a party to various legal proceedings arising in the ordinary course of our business. We are currently not a party to any pending legal proceeding that is not ordinary routine litigation incidental to our business.

ITEM 1A.

RISK FACTORS

There are certain inherent risks which will have an effect on the Company’s development in the future and the most significant risks and uncertainties known and identified by our management are described below.

RISK FACTORS

Risks Relating to the Company Generally

We need additional financing to support our technology development and ongoing operations, pay our debts and maintain ownership of our intellectual properties.

We are currently operating at a loss. We believe that our cash on hand will be sufficient to fund our operations through February 28, 2019. We need additional financing to implement our business plan and to service our ongoing operations, pay our current debts (described below) and maintain ownership of our intellectual property. There can be no assurance that we will be able to secure any needed funding, or that if such funding is available, the terms or conditions would be acceptable to us. If we are unable to obtain additional financing when it is needed, we will need to restructure our operations and/or divest all or a portion of our business. We may seek additional capital through a combination of private and public equity offerings, debt financings and strategic collaborations. Debt financing, if obtained, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, and could increase our expenses and require that our assets secure such debt. Equity financing, if obtained, could result in dilution to our then-existing stockholders and/or require such stockholders to waive certain rights and preferences. If such financing is not available on satisfactory terms, or is not available at all, we may be required to delay, scale back, eliminate the development of business opportunities or file for bankruptcy and our operations and financial condition may be materially adversely affected. There can there can be no assurance that we will be able to sell that number of shares, if any.

We need to continue as a going concern if our business is to succeed.

Because of our recurring losses and negative cash flows from operations, the audit report of our independent registered public accountants on our consolidated financial statements for the year ended September 30, 2018 contains an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern. Factors identified in the report include our historical net losses, negative working capital, and the need for additional financing to implement our business plan and service our debt repayments. If we are not able to attain profitability in the near future our financial condition could deteriorate further, which would have a material adverse impact on our business and prospects and result in a significant or complete loss of your investment. Further, we may be unable to pay our debt obligations as they become due, which include obligations to secured creditors. If we are unable to continue as a going concern, we might have to liquidate our assets and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements. Additionally, we are subject to customary operational covenants, including limitations on our ability to incur liens or additional debt, pay dividends, redeem stock, make specified investments and engage in merger, consolidation or asset sale transactions, among other restrictions. In addition, the inclusion of an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern and our lack of cash resources may materially adversely affect our share price and our ability to raise new capital or to enter into critical contractual relations with third parties.

As of December 31, 2018, we owe approximately $2,831,744 and if we do not satisfy these obligations, the lenders may have the right to demand payment in full or exercise other remedies.

On March 16, 2018, we closed a Note and Account Payable Conversion Agreement with J3E2A2Z, a Washington limited partnership, Ronald P. Erickson, our Executive Chairman of the Board and a member of the Board of Directors pursuant to which (a) all $664,233 currently owing under the J3E2A2Z Notes was converted to a Convertible Redeemable Promissory Note in the principal amount of $664,233, and (b) all $519,833 of the J3E2A2Z Account Payable was converted into a Convertible Redeemable Promissory Note in the principal amount of $519,833.

Mr. Erickson and/or entities with which he is affiliated also have accrued compensation and interest of approximately $530,102. The Company owes Mr. Erickson, or entities with which he is affiliated, $1,714,168 as of December 31, 2018.

On July 9, 2018, the Company repaid a $199,935 Business Loan Agreement with Umpqua Bank from funds previously provided by an entity affiliated with Ronald P. Erickson, our Chairman of the Board. The Company paid $27,041 and issued 800,000 shares of common stock in exchange for the conversion of this debt. Mr. Erickson is an accredited investor. These shares were issued in transactions that were not registered under the Act in reliance upon applicable exemptions from registration under Section 4(a)(2) of the Act and/or Rule 506 of SEC Regulation D under the Act.

Including Mr. Erickson, we owe $2,255,066 under various convertible promissory notes as of December 31, 2018.

We owe Capital Source $46,576 under a credit facility.

We require additional financing, to service and/or repay these debt obligations. If we raise additional capital through borrowing or other debt financing, we may incur substantial interest expense. If and when we raise more equity capital in the future, it will result in substantial dilution to our current stockholders.

We have a history of operating losses and there can be no assurance that we can achieve or maintain profitability.

We have experienced net losses since inception. As of December 31, 2018, we had an accumulated deficit of $35,561,000 and net losses in the amount of $769,000, $3,258,000 and $3,901,000 for the three months ended December 31, 2018 and years ended September 30, 2018 and 2017, respectively. There can be no assurance that we will achieve or maintain profitability. If we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Failure to become and remain profitable would impair our ability to sustain operations and adversely affect the price of our common stock and our ability to raise capital. Our operating expenses may increase as we spend resources on growing our business, and if our revenue does not correspondingly increase, our operating results and financial condition will suffer. Our ChromaID business has produced minimal revenues, and may not produce significant revenues in the near term, or at all, which would harm our ability to continue our operations or obtain additional financing and require us to reduce or discontinue our operations. You must consider our business and prospects in light of the risks and difficulties we will encounter as business with an early-stage technology in a new and rapidly evolving industry. We may not be able to successfully address these risks and difficulties, which could significantly harm our business, operating results and financial condition.

If the company were to dissolve or wind-up operations, holders of our common stock would not receive a liquidation preference.

If we were to wind-up or dissolve our company and liquidate and distribute our assets, our common stockholders would share in our assets only after we satisfy any amounts we owe to our creditors and preferred equity holders. If our liquidation or dissolution were attributable to our inability to profitably operate our business, then it is likely that we would have material liabilities at the time of liquidation or dissolution. Accordingly, it is very unlikely that sufficient assets will remain available after the payment of our creditors and preferred equity holders to enable common stockholders to receive any liquidation distribution with respect to any common stock.

We may not be able to generate sufficient revenue from the commercialization of our ChromaID and Bio-RFID technology and related products to achieve or sustain profitability.

We are in the early stages of commercializing our ChromaID and Bio-RFID technology. Failure to develop and sell products based upon our ChromaID and Bio-RFID technology, grant additional licenses and obtain royalties or develop other revenue streams will have a material adverse effect on our business, financial condition and results of operations.

To date, we have generated minimal revenue from sales of our products. We believe that our commercialization success is dependent upon our ability to significantly increase the number of customers that are using our products. In addition, demand for our products may not materialize, or increase as quickly as planned, and we may therefore be unable to increase our revenue levels as expected. We are currently not profitable. Even if we succeed in introducing our technology and related products to our target markets, we may not be able to generate sufficient revenue to achieve or sustain profitability.

We currently rely in part upon external resources for engineering and product development services. If we are unable to secure an engineering or product development partner or establish satisfactory engineering and product development capabilities, we may not be able to successfully commercialize our ChromaID and Bio-RFID technology.

Our success depends upon our ability to develop products that are accurate and provide solutions for our customers. Achieving the desired results for our customers requires solving engineering issues in concert with them. Any failure of our ChromaID and Bio-RFID technology or related products to meet customer expectations could result in customers choosing to retain their existing methods or to adopt systems other than ours.

We have not historically had sufficient internal resources which can work on engineering and product development matters. We have used third parties in the past and will continue to do so. These resources are not always readily available and the absence of their availability could inhibit our research and development efforts and our responsiveness to our customers. Our inability to secure those resources could impact our ability to provide engineering and product development services and could have an impact on our customers’ willingness to use our technology.

We are in the early stages of commercialization and our ChromaID and Bio-RFID technology and related products may never achieve significant commercial market acceptance.

Our success depends on our ability to develop and market products that are recognized as accurate and cost-effective. Many of our potential customers may be reluctant to use our new technology. Market acceptance will depend on many factors, including our ability to convince potential customers that our ChromaID and Bio-RFID technology and related products are an attractive alternative to existing light-based technologies. We will need to demonstrate that our products provide accurate and cost-effective alternatives to existing light-based authentication technologies. Compared to most competing technologies, our technology is relatively new, and most potential customers have limited knowledge of, or experience with, our products. Prior to implementing our technology and related products, potential customers are required to devote significant time and effort to testing and validating our products. In addition, during the implementation phase, customers may be required to devote significant time and effort to training their personnel on appropriate practices to ensure accurate results from our technology and products. Any failure of our technology or related products to meet customer expectations could result in customers choosing to retain their existing testing methods or to adopt systems other than ours.

Many factors influence the perception of a system including its use by leaders in the industry. If we are unable to induce industry leaders in our target markets to implement and use our technology and related products, acceptance and adoption of our products could be slowed. In addition, if our products fail to gain significant acceptance in the marketplace and we are unable to expand our customer base, we may never generate sufficient revenue to achieve or sustain profitability.

Our management has concluded that we have material weaknesses in our internal controls over financial reporting and that our disclosure controls and procedures are not effective.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company's annual or interim financial statements will not be prevented or detected on a timely basis. During the audit of our financial statements for the year ended September 30, 2018, our management identified material weaknesses in our internal control over financial reporting. If these weaknesses continue, investors could lose confidence in the accuracy and completeness of our financial reports and other disclosures.

In addition, our management has concluded that our disclosure controls and procedures were not effective due to the lack of an audit committee “financial expert.” These material weaknesses, if not remediated, create an increased risk of misstatement of the Company’s financial results, which, if material, may require future restatement thereof. A failure to implement improved internal controls, or difficulties encountered in their implementation or execution, could cause future delays in our reporting obligations and could have a negative effect on us and the trading price of our common stock.

Our services and license agreement with Allied Inventors is important to our business strategy and operations.

In November 2013, we entered into a five-year strategic relationship with Allied Inventors, formerly Xinova and Invention Development Management Company, a former subsidiary of Intellectual Ventures, a private intellectual property fund with over $5 billion under management. Allied Inventors owns over 40,000 IP assets and has broad global relationships for the invention of technology, the filing of patents and the licensing of intellectual property. Allied Inventors has worked to expand the reach and the potential application of the ChromaID technology and has filed ten patents based on the ChromaID technology, which it has licensed to us.

The amended agreement with Allied Inventors covers a number of areas that are important to our operations, including the following:

● The agreement requires Allied Inventors to identify and engage inventors to develop new applications of our ChromaID technology, present the developments to us for approval, and file at least ten patent applications to protect the developments;

● We received a worldwide, nontransferable, exclusive license to the licensed intellectual property developed under this agreement within the identification, authentication and diagnostics field of use;

● We received a nonexclusive and nontransferable option to acquire a worldwide, nontransferable, nonexclusive license to intellectual property held by Allied Inventors within that same field of use; and

● We granted to Allied Inventors certain licenses to our intellectual property outside the identification, authentication and diagnostics field of use.

Failure to operate in accordance with the Allied Inventors agreement, or an early termination or cancellation of this agreement for any reason, would have a material adverse effect on ability to execute our business strategy and on our results of operations and business.

If components used in our finished products become unavailable, or third-party manufacturers otherwise experience delays, we may incur delays in shipment to our customers, which would damage our business.

We depend on third-party suppliers for substantially all of our components and products. We purchase these products and components from third-party suppliers that serve the advanced lighting systems market and we believe that alternative sources of supply are readily available for most products and components. However, consolidation could result in one or more current suppliers being acquired by a competitor, rendering us unable to continue purchasing necessary amounts of key components at competitive prices. In addition, for certain of our customized components, arrangements for additional or replacement suppliers will take time and result in delays. We purchase products and components pursuant to purchase orders placed from time to time in the ordinary course of business. This means we are vulnerable to unanticipated price increases and product shortages. Any interruption or delay in the supply of components and products, or our inability to obtain components and products from alternate sources at acceptable prices in a timely manner, could harm our business, financial condition and results of operations.

While we believe alternative manufacturers for these products are available, we have selected these particular manufacturers based on their ability to consistently produce these products per our specifications ensuring the best quality product at the most cost-effective price. We depend on our third-party manufacturers to satisfy performance and quality specifications and to dedicate sufficient production capacity within scheduled delivery times. Accordingly, the loss of all or one of these manufacturers or delays in obtaining shipments could have a material adverse effect on our operations until such time as an alternative manufacturer could be found.

We are dependent on key personnel.

Our success depends to a significant degree upon the continued contributions of key management and other personnel, some of whom could be difficult to replace, including Ronald P. Erickson, our Chairman and Phil Bosua, our Chief Executive Officer. We do not maintain key person life insurance covering any of our officers. Our success will depend on the performance of our officers, our ability to retain and motivate our officers, our ability to integrate new officers into our operations, and the ability of all personnel to work together effectively as a team. Our officers do not currently have employment agreements. Our failure to retain and recruit officers and other key personnel could have a material adverse effect on our business, financial condition and results of operations. Our success also depends on our continued ability to identify, attract, hire, train, retain and motivate highly skilled technical, managerial, manufacturing, administrative and sales and marketing personnel. Competition for these individuals is intense, and we may not be able to successfully recruit, assimilate or retain sufficiently qualified personnel. In particular, we may encounter difficulties in recruiting and retaining a sufficient number of qualified technical personnel, which could harm our ability to develop new products and adversely impact our relationships with existing and future customers. The inability to attract and retain necessary technical, managerial, manufacturing, administrative and sales and marketing personnel could harm our ability to obtain new customers and develop new products and could adversely affect our business and operating results.

We have limited insurance which may not cover claims by third parties against us or our officers and directors.

We have limited directors’ and officers’ liability insurance and commercial liability insurance policies. Claims by third parties against us may exceed policy amounts and we may not have amounts to cover these claims. Any significant claims would have a material adverse effect on our business, financial condition and results of operations. In addition, our limited directors’ and officers’ liability insurance may affect our ability to attract and retain directors and officers.

Our inability to effectively protect our intellectual property would adversely affect our ability to compete effectively, our revenue, our financial condition and our results of operations.

We rely on a combination of patent, trademark, and trade secret laws, confidentiality procedures and licensing arrangements to protect our intellectual property rights. Obtaining and maintaining a strong patent position is important to our business. Patent law relating to the scope of claims in the technology fields in which we operate is complex and uncertain, so we cannot be assured that we will be able to obtain or maintain patent rights, or that the patent rights we may obtain will be valuable, provide an effective barrier to competitors or otherwise provide competitive advantages. Others have filed, and in the future are likely to file, patent applications that are similar or identical to ours or those of our licensors. To determine the priority of inventions, or demonstrate that we did not derive our invention from another, we may have to participate in interference or derivation proceedings in the USPTO or in court that could result in substantial costs in legal fees and could substantially affect the scope of our patent protection. We cannot be assured our patent applications will prevail over those filed by others. Also, our intellectual property rights may be subject to other challenges by third parties. Patents we obtain could be challenged in litigation or in administrative proceedings such as ex parte reexam, inter parties review, or post grant review in the United States or opposition proceedings in Europe or other jurisdictions.

There can be no assurance that:

●	any of our existing patents will continue to be held valid, if challenged;
●	patents will be issued for any of our pending applications;
●	any claims allowed from existing or pending patents will have sufficient scope or strength to protect us;
●	our patents will be issued in the primary countries where our products are sold in order to protect our rights and potential commercial advantage; or
●	any of our products or technologies will not infringe on the patents of other companies.

If we are enjoined from selling our products, or if we are required to develop new technologies or pay significant monetary damages or are required to make substantial royalty payments, our business and results of operations would be harmed.

Obtaining and maintaining a patent portfolio entails significant expense and resources. Part of the expense includes periodic maintenance fees, renewal fees, annuity fees, various other governmental fees on patents and/or applications due in several stages over the lifetime of patents and/or applications, as well as the cost associated with complying with numerous procedural provisions during the patent application process. We may or may not choose to pursue or maintain protection for particular inventions. In addition, there are situations in which failure to make certain payments or noncompliance with certain requirements in the patent process can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we choose to forgo patent protection or allow a patent application or patent to lapse purposefully or inadvertently, our competitive position could suffer.

Legal actions to enforce our patent rights can be expensive and may involve the diversion of significant management time. In addition, these legal actions could be unsuccessful and could also result in the invalidation of our patents or a finding that they are unenforceable. We may or may not choose to pursue litigation or interferences against those that have infringed on our patents, or used them without authorization, due to the associated expense and time commitment of monitoring these activities. If we fail to protect or to enforce our intellectual property rights successfully, our competitive position could suffer, which could have a material adverse effect on our results of operations and business.

Claims by others that our products infringe their patents or other intellectual property rights could prevent us from manufacturing and selling some of our products or require us to pay royalties or incur substantial costs from litigation or development of non-infringing technology.

In recent years, there has been significant litigation in the United States involving patents and other intellectual property rights. We may receive notices that claim we have infringed upon the intellectual property of others. Even if these claims are not valid, they could subject us to significant costs. Any such claims, with or without merit, could be time-consuming to defend, result in costly litigation, divert our attention and resources, cause product shipment delays or require us to enter into royalty or licensing agreements. Such royalty or licensing agreements, if required, may not be available on terms acceptable to us or at all. We have engaged in litigation and litigation may be necessary in the future to enforce our intellectual property rights or to determine the validity and scope of the proprietary rights of others. Litigation may also be necessary to defend against claims of infringement or invalidity by others. A successful claim of intellectual property infringement against us and our failure or inability to license the infringed technology or develop or license technology with comparable functionality could have a material adverse effect on our business, financial condition and operating results.

We currently have a very small sales and marketing organization at our TransTech Systems subsidiary. If we are unable to secure a sales and marketing partner or establish satisfactory sales and marketing capabilities at the Know Labs parent Company level we may not be able to successfully commercialize our ChromaID and Bio-RFID technology.

Our subsidiary, TransTech Systems, has six sales and marketing employees on staff to support the ongoing sales efforts of that business. In order to commercialize products that are approved for commercial sales, we sell directly to our customers, collaborate with third parties that have such commercial infrastructure and work with our strategic business partners to generate sales. If we are not successful entering into appropriate collaboration arrangements, or recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty successfully commercializing our ChromaID and Bio-RFID technology, which would adversely affect our business, operating results and financial condition.

We may not be able to enter into collaboration agreements on terms acceptable to us or at all. In addition, even if we enter into such relationships, we may have limited or no control over the sales, marketing and distribution activities of these third parties. Our future revenues may depend heavily on the success of the efforts of these third parties. If we elect to establish a sales and marketing infrastructure we may not realize a positive return on this investment. In addition, we must compete with established and well-funded pharmaceutical and biotechnology companies to recruit, hire, train and retain sales and marketing personnel. Factors that may inhibit our efforts to commercialize ChromaID and Bio-RFID without strategic partners or licensees include:

●	our inability to recruit and retain adequate numbers of effective sales and marketing personnel;

●	the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and

●	unforeseen costs and expenses associated with creating an independent sales and marketing organization.

Government regulatory approval may be necessary before some of our products can be sold and there is no assurance such approval will be granted.

Our ChromaID and Bio-RFID technology may have a number of potential applications in fields of use which will require prior governmental regulatory approval before the technology can be introduced to the marketplace. For example, we are exploring the use of our ChromaID and Bio-RFID technology for certain medical diagnostic applications, with an initial focus on the continuous monitoring of blood glucose.

There is no assurance that we will be successful in developing continuous glucose monitoring medical applications for our technology.

If we were to be successful in developing continuous glucose monitoring medical applications of our technology, prior approval by the FDA and other governmental regulatory bodies will be required before the technology could be introduced into the marketplace.

There is no assurance that such regulatory approval would be obtained for a continuous glucose monitoring medical diagnostic or other applications requiring such approval.

The FDA can refuse to grant, delay, limit or deny approval of an application for approval of our UBAND CGM for many reasons.

We may not obtain the necessary regulatory approvals or clearances to market these continuous glucose monitoring systems in the United States or outside of the United States.

Any delay in, or failure to receive or maintain, approval or clearance for our products could prevent us from generating revenue from these products or achieving profitability.

Cybersecurity risks and cyber incidents could result in the compromise of confidential data or critical data systems and give rise to potential harm to customers, remediation and other expenses, expose us to liability under HIPAA, consumer protection laws, or other common law theories, subject us to litigation and federal and state governmental inquiries, damage our reputation, and otherwise be disruptive to our business and operations.

Cyber incidents can result from deliberate attacks or unintentional events. We collect and store on our networks sensitive information, including intellectual property, proprietary business information and personally identifiable information of our customers. The secure maintenance of this information and technology is critical to our business operations. We have implemented multiple layers of security measures to protect the confidentiality, integrity and availability of this data and the systems and devices that store and transmit such data. We utilize current security technologies, and our defenses are monitored and routinely tested internally and by external parties. Despite these efforts, threats from malicious persons and groups, new vulnerabilities and advanced new attacks against information systems create risk of cybersecurity incidents. These incidents can include, but are not limited to, gaining unauthorized access to digital systems for purposes of misappropriating assets or sensitive information, corrupting data, or causing operational disruption. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and may not immediately produce signs of intrusion, we may be unable to anticipate these incidents or techniques, timely discover them, or implement adequate preventative measures.

These threats can come from a variety of sources, ranging in sophistication from an individual hacker to malfeasance by employees, consultants or other service providers to state-sponsored attacks. Cyber threats may be generic, or they may be custom-crafted against our information systems. Over the past several years, cyber-attacks have become more prevalent and much harder to detect and defend against. Our network and storage applications may be vulnerable to cyber-attack, malicious intrusion, malfeasance, loss of data privacy or other significant disruption and may be subject to unauthorized access by hackers, employees, consultants or other service providers. In addition, hardware, software or applications we develop or procure from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise information security. Unauthorized parties may also attempt to gain access to our systems or facilities through fraud, trickery or other forms of deceiving our employees, contractors and temporary staff.

There can be no assurance that we will not be subject to cybersecurity incidents that bypass our security measures, impact the integrity, availability or privacy of personal health information or other data subject to privacy laws or disrupt our information systems, devices or business, including our ability to deliver services to our customers. As a result, cybersecurity, physical security and the continued development and enhancement of our controls, processes and practices designed to protect our enterprise, information systems and data from attack, damage or unauthorized access remain a priority for us. As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any cybersecurity vulnerabilities.

We may engage in acquisitions, mergers, strategic alliances, joint ventures and divestures that could result in final results that are different than expected.

In the normal course of business, we engage in discussions relating to possible acquisitions, equity investments, mergers, strategic alliances, joint ventures and divestitures. Such transactions are accompanied by a number of risks, including the use of significant amounts of cash, potentially dilutive issuances of equity securities, incurrence of debt on potentially unfavorable terms as well as impairment expenses related to goodwill and amortization expenses related to other intangible assets, the possibility that we may pay too much cash or issue too many of our shares as the purchase price for an acquisition relative to the economic benefits that we ultimately derive from such acquisition, and various potential difficulties involved in integrating acquired businesses into our operations.

From time to time, we have also engaged in discussions with candidates regarding the potential acquisitions of our product lines, technologies and businesses. If a divestiture such as this does occur, we cannot be certain that our business, operating results and financial condition will not be materially and adversely affected. A successful divestiture depends on various factors, including our ability to effectively transfer liabilities, contracts, facilities and employees to any purchaser; identify and separate the intellectual property to be divested from the intellectual property that we wish to retain; reduce fixed costs previously associated with the divested assets or business; and collect the proceeds from any divestitures.

If we do not realize the expected benefits of any acquisition or divestiture transaction, our financial position, results of operations, cash flows and stock price could be negatively impacted.

Our growth strategy depends in part on our ability to execute successful strategic acquisitions. We have made strategic acquisitions in the past and may do so in the future, and if the acquired companies do not perform as expected, this could adversely affect our operating results, financial condition and existing business.

We may continue to expand our business through strategic acquisitions. The success of any acquisition will depend on, among other things:

●

the availability of suitable candidates;

●

higher than anticipated acquisition costs and expenses;

●

competition from other companies for the purchase of available candidates;

●

our ability to value those candidates accurately and negotiate favorable terms for those acquisitions;

●

the availability of funds to finance acquisitions and obtaining any consents necessary under our credit facility;

●

the ability to establish new informational, operational and financial systems to meet the needs of our business;

●

the ability to achieve anticipated synergies, including with respect to complementary products or services; and

●

the availability of management resources to oversee the integration and operation of the acquired businesses.

We may not be successful in effectively integrating acquired businesses and completing acquisitions in the future. We also may incur substantial expenses and devote significant management time and resources in seeking to complete acquisitions. Acquired businesses may fail to meet our performance expectations. If we do not achieve the anticipated benefits of an acquisition as rapidly as expected, or at all, investors or analysts may not perceive the same benefits of the acquisition as we do. If these risks materialize, our stock price could be materially adversely affected.

We are subject to corporate governance and internal control requirements, and our costs related to compliance with, or our failure to comply with existing and future requirements could adversely affect our business.

We must comply with corporate governance requirements under the Sarbanes-Oxley Act of 2002 and the Dodd–Frank Wall Street Reform and Consumer Protection Act of 2010, as well as additional rules and regulations currently in place and that may be subsequently adopted by the SEC and the Public Company Accounting Oversight Board. These laws, rules, and regulations continue to evolve and may become increasingly stringent in the future. The financial cost of compliance with these laws, rules, and regulations is expected to remain substantial.

Our management has concluded that our disclosure controls and procedures were not effective due to the lack of an audit committee “financial expert.” We expect to appoint an additional independent director to serve as Audit Committee Chairman. This director will be an “audit committee financial expert” as defined by the SEC. However, we cannot assure you that we will be able to fully comply with these laws, rules, and regulations that address corporate governance, internal control reporting, and similar matters in the future. Failure to comply with these laws, rules and regulations could materially adversely affect our reputation, financial condition, and the value of our securities.

The Capital Source credit facility with TransTech contains covenants that may limit our flexibility in operating our business and failure to comply with any of these covenants could have a material adverse effect on our business.

In December 8, 2009, we entered into the Capital Source credit facility. On December 6, 2018, Capital Source notified TransTech that the Loan and Security Agreement and Capital Source Credit Facility would be cancelled as of March 12, 2019. Effective December 12, 2018, TransTech entered into the Sixth Modification to the Loan and Security Agreement which reduced the secured credit facility to $200,000.

This Capital Source credit facility contains covenants that limit our ability to engage in specified types of transactions. These covenants limit our ability to, among other things:

●

sell, transfer, lease or dispose of certain assets;

●

engage in certain mergers and consolidations;

●

incur debt or encumber or permit liens on certain assets, except in the limited circumstances permitted under the loan and security agreements;

●

make certain restricted payments, including paying dividends on, or repurchasing or making distributions with respect to, our common stock; and

●

enter into certain transactions with affiliates.

A breach of any of the covenants under the Capital Source credit facility could result in a default under the Capital Source credit facility. Upon the occurrence of an event of default under the Capital Source credit facility, the lenders could elect to declare all amounts outstanding to be immediately due and payable and terminate all commitments to extend further credit. If we are unable to repay those amounts, the lenders could proceed against the collateral granted to them to secure such indebtedness. We expect to replace the credit facility by March 12, 2019.

Our wholly-owned TransTech subsidiary revenues are declining

The financial results from our TransTech subsidiary have been diminishing as vendors of their products increasingly move to the Internet and direct sales to their customers. While it does provide our current revenues, it is not central to our current focus as a Company. Moreover, we have written down any goodwill associated with its historic acquisition. We continue to closely monitor this subsidiary. We may not be able to successfully address this revenue decline, which could significantly harm our business, operating results and financial condition and result in winding down this subsidiary.

The exercise prices of certain warrants, convertible notes payable and the Series A, C, and D Preferred Shares may require further adjustment.

In the future, if we sell our common stock at a price below $0.25 per share, the exercise price of 20,000 outstanding shares of Series A Preferred Stock, 1,785,715 outstanding shares of Series C Preferred Stock, 3,108,356 outstanding shares Series D Preferred Stock that adjust below $0.25 per share pursuant to the documents governing such instruments. In addition, the conversion price of a Convertible Note Payable of $2,255,066 (currently 9,020,264 at $0.25 per share) and the exercise price of additional outstanding warrants to purchase 12,714,385 shares of common stock would adjust below $0.25 per share pursuant to the documents governing such instruments.

Risks Relating to Our Stock

The price of our common stock is volatile, which may cause investment losses for our stockholders.

The market price of our common stock has been and is likely in the future to be volatile. Our common stock price may fluctuate in response to factors such as:

	●	Announcements by us regarding liquidity, significant acquisitions, equity investments and divestitures, strategic relationships, addition or loss of significant customers and contracts, capital expenditure commitments and litigation;
	●	Issuance of convertible or equity securities and related warrants for general or merger and acquisition purposes;
	●	Issuance or repayment of debt, accounts payable or convertible debt for general or merger and acquisition purposes;
	●	Sale of a significant number of shares of our common stock by stockholders;
	●	General market and economic conditions;
	●	Quarterly variations in our operating results;
	●	Investor and public relation activities;
	●	Announcements of technological innovations;
	●	New product introductions by us or our competitors;
	●	Competitive activities; and
	●	Additions or departures of key personnel.

These broad market and industry factors may have a material adverse effect on the market price of our common stock, regardless of our actual operating performance. These factors could have a material adverse effect on our business, financial condition and results of operations.

Transfers of our securities may be restricted by virtue of state securities “blue sky” laws, which prohibit trading absent compliance with individual state laws. These restrictions may make it difficult or impossible to sell shares in those states.

Transfers of our common stock may be restricted under the securities or securities regulations laws promulgated by various states and foreign jurisdictions, commonly referred to as “blue sky” laws. Absent compliance with such individual state laws, our common stock may not be traded in such jurisdictions. Because the securities held by many of our stockholders have not been registered for resale under the blue sky laws of any state, the holders of such shares and persons who desire to purchase them should be aware that there may be significant state blue sky law restrictions upon the ability of investors to sell the securities and of purchasers to purchase the securities. These restrictions may prohibit the secondary trading of our common stock. Investors should consider the secondary market for our securities to be a limited one.

Three individual investors could have significant influence over matters submitted to stockholders for approval.

As of December 31, 2018, four individuals in the aggregate, assuming the exercise of all warrants to purchase common stock, hold shares representing approximately 61% of our common stock on a fully-converted basis and could be considered a control group for purposes of SEC rules. However, the agreement with one of these individuals limits his ownership to 4.99% individually. Beneficial ownership includes shares over which an individual or entity has investment or voting power and includes shares that could be issued upon the exercise of options and warrants within 60 days after the date of determination. If these persons were to choose to act together, they would be able to significantly influence all matters submitted to our stockholders for approval, as well as our officers, directors, management and affairs. For example, these persons, if they choose to act together, could significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of us on terms that other stockholders may desire.

The sale of a significant number of our shares of common stock could depress the price of our common stock.

Sales or issuances of a large number of shares of common stock in the public market or the perception that sales may occur could cause the market price of our common stock to decline. As of December 31, 2018, we had 17,811,431 shares of common stock issued and outstanding, held by 123 stockholders of record. The number of stockholders, including beneficial owners holding shares through nominee names, is approximately 2,300. Each share of common stock entitles its holder to one vote on each matter submitted to the stockholders for a vote, and no cumulative voting for directors is permitted. Stockholders do not have any preemptive rights to acquire additional securities issued by us. As of December 31, 2018, there were options outstanding for the purchase of 2,282,668 common shares, warrants for the purchase of 15,173,398 common shares, and 4,914,071 shares of our common stock issuable upon the conversion of Series A, Series C and Series D Convertible Preferred Stock. In addition, we have an unknown number of shares (9,020,264 common shares at the current price of $0.25 per share) are issuable upon conversion of convertible debentures of $2,255,066. All of which could potentially dilute future earnings per share.

Significant shares of common stock are held by our principal stockholders, other company insiders and other large stockholders. As “affiliates” of Know Labs, as defined under Securities and Exchange Commission Rule 144 under the Securities Act of 1933, our principal stockholders, other of our insiders and other large stockholders may only sell their shares of common stock in the public market pursuant to an effective registration statement or in compliance with Rule 144.

These options, warrants, convertible notes payable and convertible preferred stock could result in further dilution to common stock holders and may affect the market price of the common stock.

Future issuance of additional shares of common stock and/or preferred stock could dilute existing stockholders. We have and may issue preferred stock that could have rights that are preferential to the rights of common stock that could discourage potentially beneficially transactions to our common stockholders.

Pursuant to our certificate of incorporation, we currently have authorized 100,000,000 shares of common stock and 5,000,000 shares of preferred stock. To the extent that common shares are available for issuance, subject to compliance with applicable stock exchange listing rules, our board of directors has the ability to issue additional shares of common stock in the future for such consideration as the board of directors may consider sufficient. The issuance of any additional securities could, among other things, result in substantial dilution of the percentage ownership of our stockholders at the time of issuance, result in substantial dilution of our earnings per share and adversely affect the prevailing market price for our common stock.

An issuance of additional shares of preferred stock could result in a class of outstanding securities that would have preferences with respect to voting rights and dividends and in liquidation over our common stock and could, upon conversion or otherwise, have all of the rights of our common stock. Our Board of Directors’ authority to issue preferred stock could discourage potential takeover attempts or could delay or prevent a change in control through merger, tender offer, proxy contest or otherwise by making these attempts more difficult or costly to achieve. The issuance of preferred stock could impair the voting, dividend and liquidation rights of common stockholders without their approval.

Future capital raises may dilute our existing stockholders’ ownership and/or have other adverse effects on our operations.

If we raise additional capital by issuing equity securities, our existing stockholders’ percentage ownership will be reduced and these stockholders may experience substantial dilution. We may also issue equity securities that provide for rights, preferences and privileges senior to those of our common stock. If we raise additional funds by issuing debt securities, these debt securities would have rights senior to those of our common stock and the terms of the debt securities issued could impose significant restrictions on our operations, including liens on our assets. If we raise additional funds through collaborations and licensing arrangements, we may be required to relinquish some rights to our technologies or candidate products, or to grant licenses on terms that are not favorable to us.

We do not anticipate paying any cash dividends on our capital stock in the foreseeable future.

We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business, and we do not anticipate paying any cash dividends on our capital stock in the foreseeable future. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.

Anti-takeover provisions may limit the ability of another party to acquire our company, which could cause our stock price to decline.

Our certificate of incorporation, as amended, our bylaws and Nevada law contain provisions that could discourage, delay or prevent a third party from acquiring our company, even if doing so may be beneficial to our stockholders. In addition, these provisions could limit the price investors would be willing to pay in the future for shares of our common stock.

Our articles of incorporation allow for our board to create new series of preferred stock without further approval by our stockholders, which could adversely affect the rights of the holders of our common stock; our Series A Preferred Stock contains provisions that restrict our ability to take certain actions without the consent of at least 66% of the Series A Preferred Stock then outstanding.

Our Board of Directors has the authority to fix and determine the relative rights and preferences of preferred stock. Our Board of Directors also has the authority to issue preferred stock without further stockholder approval. As a result, our Board of Directors could authorize the issuance of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of common stock and the right to the redemption of the shares, together with a premium, prior to the redemption of our common stock. In addition, our Board of Directors could authorize the issuance of a series of preferred stock that has greater voting power than our common stock or that is convertible into our common stock, which could decrease the relative voting power of our common stock or result in dilution to our existing stockholders.

In addition, our articles of incorporation restrict our ability to take certain actions without the approval of at least 66% of the Series A Preferred Stock then outstanding. These actions include, among other things;

● authorizing, creating, designating, establishing or issuing an increased number of shares of Series A Preferred Stock or any other class or series of capital stock ranking senior to or on a parity with the Series A Preferred Stock;

● adopting a plan for the liquidation, dissolution or winding up the affairs of our company or any recapitalization plan (whether by merger, consolidation or otherwise);

● amending, altering or repealing, whether by merger, consolidation or otherwise, our articles of incorporation or bylaws in a manner that would adversely affect any right, preference, privilege or voting power of the Series A Preferred Stock; and

● declaring or paying any dividend (with certain exceptions) or directly or indirectly purchase, redeem, repurchase or otherwise acquire any shares of our capital stock, stock options or convertible securities (with certain exceptions).

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the three months ended December 31, 2018, we had the following unregistered sales of equity securities:

We issued 279,929 shares of common stock and cancelled warrants to purchase 20,071 shares of common stock at $0.25 per share to a consultant and an investor related to the exercise of warrants. These shares were issued in transactions that were not registered under the Act in reliance upon applicable exemptions from registration under Section 4(a)(2) of the Act and/or Rule 506 of SEC Regulation D under the Act.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

There have been no events which are required to be reported under this item.

ITEM 4.

MINE SAFETY DISCLOSURES

N/A.

ITEM 5. OTHER INFORMATION

This item is not applicable.

ITEM 6.

EXHIBITS

The exhibits required to be filed herewith by Item 601 of Regulation S-K, as described in the following index of exhibits, are attached hereto unless otherwise indicated as being incorporated by reference, as follows:

(a) Exhibits

Exhibit No.	Description

3.1	Restatement of the Articles of Incorporation dated September 13, 2013 (incorporated by reference to the Company's Current Report on Form 8-K/A2, filed September 17, 2013)

3.2	Amended and Restated Bylaws (incorporated by reference to the Company's Form 8-K, filed August 17, 2012)

3.3	Certificate of Amendment to the Restatement of the Articles of Incorporation dated June 11, 2015 (incorporated by reference to the Company's Current Report on Form 8-K, filed June 17, 2015)

3.4	Amended and Restated Certificate of Designations, Preferences and Rights of the Company's Series A Convertible Preferred Stock dated July 21, 2015 (incorporated by reference to the Company's Current Report on Form 8-K, filed July 29, 2015)

3.5	Correction to Amended and Restated Certificate of Designations, Preferences and Rights of its Series A Convertible Preferred Stock dated March 8, 2016 (incorporated by reference to the Company's Current Report on Form 8-K, filed March 15, 2016)

3.6	Amendment 2 of Series A Preferred Stock Terms dated February 19, 2016 (incorporated by reference to the Company's Current Report on Form 8-K, filed March 15, 2016)

3.7	Certificate of Designations, Preferences and Rights of Series C Convertible Preferred Stock (incorporated by reference to the Company's Current Report on Form 8-K, filed August 11, 2016)

3.8	Form of Series C Convertible Preferred Stock 2016 (incorporated by reference to the Company's Registration Statement on Form S-1, filed September 1, 2016)

3.9	Certificate of Correction and Certificate of Designations, Preferences and Rights of Series C Convertible Preferred Stock (incorporated by reference to the Company's Amended Current Report on Form 8-K/A, filed January 9, 2017)

3.10	Certificate of Designations, Preferences and Rights of Series D Convertible Preferred Stock (incorporated by reference to the Company's Current Report on Form 8-K, filed on February 10, 2017)

3.11	Amended and Restated Certificate of Designations, Preferences and Rights of Series D Convertible Preferred Stock. (incorporated by reference to the Company's Current Report on Form 8-K, filed May 5, 2017)

3.12	Second Amended and Restated Certificate of Designations, Preferences and Rights of Series D Convertible Preferred Stock (incorporated by reference to the Company's Current Report on Form 8-K, filed July 19, 2018)

3.13	Articles of Merger (incorporated by reference to the Company's Current Report on Form 8-K, filed May 3, 2018)

3.14	Second Amended and Restated Certificate of Designations, Preferences and Rights of Series D Convertible Preferred Stock (incorporated by reference to the Company's Current Report on Form 8-K, filed July 20, 2018)

3.15	Certificate of Designation of Series F Preferred Stock (incorporated by reference to the Company's Current Report on Form 8-K, filed August 3, 2018)

4.1	2011 Stock Incentive Plan (incorporated by reference to the Company's Definitive Proxy Statement on Schedule 14A, filed January 11, 2013)

10.1	Form of Preferred Stock and Warrant Purchase Agreement by and between Visualant, Incorporated and Clayton A. Struve (incorporated by reference to the Company's Current Report on Form 8-K, filed May 5, 2017)

10.2	Form of Amended and Restated Registration Rights Agreement. by and between Visualant, Incorporated and Clayton A. Struve (incorporated by reference to the Company's Current Report on Form 8-K, filed May 5, 2017)

10.3	Form of Series F Warrant to Purchase Common Stock by and between Visualant, Incorporated and Clayton A. Struve (incorporated by reference to the Company's Current Report on Form 8-K, filed May 5, 2017)

10.4	Securities Purchase Agreement dated August 14, 2017 by and between Visualant, Incorporated and accredited investor (incorporated by reference to the Company's Current Report on Form 8-K, filed August 18, 2017)

10.5	Senior Secured Convertible Redeemable Debenture dated December 12, 2017 by and between Visualant, Incorporated and accredited investor. (incorporated by reference to the Company's Current Report on Form 8-K, filed December 22, 2017)

10.6	General Security Agreement dated December 12, 2017 by and between Visualant, Incorporated and accredited investor (incorporated by reference to the Company's Current Report on Form 8-K, filed August 18, 2017)

10.7	Common Stock Purchase Warrant dated December 12, 2017 issued by Visualant, Incorporated to accredited investor. (incorporated by reference to the Company's Current Report on Form 8-K, filed December 22, 2017)

10.8	Schedule A to Subordination Agreement dated December 12, 2017 by and between an entity affiliated with Ronald P. Erickson and accredited investor. (incorporated by reference to the Company's Current Report on Form 8-K, filed December 22, 2017)

10.9	Senior Secured Convertible Redeemable Debenture dated February 28, 2018 by and between Visualant, Incorporated and accredited investor. (incorporated by reference to the Company's Current Report on Form 8-K, filed March 7, 2018)

10.10	Common Stock Purchase Warrant dated February 28, 2018 issued by Visualant, Incorporated to accredited investor. (incorporated by reference to the Company's Current Report on Form 8-K, filed March 7, 2018)

10.11	Consulting and Services Agreement dated July 6, 2017 amongst Visualant, Incorporated, Blaze, Inc. and Phillip A. Bosua (incorporated by reference to the Company's Form 10-K filed on December 29, 2017)

10.12	Note and Account Payable Conversion Agreement dated January 31, 2018 by and between Visualant, Incorporated and J3E2A2Z LP (incorporated by reference to the Company's Current Report on Form 8-K, filed March 21, 2018)

10.13	Convertible Redeemable Promissory Note dated January 31, 2018 by and between Visualant, Incorporated and J3E2A2Z LP (incorporated by reference to the Company's Current Report on Form 8-K, filed March 21, 2018)

10.14	Convertible Redeemable Promissory Note for Accounts Payable dated January 31, 2018 by and between Visualant, Incorporated and J3E2A2Z LP (incorporated by reference to the Company's Current Report on Form 8-K, filed March 21, 2018)

10.15	Common Stock Purchase Warrant dated January 31, 2018 by and between Visualant, Incorporated and Ronald P. Erickson (incorporated by reference to the Company's Current Report on Form 8-K, filed March 21, 2018)

10.16	Common Stock Purchase Warrant dated January 31, 2018 by and between Visualant, Incorporated and J3E2A2ZLP (incorporated by reference to the Company's Current Report on Form 8-K, filed March 21, 2018)

10.17	Employment Agreement dated April 10, 2018 by and between Visualant, Incorporated and Phillip A. Bosua. (incorporated by reference to the Company's Annual Report on Form 10-K, filed December 21, 2018)

10.18	Amended Employment Agreement dated April 10, 2018 by and between Visualant, Incorporated and Ronald P. Erickson. (incorporated by reference to the Company's Annual Report on Form 10-K, filed December 21, 2018)

10.19	Agreement and Plan of Merger, dated as of April 10, 2018, by and among Visualant, Incorporated, 500 Union Corporation, and RAAI Lighting, Inc. (incorporated by reference to the Company's Annual Report on Form 10-K, filed December 21, 2018)

10.20	Certificate of Merger, dated as of April 10, 2018, by 500 Union Corporation (incorporated by reference to the Company's Current Report on Form 8-K, filed April 17, 2018)

10.21	Fifth Modification of Loan and Security Agreement dated June 6, 2017 by and between TransTech Systems, Inc. and Capital Source Business Finance Group (incorporated by reference to the Company's Current Report on Form 8-K, filed June 26, 2018)

10.22	Form of subscription agreement (incorporated by reference to the Company's Current Report on Form 8-K, filed June 29, 2018)

10.23	Form of common stock purchase warrant (incorporated by reference to the Company's Current Report on Form 8-K, filed June 29, 2018)

10.24	Amendment 1 dated November 16, 2018 to Senior Secured Convertible Redeemable Note dated September 30, 2016 by and between Know Labs, Inc. and Clayton A. Struve (incorporated by reference to the Company's Current Report on Form 8-K, filed November 16, 2018)

10.25	Amendment 1 dated November 16, 2018 to Senior Secured Convertible Redeemable Note dated August 14, 2017 by and between Know Labs, Inc. and Clayton A. Struve (incorporated by reference to the Company's Current Report on Form 8-K, filed November 16, 2018)

10.26	Amendment 1 dated November 16, 2018 to Senior Secured Convertible Redeemable Note dated December 12, 2017 by and between Know Labs, Inc. and Clayton A. Struve (incorporated by reference to the Company's Current Report on Form 8-K, filed November 16, 2018)

10.27	Sixth Modification of Loan and Security Agreement effective December 12, 2018 by and between TransTech Systems, Inc. and Capital Source Business Finance Group (incorporated by reference to the Company's Current Report on Form 8-K, filed December 20, 2018)

14.1	Code of Ethics dated November 2018 (incorporated by reference to the Company's Current Report on Form 8-K, filed November 27, 2018)

31.01	Certification of Principal Executive Officer Pursuant to Rule 13a-14. Filed herewith.

31.02	Certification of Principal Financial Officer Pursuant to Rule 13a-14. Filed herewith.

32.01	CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act. Filed herewith.

32.02	CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act. Filed herewith.

99.1	Audit Committee Charter dated November 2018 (incorporated by reference to the Company's Current Report on Form 8-K, filed November 27, 2018)

99.2	Compensation Committee Charter dated November 2018 (incorporated by reference to the Company's Current Report on Form 8-K, filed November 27, 2018)

99.3	Nominations and Corporate Governance Committee Charter dated November 2018 (incorporated by reference to the Company's Current Report on Form 8-K, filed November 27, 2018)

101.INS*	XBRL Instance Document

101.SCH*	XBRL Taxonomy Extension Schema Document

101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB*	XBRL Taxonomy Extension Labels Linkbase Document

101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document

*Filed Herewith. Pursuant to Regulation S-T, this interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

KNOW LABS, INC.

(Registrant)


Date: February 12, 2019	By:	/s/ Phillip A Bosua
		Phillip A. Bosua
		Chief Executive Officer, and Director
		(Principal Executive Officer)


Date: February 12, 2019	By:	/s/ Ronald P. Erickson
		Ronald P. Erickson
		Interim Chief Financial Officer, and Treasurer
		(Principal Financial and Accounting Officer)

EX-31.1 2 exhibit_31-1.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13A-14. Blueprint

EXHIBIT 31.1

SECTION 302 CERTIFICATIONS

I, Phillip A. Bosua, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Know Labs, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant’s other certifying officer(a) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 12, 2019

/s/ Phillip A. Bosua

Phillip A. Bosua

Principal Executive Officer

EX-31.2 3 exhibit_31-2.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13A-14. Blueprint

EXHIBIT 31.2

SECTION 302 CERTIFICATIONS

I, Ronald P. Erickson, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Know Labs, Inc.;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Ronald P. Erickson

Interim Chief Financial Officer (Principal Accounting Officer)

February 12, 2019

EX-32.1 4 exhibit_32-1.htm CEO CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT. Blueprint

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Know Labs, Inc. (the "Company") on Form 10-Q for the quarter ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Phillip A. Bosua, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by the Report.

This certificate is being made for the exclusive purpose of compliance by the Chief Executive and Financial and Accounting Officer of the Company with the requirements of Section 906 of the Sarbanes-Oxley Act of 2002, and may not be disclosed, distributed or used by any person or for any reason other than as specifically required by law.

/s/ Phillip A. Bosua

Phillip A. Bosua

Principal Executive Officer

February 12, 2019

EX-32.2 5 exhibit_32-2.htm CFO CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT. Blueprint

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Know Labs, Inc. (the "Company") on Form 10-Q for the quarter ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Ronald P. Erickson, Interim Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by the Report.

/s/ Ronald P. Erickson

Interim Chief Financial Officer (Principal Accounting Officer)

February 12, 2019

GRAPHIC 6 knowlabs-logo.jpg IMAGE begin 644 knowlabs-logo.jpg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end EX-101.INS 7 knwn-20181231.xml XBRL INSTANCE DOCUMENT 0001074828 2018-10-01 2018-12-31 0001074828 2018-12-31 0001074828 2018-09-30 0001074828 us-gaap:PreferredClassAMember 2018-12-31 0001074828 us-gaap:PreferredClassAMember 2018-09-30 0001074828 KNWN:PreferredClassCMember 2018-12-31 0001074828 KNWN:PreferredClassDMember 2018-12-31 0001074828 KNWN:PreferredClassCMember 2018-09-30 0001074828 KNWN:PreferredClassDMember 2018-09-30 0001074828 2017-09-30 0001074828 KNWN:PurchasedMember 2018-12-31 0001074828 us-gaap:CapitalLeaseObligationsMember 2018-12-31 0001074828 srt:MinimumMember 2018-10-01 2018-12-31 0001074828 srt:MaximumMember 2018-10-01 2018-12-31 0001074828 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2018-10-01 2018-12-31 0001074828 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2018-10-01 2018-12-31 0001074828 us-gaap:EmployeeStockOptionMember 2018-09-30 0001074828 us-gaap:EmployeeStockOptionMember 2018-12-31 0001074828 us-gaap:EmployeeStockOptionMember 2017-09-30 0001074828 us-gaap:EmployeeStockOptionMember 2018-10-01 2018-12-31 0001074828 KNWN:StockIncentivePlanMember 2018-12-31 0001074828 KNWN:RangeofExercisePricesTotalMember 2018-12-31 0001074828 KNWN:WarrantOneMember 2018-12-31 0001074828 KNWN:WarrantTwoMember 2018-12-31 0001074828 KNWN:WarrantThreeMember 2018-12-31 0001074828 KNWN:WarrantOneMember 2018-10-01 2018-12-31 0001074828 KNWN:WarrantTwoMember 2018-10-01 2018-12-31 0001074828 KNWN:WarrantThreeMember 2018-10-01 2018-12-31 0001074828 us-gaap:ChiefExecutiveOfficerMember 2018-10-01 2018-12-31 0001074828 2017-12-31 0001074828 2017-10-01 2017-12-31 0001074828 2017-10-01 2018-09-30 0001074828 2016-10-01 2017-09-30 0001074828 KNWN:WarrantFourMember 2018-10-01 2018-12-31 0001074828 KNWN:WarrantFourMember 2018-12-31 0001074828 us-gaap:EmployeeStockOptionMember 2017-10-01 2018-09-30 0001074828 us-gaap:EmployeeStockOptionMember 2016-10-01 2017-09-30 0001074828 us-gaap:TechnologyBasedIntangibleAssetsMember 2018-12-31 0001074828 us-gaap:TechnologyBasedIntangibleAssetsMember 2018-09-30 0001074828 KNWN:RangeofExercisePricesTotalMember 2018-10-01 2018-12-31 0001074828 2019-02-12 0001074828 KNWN:ConvertiblePromissoryNoteMember 2018-12-31 0001074828 KNWN:ConvertibleRedeemablePromissoryNoteMember 2018-12-31 0001074828 us-gaap:EmployeeStockOptionMember 2016-09-30 0001074828 KNWN:RangeofExercisePrices.25Member 2018-10-01 2018-12-31 0001074828 KNWN:RangeofExercisePrices13.500Member 2018-10-01 2018-12-31 0001074828 KNWN:RangeofExercisePrices15.000Member 2018-10-01 2018-12-31 0001074828 KNWN:RangeofExercisePrices1.28Member 2018-10-01 2018-12-31 0001074828 KNWN:RangeofExercisePrices3.03Member 2018-10-01 2018-12-31 0001074828 KNWN:RangeofExercisePrices4.08Through4.20Member 2018-10-01 2018-12-31 0001074828 KNWN:RangeofExercisePrices.25Member 2018-12-31 0001074828 KNWN:RangeofExercisePrices1.28Member 2018-12-31 0001074828 KNWN:RangeofExercisePrices3.03Member 2018-12-31 0001074828 KNWN:RangeofExercisePrices4.08Through4.20Member 2018-12-31 0001074828 KNWN:RangeofExercisePrices13.500Member 2018-12-31 0001074828 KNWN:RangeofExercisePrices15.000Member 2018-12-31 0001074828 KNWN:RangeofExercisePrices4.08Through4.20Member srt:MinimumMember 2018-12-31 0001074828 KNWN:RangeofExercisePrices4.08Through4.20Member srt:MaximumMember 2018-12-31 0001074828 KNWN:RangeofExercisePrices4.08Through4.20Member srt:MinimumMember 2018-10-01 2018-12-31 0001074828 KNWN:RangeofExercisePrices4.08Through4.20Member srt:MaximumMember 2018-10-01 2018-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure KNOW LABS, INC. 0001074828 10-Q 2018-12-31 --09-30 Yes Non-accelerated Filer 2019

0.001

5000000

23334

1785715

1016014

1785715

1016014

100000000

P2Y

P10Y

P5Y

P20Y

false Q1 false true 18107319

1256082

2102948

7170

404445

447778

153690

169333

153690

690777

1478667

159223

203582

14691

20140

206084

320538

310779

934407

103181

92258

4461377

4710538

46576

145186

2255066

55959

676681

657551

71036

72140

12019

1412018

1512617

1790

1015

1790

1015

17811

17532

1256082

2102948

-3205295

-2607590

-35560527

-34791324

32334605

32163386

60000

20000

1785715

1016014

1785715

1016014

20000

1785715

1016014

1785715

1016014

17811431

17531502

17811431

17531502

-766513

-254251

689446

414365

206990

87720

129923

247834

472286

985023

602209

1232857

-2690

-274014

6436

19188

9126

293202

-769203

-528265

-769203

-528265

-0.04

-0.11

17571057

4655486

216774

9126

11723

-623628

-10923

-98610

358764

300000

98610

-58764

-2848

1710

2848

-522170

-371397

-1117131

-1264324

-55959

-94593

-90162

-2100

-44359

-64597

-5449

9499

-113083

40117

1710

171499

5187

61824

13898

216774

1371

Know Labs, Inc. (the “Company”) was incorporated under the laws of the State of Nevada in 1998. The Company has authorized 105,000,000 shares of capital stock, of which 100,000,000 are shares of voting common stock, par value $0.001 per share, and 5,000,000 are shares preferred stock, par value $0.001 per share.    The Company is focused on the development, marketing and sales of a proprietary technologies which are capable of uniquely authenticating or diagnosing almost any substance or material using electromagnetic energy to create, record and detect the unique “signature” of the substance. The Company’s call these our “ChromaID™” and “Bio-RFID™” technologies.   Overview   Historically, the Company focused on the development of our proprietary ChromaID technology. Using light from low-cost LEDs (light emitting diodes) the Company’s map the color of substances, fluids and materials and with our proprietary processes we can authenticate, identify and diagnose based upon the color that is present. The color is both visible to us as humans but also outside of the humanly visible color spectrum in the near infra-red and near ultra-violet and beyond. The Company’s ChromaID scanner sees what we like to call “Nature’s Color Fingerprint.” Everything in nature has a unique color identifier and with ChromaID the Company can see it, and identify, authenticate and diagnose based upon the color that is present. The Company’s ChromaID scanner is capable of uniquely identifying and authenticating almost any substance or liquid using light to create, record and detect its unique color signature. The Company will continue to develop and enhance its ChromaID technology and extend its capacity. More recently, the Company has focused upon extensions and new inventions that are derived from and extend beyond our ChromaID technology. The Company’s call this technology Bio-RFID. The rapid advances made with our Bio-RFID technology in our laboratory have caused us to move quickly in to the commercialization phase of our Company as we work to create revenue generating products for the marketplace. The Company will also, as resources permit, pursue licensing opportunities with third parties who have ready applications for our technologies.   In 2010, the Company acquired TransTech Systems, Inc. as an adjunct to its business. TransTech is a distributor of products for employee and personnel identification. TransTech currently provides substantially all of the Company’s revenues.   The Company is in the process of commercializing its technology. To date, the Company has entered into License Agreements with Sumitomo Precision Products Co., Ltd. In addition, it has a technology license agreement with Allied Inventors, formerly Xinova and Invention Development Management Company, a subsidiary of Intellectual Ventures.   The Company believes that its commercialization success is dependent upon its ability to significantly increase the number of customers that are purchasing and using its products. To date the Company has generated minimal revenue from sales of its ChromaID and Bio-RFID products. The Company is currently not profitable. Even if the Company succeeds in introducing the ChromaID and Bio-RFID technology and related products to its target markets, the Company may not be able to generate sufficient revenue to achieve or sustain profitability.   ChromaID was invented by scientists under contract with the Company. Bio-RFID was invented by individuals working for the Company. The Company actively pursues a robust intellectual property strategy and has been granted twelve patents. The Company also has 20 patents pending. The Company possesses all right, title and interest to the issued patents. Ten of the pending patents are licensed exclusively to the Company in perpetuity by the Company’s strategic partner, Allied Inventors.    Merger with RAAI Lighting, Inc.   On April 10, 2018, the Company entered into an Agreement and Plan of Merger with 500 Union Corporation, a Delaware corporation and a wholly owned subsidiary of the Company, and RAAI Lighting, Inc., a Delaware corporation. Pursuant to the Merger Agreement, we have acquired all the outstanding shares of RAAI’s capital stock through a merger of Merger Sub with and into RAAI (the “Merger”), with RAAI surviving the Merger as a wholly owned subsidiary of the Company.   Under the terms of the Merger Agreement, each share of RAAI common stock issued and outstanding immediately before the Merger (1,000 shares) were cancelled and we issued 2,000,000 shares of our common stock. As a result, we issued 2,000,000 shares of its common stock to Phillip A. Bosua, formerly the sole stockholder of RAAI. The consideration for the Merger was determined through arms-length bargaining by the Company and RAAI. The Merger was structured to qualify as a tax-free reorganization for U.S. federal income tax purposes. As a result of the Merger, the Company received certain intellectual property, related to RAAI.   Appointment of Director   On April 10, 2018, the Board increased the size of the Board from three to four members and Phillip A. Bosua was appointed as a member of the Board. Mr. Bosua’s term of office expires at the next annual meeting of our stockholders. On May 24, 2018, the Board of Directors increased the size of the Board from four to five members and appointed (Ret.) Admiral William Owens as a member of the Board. Admiral Owen’s term of office expires at the next annual meeting of our stockholders.   Appointment of Officer     On April 10, 2018, the Company appointed Mr. Bosua as Chief Executive Officer of the Company, replacing Ronald P. Erickson, who remains Chairman of the Company. Previously, Mr. Bosua served as the Company’s Chief Product Officer since August 2017. The Company entered into a Consulting Agreement with Mr. Bosua’s company, Blaze Clinical on July 7, 2017.   On April 10, 2018, the Company entered into an Employment Agreement with Mr. Bosua reflecting Mr. Bosua’s appointment as Chief Executive Officer. The Employment Agreement is for an initial term of 12 months (subject to earlier termination) and will be automatically extended for additional 12-month terms unless either party notifies the other party of its intention to terminate the Employment Agreement. Mr. Bosua will be paid a base salary of $225,000 per year, received 500,000 shares of common stock valued at $0.33 per share and may be entitled to bonuses and equity awards at the discretion of the Board or a committee of the Board. The Employment Agreement provides for severance pay equal to 12 months of base salary if Mr. Bosua is terminated without “cause” or voluntarily terminates his employment for “good reason.”   On April 10, 2018, the Company entered into an Amended Employment Agreement for Ronald P. Erickson which amends the Employment Agreement dated July 1, 2017. The Agreement expires March 21, 2019.   Merger with Know Labs, Inc.   On May 1, 2018, Know Labs, Inc., a Nevada corporation incorporated on April 3, 2018, and our wholly-owned subsidiary, merged with and into the Company pursuant to an Agreement and Plan of Merger dated May 1, 2018. In connection with the merger, our Articles of Incorporation were effectively amended to change our name to Know Labs, Inc. by and through the filing of Articles of Merger. This parent-subsidiary merger was approved by us, the parent, in accordance with Nevada Revised Statutes Section 92A.180. Stockholder approval was not required. This amendment was filed with the Nevada Secretary of State and became effective on May 1, 2018.   Corporate Name Change and Symbol Change   On May 24, 2018, the Financial Industry Regulatory Authority (“FINRA”) announced the effectiveness of a change in our name from Visualant Incorporated to Know Labs, Inc. and a change in our ticker symbol from VSUL to the new trading symbol KNWN which became effective on the opening of trading as of May 25, 2018. In addition, in connection with the name change and symbol change, we were assigned the CUSIP number of 499238103.   Closing of Financing on June 25, 2018   On June 25, 2018, the Company closed a private placement and received gross proceeds of $1,750,000 in exchange for issuing 7,000,000 shares of common stock and warrants to purchase 3,500,000 shares of common stock in a private placement to accredited investors pursuant to a series of substantially identical subscription agreements.   The initial exercise price of the warrants described above is $0.25 per share, subject to certain adjustments, and the warrants expire five years after their issuance.   The shares and the warrants described above were issued in transactions that were not registered under the Securities Act of 1933, as amended (the “Act”) in reliance upon applicable exemptions from registration under Section 4(a)(2) of the Act and/or Rule 506 of SEC Regulation D under the Act.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company incurred net losses of $769,203, $3,257,597 and $3,901,232 for the three months ended December 31, 2018 and the years ended September 30, 2018 and 2017, respectively. Net cash used in operating activities was $522,170, $1,117,131 and $1,264,324 for the three months ended December 31, 2018 and for the years ended September 30, 2018 and 2017, respectively.   The Company anticipates that it will record losses from operations for the foreseeable future. As of December 31, 2018, the Company’s accumulated deficit was $35,560,527.  The Company has limited capital resources, and operations to date have been funded with the proceeds from private equity and debt financings and loans from Ronald P. Erickson, the Company’s Chief Executive Officer, or entities with which he is affiliated. These conditions raise substantial doubt about our ability to continue as a going concern. The audit report prepared by the Company’s independent registered public accounting firm relating to our financial statements for the year ended September 30, 2018 includes an explanatory paragraph expressing the substantial doubt about the Company’s ability to continue as a going concern.   The Company believe that its cash on hand will be sufficient to fund our operations until February 28, 2019. We need additional financing to implement our business plan and to service our ongoing operations and pay our current debts. There can be no assurance that we will be able to secure any needed funding, or that if such funding is available, the terms or conditions would be acceptable to us. If we are unable to obtain additional financing when it is needed, we will need to restructure our operations, and divest all or a portion of our business. We may seek additional capital through a combination of private and public equity offerings, debt financings and strategic collaborations. Debt financing, if obtained, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, and could increase our expenses and require that our assets secure such debt. Equity financing, if obtained, could result in dilution to the Company’s then-existing stockholders and/or require such stockholders to waive certain rights and preferences. If such financing is not available on satisfactory terms, or is not available at all, the Company may be required to delay, scale back, eliminate the development of business opportunities or file for bankruptcy and our operations and financial condition may be materially adversely affected.

Basis of Presentation – The accompanying unaudited consolidated financial statements include the accounts of the Company. Intercompany accounts and transactions have been eliminated. The preparation of these unaudited condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (“GAAP”).   Principles of Consolidation – The consolidated financial statements include the accounts of the Company and its wholly owned and majority-owned subsidiaries, TransTech Systems, Inc and RAAI Lighting, Inc. Inter-Company items and transactions have been eliminated in consolidation.   Cash and Cash Equivalents – The Company classifies highly liquid temporary investments with an original maturity of three months or less when purchased as cash equivalents. The Company maintains cash balances at various financial institutions. Balances at US banks are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant risk for cash on deposit.     Accounts Receivable and Allowance for Doubtful Accounts – Accounts receivable consist primarily of amounts due to the Company from normal business activities. The Company maintains an allowance for doubtful accounts to reflect the expected non-collection of accounts receivable based on past collection history and specific risks identified within the portfolio. If the financial condition of the customers were to deteriorate resulting in an impairment of their ability to make payments, or if payments from customers are significantly delayed, additional allowances might be required.   Inventories – Inventories consist primarily of printers and consumable supplies, including ribbons and cards, badge accessories, capture devices, and access control components held for resale and are stated at the lower of cost or market on the first-in, first-out (“FIFO”) method.  Inventories are considered available for resale when drop shipped and invoiced directly to a customer from a vendor, or when physically received by TransTech at a warehouse location.  The Company records a provision for excess and obsolete inventory whenever an impairment has been identified. There is a $35,000 reserve for impaired inventory as of December 31, 2018 and September 30, 2018, respectively.   Equipment – Equipment consists of machinery, leasehold improvements, furniture and fixtures and software, which are stated at cost less accumulated depreciation and amortization. Depreciation is computed by the straight-line method over the estimated useful lives or lease period of the relevant asset, generally 2-10 years, except for leasehold improvements which are depreciated over 2-3 years.    Long-Lived Assets – The Company reviews its long-lived assets for impairment annually or when changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Long-lived assets under certain circumstances are reported at the lower of carrying amount or fair value. Assets to be disposed of and assets not expected to provide any future service potential to the Company are recorded at the lower of carrying amount or fair value (less the projected cost associated with selling the asset). To the extent carrying values exceed fair values, an impairment loss is recognized in operating results.   Intangible Assets – Intangible assets are capitalized and amortized on a straight-line basis over their estimated useful life, if the life is determinable. If the life is not determinable, amortization is not recorded. We regularly perform reviews to determine if facts and circumstances exist which indicate that the useful lives of our intangible assets are shorter than originally estimated or the carrying amount of these assets may not be recoverable. When an indication exists that the carrying amount of intangible assets may not be recoverable, we assess the recoverability of our assets by comparing the projected undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. Such impairment test is based on the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. Impairment, if any, is based on the excess of the carrying amount over the estimated fair value of those assets.   Research, Development and Engineering Expenses – Research, development and engineering expenses consist of the cost of employees, consultants and contractors who design, engineer and develop new products and processes as well as materials, supplies and facilities used in producing prototypes.   The Company’s research and development efforts are primarily focused improving the core foundational ChromaID technology and developing new and unique applications for the technology. As part of this effort, the Company typically conduct testing to ensure that ChromaID application methods are compatible with the customer’s requirements, and that they can be implemented in a cost effective manner. The Company is also actively involved in identifying new application methods. Know Lab’s team has considerable experience working with the application of light-based technologies and their application to various industries. The Company believes that its continued development of new and enhanced technologies relating to our core business is essential to its future success. The Company spent $206,990, $570,514 and $79,405 during the three months ended December 31, 2018 and the years ended September 30, 2018 and 2017, respectively, on research and development activities.   Fair Value Measurements and Financial Instruments – ASC Topic 820, Fair Value Measurement and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.  This topic also establishes a fair value hierarchy, which requires classification based on observable and unobservable inputs when measuring fair value.  The fair value hierarchy distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs).  The hierarchy consists of three levels:   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 100%; font: 12pt Times New Roman, Times, Serif">Level 1 – Quoted prices in active markets for identical assets and liabilities;</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 100%"> Level 2 – Inputs other than level one inputs that are either directly or indirectly observable; and.   Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.  </td></tr> </table> The recorded value of other financial assets and liabilities, which consist primarily of cash and cash equivalents, accounts receivable, other current assets, and accounts payable and accrued expenses approximate the fair value of the respective assets and liabilities as of December 31, 2018 and September 30, 2018 are based upon the short-term nature of the assets and liabilities.    Derivative Financial Instruments -The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.   Revenue Recognition – Know Lab and TransTech revenue are derived from products and services. Revenue is considered realized when the products or services have been provided to the customer, the work has been accepted by the customer and collectability is reasonably assured. Furthermore, if an actual measurement of revenue cannot be determined, the Company defers all revenue recognition until such time that an actual measurement can be determined. If during the course of a contract management determines that losses are expected to be incurred, such costs are charged to operations in the period such losses are determined. Revenues are deferred when cash has been received from the customer but the revenue has not been earned.   Stock Based Compensation – The Company has share-based compensation plans under which employees, consultants, suppliers and directors may be granted restricted stock, as well as options to purchase shares of Company common stock at the fair market value at the time of grant. Stock-based compensation cost is measured by the Company at the grant date, based on the fair value of the award, over the requisite service period. For options issued to employees, the Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit.  Grants of stock options and stock to non-employees and other parties are accounted for in accordance with the ASC 505.   Convertible Securities – Based upon ASC 815-15, we have adopted a sequencing approach regarding the application of ASC 815-40 to convertible securities. We will evaluate our contracts based upon the earliest issuance date. In the event partial reclassification of contracts subject to ASC 815-40-25 is necessary, due to our inability to demonstrate we have sufficient shares authorized and unissued, shares will be allocated on the basis of issuance date, with the earliest issuance date receiving first allocation of shares. If a reclassification of an instrument were required, it would result in the instrument issued latest being reclassified first.   Net Loss per Share – Under the provisions of ASC 260, “Earnings Per Share,” basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of the Company, subject to anti-dilution limitations. As of December 31, 2018, there were options outstanding for the purchase of 2,282,668 common shares, warrants for the purchase of 15,173,398 common shares, and 4,914,071 shares of the Company’s common stock issuable upon the conversion of Series A, Series C and Series D Convertible Preferred Stock. In addition, the Company has an unknown number of shares (9,020,264 common shares at the current price of $0.25 per share) are issuable upon conversion of convertible debentures of $2,255,066. All of which could potentially dilute future earnings per share.   As of December 31, 2017, there were options outstanding for the purchase of 15,404 common shares, warrants for the purchase of 7,767,416 common shares, 2,825,053 shares of the Company’s common stock issuable upon the conversion of Series A, Series C and Series D Convertible Preferred Stock and up to 332,940 shares of the Company’s common stock issuable upon the exercise of placement agent warrants. In addition, the Company has an unknown number of shares issuable upon conversion of convertible debentures of $870,000. All of which could potentially dilute future earnings per share.      Dividend Policy – The Company has never paid any cash dividends and intends, for the foreseeable future, to retain any future earnings for the development of our business. Our future dividend policy will be determined by the board of directors on the basis of various factors, including our results of operations, financial condition, capital requirements and investment opportunities.   Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.   Recent Accounting Pronouncements   A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, management has not determined whether implementation of such proposed standards would be material to the Company’s consolidated financial statements.

Accounts receivable were $206,084 and $320,538, net of allowance, as of December 31, 2018 and September 30, 2018, respectively. The Company had one customer in excess of 10% (12.6% and 11.3%) of the Company’s consolidated revenues for the three months ended December 31, 2018. The Company had three customers in excess of 10% (21.2%, 16.1%, and 10.7%) with accounts receivable in excess of 10% as of December 31, 2018. The Company has a total allowance for bad debt in the amount of $60,000 as of December 31, 2018.

Inventories were and $159,223 and $203,582 as of December 31, 2018 and September 30, 2018, respectively. Inventories consist primarily of printers and consumable supplies, including ribbons and cards, badge accessories, capture devices, and access control components held for resale. There was a $35,000 reserve for impaired inventory as of September 30, 2018 and 2017, respectively.

Fixed assets, net of accumulated depreciation, was $153,690 and $169,333 as of December 31, 2018 and September 30, 2018, respectively. Accumulated depreciation was $689,157 and $670,666 as of December 31, 2018 and September 30, 2018, respectively. Total depreciation expense was $18,491 and $13,828 for the three months ended December 31, 2018 and 2017, respectively. All equipment is used for selling, general and administrative purposes and accordingly all depreciation is classified in selling, general and administrative expenses.    Property and equipment as of December 31, 2018 was comprised of the following:    <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="text-align: center">Estimated</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">December 31, 2018    </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> Useful Lives</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Purchased</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Capital Leases</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 30%">Machinery and equipment</td> <td style="width: 18%; text-align: center">2-10 years</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">335,154</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">42,681</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">377,835</td> <td style="width: 5%"> </td></tr> <tr style="vertical-align: bottom"> <td>Leasehold improvements</td> <td style="text-align: center">2-3 years</td> <td> </td> <td> </td> <td style="text-align: right">276,112</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">276,112</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Furniture and fixtures</td> <td style="text-align: center">2-3 years</td> <td> </td> <td> </td> <td style="text-align: right">58,050</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">95,020</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">153,070</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Software and websites</td> <td style="text-align: center">3- 7 years</td> <td> </td> <td> </td> <td style="text-align: right">35,830</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">35,830</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Less: accumulated depreciation</td> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(551,456</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(137,701</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(689,157</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">153,690</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">153,690</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

Intangible assets as of December 31, 2018 and September 30, 2018 consisted of the following:    <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="text-align: center">Estimated</td> <td> </td> <td colspan="2" style="text-align: center">December 31,</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">September 30,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> Useful Lives</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 44%">Technology</td> <td style="width: 20%; text-align: center">3 years</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">520,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">520,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Less: accumulated amortization</td> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(115,555</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(72,222</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td>    Intangible assets, net</td> <td> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">404,445</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">447,778</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   Total amortization expense was $43,332 and $72,222 for the three months ended December 31, 2018 and the year ended December 31, 2018, respectively.   Merger with RAAI Lighting, Inc.   On April 10, 2018, the Company entered into an Agreement and Plan of Merger with 500 Union Corporation, a Delaware corporation and a wholly owned subsidiary of the Company, and RAAI Lighting, Inc., a Delaware corporation. Pursuant to the Merger Agreement, we have acquired all the outstanding shares of RAAI’s capital stock through a merger of Merger Sub with and into RAAI (the “Merger”), with RAAI surviving the Merger as a wholly owned subsidiary of the Company.   Under the terms of the Merger Agreement, each share of RAAI common stock issued and outstanding immediately before the Merger (1,000 shares) were cancelled and converted into the right to receive 2,000 shares of the Company’s common stock. As a result, the Company issued 2,000,000 shares of its common stock to Phillip A. Bosua, formerly the sole stockholder of RAAI. The consideration for the Merger was determined through arms-length bargaining by the Company and RAAI. The Merger was structured to qualify as a tax-free reorganization for U.S. federal income tax purposes. As a result of the Merger, the Company received certain intellectual property, related to RAAI.   Merger with Know Labs, Inc.   On May 1, 2018, Know Labs, Inc., a Nevada corporation incorporated on April 3, 2018, and our wholly-owned subsidiary, merged with and into the Company pursuant to an Agreement and Plan of Merger dated May 1, 2018. In connection with the merger, our Articles of Incorporation were effectively amended to change our name to Know Labs, Inc. by and through the filing of Articles of Merger. This parent-subsidiary merger was approved by us, the parent, in accordance with Nevada Revised Statutes Section 92A.180. Stockholder approval was not required. This amendment was filed with the Nevada Secretary of State and became effective on May 1, 2018.   RAAI had no outstanding indebtedness or assets at the closing of the Merger. The 2,000,000 shares of the Company’s common stock issued for RAAI’s shares were recorded at the fair value at the date of the merger at $520,000 and the value assigned to the patent acquired with RAAI.   The fair value of the intellectual property associated with the assets acquired was $520,000 estimated by using a discounted cash flow approach based on future economic benefits. In summary, the estimate was based on a projected income approach and related discounted cash flows over five years, with applicable risk factors assigned to assumptions in the forecasted results.

Accounts payable were $1,412,018 and $1,517,617 as of December 31, 2918 and September 30, 2018, respectively. Such liabilities consisted of amounts due to vendors for inventory purchases and technology development, external audit, legal and other expenses incurred by the Company. The Company had one vendor (19.8%) with accounts payable in excess of 10% of its accounts payable as of December 31, 2018. The Company does expect to have vendors with accounts payable balances of 10% of total accounts payable in the foreseeable future.

In April 2008, the FASB issued a pronouncement that provides guidance on determining what types of instruments or embedded features in an instrument held by a reporting entity can be considered indexed to its own stock for the purpose of evaluating the first criteria of the scope exception in the pronouncement on accounting for derivatives. This pronouncement was effective for financial statements issued for fiscal years beginning after December 15, 2008. The adoption of these requirements can affect the accounting for warrants and many convertible instruments with provisions that protect holders from a decline in the stock price (or “down-round” provisions). For example, warrants or conversion features with such provisions are no longer recorded in equity. Down-round provisions reduce the exercise price of a warrant or convertible instrument if a company either issues equity shares for a price that is lower than the exercise price of those instruments or issues new warrants or convertible instruments that have a lower exercise price.   There was no derivative liability as of December 31, 2018 and September 30, 2018. For the year ended September 30, 2017, the Company recorded non-cash loss of $217,828 related to the “change in fair value of derivative” expense related to its derivative instruments. The Company early adopted ASU 2017-11 and has reclassified its financial instrument with down round features to equity in the amount of $410,524.

Convertible notes payable as of December 31, 2018 and September 30, 2018 consisted of the following:   Convertible Promissory Note dated September 30, 2016   On September 30, 2016, the Company entered into a $210,000 Convertible Promissory Note with Clayton A. Struve, an accredited investor of the Company, to fund short-term working capital. The Convertible Promissory Note accrued interest at a rate of 10% per annum and was due on March 30, 2017. The Note holder can convert the Note into common stock at $0.70 per share. During the year ended September 30, 2017, the Company recorded interest of $21,000 related to the convertible note. This note was extended in the Securities Purchase Agreement, General Security Agreement and Subordination Agreement dated August 14, 2017 with a maturity date of August 13, 2018. Also, the conversion price of the Debenture was adjusted to $0.25 per share, subject to certain adjustments. The balance was increased $75,000 during the year ended September 30, 2018. On November 16, 2018, we signed Amendment 1 to Senior Secured Convertible Redeemable Notes dated September 30, 2016 extending the due dates of the Note to February 27, 2019. On September 24, 2018, Mr. Struve converted $200,000 of the Note into 800,000 shares of our common stock. The Company recorded accrued interest of $63,493 as of December 31, 2018.   Securities Purchase Agreement dated August 14, 2017   On August 14, 2017, the Company issued a senior convertible exchangeable debenture with a principal amount of $360,000 and a common stock purchase warrant to purchase 1,440,000 shares of common stock in a private placement to Clayton Struve for gross proceeds of $300,000 pursuant to a Securities Purchase Agreement dated August 14, 2017. The debenture accrues interest at 20% per annum and matures August 13, 2018. The convertible debenture contains a beneficial conversion valued at $110,629. The warrants were valued at $111,429. Because the note is immediately convertible, the warrants and beneficial conversion were expensed as interest.   On the same date, the Company entered into a General Security Agreement with the Mr. Struve, pursuant to which the Company has agreed to grant a security interest to the investor in substantially all of our assets, effective upon the filing of a UCC-3 termination statement to terminate the security interest held by Capital Source Business Finance Group in the assets of the Company. In addition, an entity affiliated with Ronald P. Erickson, out then Chief Executive Officer, entered into a Subordination Agreement with the investor pursuant to which all debt owed by us to such entity is subordinated to amounts owed by us to Mr. Struve under the Debenture (including amounts that become owing under any Debentures issued to the investor in the future).   The initial conversion price of the Debenture is $0.25 per share, subject to certain adjustments. The initial exercise price of the Warrant is $0.25 per share, also subject to certain adjustments.   As part of the Purchase Agreement, the Company granted the investor “piggyback” registration rights to register the shares of common stock issuable upon the conversion of the Debenture and the exercise of the Warrant with the Securities and Exchange Commission for resale or other disposition.   The Debenture and the Warrant were issued in a transaction that was not registered under the Securities Act of 1933, as amended in reliance upon applicable exemptions from registration under Section 4(a)(2) of the Act and Rule 506 of SEC Regulation D under the Act.     Under the terms of the Purchase Agreement, Mr. Struve may purchase up to an aggregate of $1,000,000 principal amount of Debentures (before a 20% original issue discount) (and Warrants to purchase up to an aggregate of 250,000 shares of common stock). These securities are being offered on a “best efforts” basis by the placement agent.   During the year ended September 30, 2017, $156,941 was recorded as interest expense related to debt discounts, beneficial conversions and warrants associated with Convertible Promissory Notes.   On December 12, 2017, the Company closed an additional $250,000 and issued a senior convertible exchangeable debenture with a principal amount of $300,000 and a common stock purchase warrant to purchase 1,200,000 shares of common stock in a private placement dated December 12, 2017 with Mr. Struve pursuant to a Securities Purchase Agreement dated August 14, 2017. The convertible debenture contains a beneficial conversion valued at $93,174. The warrants were valued at $123,600. Because the note is immediately convertible, the warrants and beneficial conversion were expensed as interest.   On March 2, 2018, the Company received gross proceeds of $280,000 in exchange for issuing a senior convertible redeemable debenture with a principal amount of $336,000 and a warrant to purchase 1,344,000 shares of common stock in a private placement dated February 28, 2018 with Mr. Struve pursuant to a Securities Purchase Agreement dated August 14, 2017. The convertible debenture contains a beneficial conversion valued at $252,932. The warrants were valued at $348,096. Because the note is immediately convertible, the warrants and beneficial conversion were expensed as interest.   In connection with the February 28, 2018 private placement, the placement agent for the debenture and the warrant received a cash fee of $28,000 and the Company issued warrants to purchase shares of the Company’s common stock to the placement agent or its affiliates based on 10% of proceeds.   On November 16, 2018, the Company signed Amendment 1 to Senior Secured Convertible Redeemable Notes dated August 14, 2017 and December 12, 2017, extending the due dates of the Notes to February 27, 2019.   Convertible Redeemable Promissory Notes with Ronald P. Erickson and J3E2A2Z   On March 16, 2018, the Company entered into a Note and Account Payable Conversion Agreement pursuant to which (a) all $664,233 currently owing under the J3E2A2Z Notes was converted to a Convertible Redeemable Promissory Note in the principal amount of $664,233, and (b) all $519,833 of the J3E2A2Z Account Payable was converted into a Convertible Redeemable Promissory Note in the principal amount of $519,833 together with a warrant to purchase up to 1,039,666 shares of common stock of the Company for a period of five years. The initial exercise price of the warrants described above is $0.50 per share, also subject to certain adjustments. The warrants were valued at $110,545. Because the note is immediately convertible, the warrants and beneficial conversion were expensed as interest. The Company recorded accrued interest of $32,602 as of December 31, 2018.

Notes payable, capitalized leases and long-term debt as of December 31, 2018 and September 30, 2018 consisted of the following:    <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">December 31,</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">September 30,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 64%">Capital Source Business Finance Group</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: black 1pt solid">$</td> <td style="width: 15%; border-bottom: black 1pt solid; text-align: right">46,576</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: black 1pt solid">$</td> <td style="width: 15%; border-bottom: black 1pt solid; text-align: right">145,186</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Total debt</td> <td> </td> <td> </td> <td style="text-align: right">46,576</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">145,186</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Less current portion of long term debt</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(46,576</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(145,186</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td>Long term debt</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   Capital Source Business Finance Group   Know Labs, Inc. (the “Company”) finances its TransTech operations from operations and a Secured Credit Facility with Capital Source Business Finance Group. On June 15, 2018, TransTech entered into a Fifth Modification to the Loan and Security Agreement related to the $500,000 secured credit facility with Capital Source to fund its operations. The Modification extended the maturity to December 12, 2018. The secured credit facility provides for a prime rate interest floor for prime interest of 4.5% plus 2.5%. The eligible borrowing is based on 80% of eligible trade accounts receivable, not to exceed $500,000. The secured credit facility is collateralized by the assets of TransTech, with a guarantee by Know Labs, including a security interest in all assets of Know Labs. The remaining balance on the accounts receivable must be repaid by the time the secured credit facility expires on December 12, 2018, unless we renew by automatic extension for the next successive term. TransTech has $23,000 available as of December 31, 2018.   On December 6, 2018, Capital Source notified TransTech that the Loan and Security Agreement and Capital Source Credit Facility would be cancelled as of March 12, 2019. Effective December 12, 2018, TransTech entered into the Sixth Modification to the Loan and Security Agreement which reduced the secured credit facility to $200,000.

Authorized Capital Stock   The Company authorized 105,000,000 shares of capital stock, of which 100,000,000 are shares of voting common stock, par value $0.001 per share, and 5,000,000 are shares preferred stock, par value $0.001 per share.   The Company has authorized to issue up to 100,000,000 shares of common stock with a par value of $0.001. As of December 31, 2018, we had 17,811,431 shares of common stock issued and outstanding, held by 123 shareholders of record. The number of shareholders, including beneficial owners holding shares through nominee names, is approximately 2,300. Each share of common stock entitles its holder to one vote on each matter submitted to the shareholders for a vote, and no cumulative voting for directors is permitted.  Shareholders do not have any preemptive rights to acquire additional securities issued by us.  As of December 31, 2018, there were options outstanding for the purchase of 2,282,668 common shares, warrants for the purchase of 15,173,398 common shares, and 4,914,071 shares of the Company’s common stock issuable upon the conversion of Series A, Series C and Series D Convertible Preferred Stock. In addition, the Company has an unknown number of shares (9,020,264 common shares at the current price of $0.25 per share) are issuable upon conversion of convertible debentures of $2,255,066. All of which could potentially dilute future earnings per share.   Voting Preferred Stock   The Company is authorized to issue up to 5,000,000 shares of preferred stock with a par value of $0.001.   Series A Preferred Stock   In July 2015, the Company sold Series A Preferred Stock to two investors for a total of $350,000. As of December 31, 2018, the Company had 20,000 Series A Preferred Stock issued and outstanding.   Each holder of outstanding shares of Series A Preferred is entitled to the number of votes equal to the number of whole shares of common stock into which the shares of Series A Preferred held by such holder are then convertible as of the applicable record date. The Series A Preferred may not be redeemed without the consent of the holder. The Company cannot amend, alter or repeal any preferences, rights, or other terms of the Series A Preferred so as to adversely affect the Series A Preferred, without the written consent or affirmative vote of the holders of at least 66% of the then outstanding shares of Series A Preferred, voting as a separate voting group, given by written consent or by vote at a meeting called for such purpose for which notice shall have been duly given to the holders of the Series A Preferred.    In connection with the issuance of the Series A Preferred, the Company also issued (i) a Series C five-year Warrant for 2 shares of common stock and (ii) a Series D five-year Warrant for 23,334 shares of common stock. The Series A Preferred Stock and Series C and D Warrants currently have no registration rights.   On August 14, 2017, the price of the Series A Preferred Stock and Series C and D Warrants were adjusted to $0.25 per share pursuant to the documents governing such instruments.    On September 23, 2018, a holder of Series A Preferred Stock converted 3,334 shares into 3,334 shares of common stock. In addition, the holder exercised Series C and D Warrants for 6,668 shares of common stock at $0.25 per share.   Series C and D Preferred Stock and Warrants   On August 5, 2016, the Company closed a Series C Preferred Stock and Warrant Purchase Agreement with Clayton A. Struve, an accredited investor for the purchase of $1,250,000 of preferred stock with a conversion price of $0.70 per share. The preferred stock has a yield of 8% and an ownership blocker of 4.99%. In addition, Mr. Struve received a five-year warrant to acquire 1,785,714 shares of common stock at $0.70 per share.   To determine the effective conversion price, a portion of the proceeds received by the Company upon issuance of the Series C Preferred Stock was first allocated to the freestanding warrants issued as part of this transaction. Given that the warrants will not subsequently be measured at fair value, the Company determined that the warrants should receive an allocation of the proceeds based on their relative fair value. This is based on the understanding that the FASB staff and the SEC staff believe that a freestanding instrument issued in a basket transaction should be initially measured at fair value if it is required to be subsequently measured at fair value pursuant to US generally accepted accounting principles (“GAAP”), with the residual proceeds from the transaction allocated to any remaining instruments based on their relative fair values. As such, the warrants were allocated a fair value of approximately $514,706 upon issuance, with the remaining $735,294 of proceeds allocated to the Series C Preferred Stock.   Proportionately, this allocation resulted in approximately 59% of the face amount of the Series C Preferred Stock issuance remaining, which applied to the stated conversion price of $0.70 resulted in an effective conversion price of approximately $0.41.   Having determined the effective conversion price, the Company then compared this to the fair value of the underlying Common Stock as of the commitment date, which was approximately $1.06 per share, and concluded that the conversion feature did have an intrinsic value of $0.65 per share. As such, the Company concluded that the Series C Preferred Stock did contain a beneficial conversion feature and an accounting entry and additional financial statement disclosure was required.   Because our preferred stock is perpetual, with no stated maturity date, and the conversions may occur any time from inception, the dividend is recognized immediately when a beneficial conversion exists at issuance. During the year ending September 30, 2016, the Company recognized preferred stock dividends of $1.16 million on Series C preferred stock related to the beneficial conversion feature arising from a common stock effective conversion rate of $0.41 versus a current market price of $1.06 per common share.   On November 14, 2016, the Company issued 187,500 shares of Series D Convertible Preferred Stock and a warrant to purchase 187,500 shares of common stock in a private placement to certain accredited investors for gross proceeds of $150,000 pursuant to a Series D Preferred Stock and Warrant Purchase Agreement dated November 10, 2016.   The warrants associated with the November 14, 2016 issuance were allocated a fair value of approximately $56,539 upon issuance, with the remaining $63,539 of net proceeds allocated to the Series D Preferred Stock. Proportionately, this allocation resulted in approximately 53% of the amount of the Series D Preferred Stock issuance remaining, which applied to the stated conversion price of $0.80 resulted in an effective conversion price of approximately $0.34. Having determined the effective conversion price, the Company then compared this to the fair value of the underlying Common Stock as of the commitment date, which was approximately $1.14 per share, and concluded that the conversion feature did have an intrinsic value of $0.80 per share. As such, the Company concluded that the Series D Preferred Stock did contain a beneficial conversion feature of $150,211 which was recorded as a beneficial conversion in stockholders’ equity.   On December 19, 2016, the Company issued 187,500 shares of Series D Convertible Preferred Stock and a warrant to purchase 187,500 shares of common stock in a private placement to an accredited investor for gross proceeds of $150,000 pursuant to a Series D Preferred Stock and Warrant Purchase Agreement dated December 14, 2016.   The warrants associated with the December 19, 2016 issuance were allocated a fair value of approximately $60,357 upon issuance, with the remaining $69,643 of net proceeds allocated to the Series D Preferred Stock. Proportionately, this allocation resulted in approximately 54% of the amount of the Series D Preferred Stock issuance remaining, which applied to the stated conversion price of $0.80 resulted in an effective conversion price of approximately $0.37. Having determined the effective conversion price, the Company then compared this to the fair value of the underlying Common Stock as of the commitment date, which was approximately $0.81 per share, and concluded that the conversion feature did have an intrinsic value of $0.44 per share. As such, the Company concluded that the Series C Preferred Stock did contain a beneficial conversion feature of $82,232 which was recorded as a beneficial conversion in stockholders’ equity.   Because the Company’s preferred stock is perpetual, with no stated maturity date, and the conversions may occur any time from inception, the dividend is recognized immediately when a beneficial conversion exists at issuance. During the year ending September 30, 2017, the Company recognized preferred stock dividends of $2.3 million on Series D preferred stock related to the beneficial conversion feature arising from a common stock effective conversion rate of $0.34 and $0.37 versus the original market price of $1.14 and $1.06 per common share, respectively.   On May 1, 2017, the Company issued 357,143 shares of Series D Convertible Preferred Stock and a warrant to purchase 357,143 shares of common stock in a private placement to an accredited investor for gross proceeds of $250,000 pursuant to a Series D Preferred Stock and Warrant Purchase Agreement dated May 1, 2016.   The initial conversion price of the Series D Shares is $0.70 per share, subject to certain adjustments. The initial exercise price of the warrant is $0.70 per share, also subject to certain adjustments. The Company also amended and restated the Certificate of Designations, resulting in an adjustment to the conversion price of all currently outstanding Series D Shares to $0.70 per share.   On August 14, 2017, the price of the Series C and D Preferred Stock were adjusted to $0.25 per share pursuant to the documents governing such instruments. After adjustment there were 3,108,356 shares of Series D preferred stock authorized.   On July 17, 2018, the Company filed with the State of Nevada a second Amended and Restated Certificate of Designation of Preferences, Powers, and Rights of the Series D Convertible Preferred Stock. The Amended Certificate restates the prior Certificate of Designation filed on May 8, 2017 to decrease the number of authorized Series D shares from 3,906,250 shares to 1,016,014 shares. No other amendments were made to the preferences and rights of the Series D Convertible Preferred Stock. The filing of the Amended Certificate was unanimously approved by the Board of Directors and the shareholders of Series D Convertible Preferred Stock.   Series F Preferred Stock   On August 1, 2018, the Company filed with the State of Nevada a Certificate of Designation establishing the Designations, Preferences, Limitations and Relative Rights of Series F Preferred Stock (the “Designation”). The Designation authorized 500 shares of Series F Preferred Stock. The Series F Preferred Stock shall only be issued to the current Board of Directors on the date of the Designation’s filing and is not convertible into common stock. As set forth in the Designation, the Series F Preferred Stock has no rights to dividends or liquidation preference and carries rights to vote 100,000 shares of common stock per share of Series F upon a Trigger Event, as defined in the Designation. A Trigger Event includes certain unsolicited bids, tender offers, proxy contests, and significant share purchases, all as described in the Designation. Unless and until a Trigger Event, the Series F shall have no right to vote. The Series F Preferred Stock shall remain issued and outstanding until the date which is 731 days after the issuance of Series F Preferred Stock (“Explosion Date”), unless a Trigger Event occurs, in which case the Explosion Date shall be extended by 183 days.   Securities Subject to Price Adjustments   In the future, if we sell our common stock at a price below $0.25 per share, the exercise price of 20,000 outstanding shares of Series A Preferred Stock, 1,785,715 outstanding shares of Series C Preferred Stock, 1,016,004 outstanding shares Series D Preferred Stock that adjust below $0.25 per share pursuant to the documents governing such instruments. In addition, the conversion price of a Convertible Note Payable of $2,255,066 (9,020,264 common shares at the current price of $0.25 per share) and the exercise price of additional outstanding warrants to purchase 12,714,385 shares of common stock would adjust below $0.25 per share pursuant to the documents governing such instruments.     Common Stock   All of the offerings and sales described below were deemed to be exempt under Rule 506 of Regulation D and/or Section 4(a)(2) of the Securities Act. No advertising or general solicitation was employed in offering the securities, the offerings and sales were made to a limited number of persons, all of whom were accredited investors and transfer was restricted by the company in accordance with the requirements of Regulation D and the Securities Act. All issuances to accredited and non-accredited investors were structured to comply with the requirements of the safe harbor afforded by Rule 506 of Regulation D, including limiting the number of non-accredited investors to no more than 35 investors who have sufficient knowledge and experience in financial and business matters to make them capable of evaluating the merits and risks of an investment in our securities.   The following equity issuances occurred during the three months ended December 31, 2018:   The Company issued 279,929 shares of common stock and cancelled warrants to purchase 20,071 shares of common stock at $0.25 per share to a consultant and an investor related to the cashless exercise of warrants.   Warrants to Purchase Common Stock   The following warrants were issued during the three months ended December 31, 2018:   The Company issued 279,929 shares of common stock and cancelled warrants to purchase 20,071 shares of common stock at $0.25 per share to a consultant and an investor related to the cashless exercise of warrants.   A summary of the warrants outstanding as of December 31, 2018 were as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">December 31, 2018  </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Price</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 64%">Outstanding at beginning of period</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">15,473,398</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.326</td> <td style="width: 3%"> </td></tr> <tr style="vertical-align: bottom"> <td>Issued</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">(279,929</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(0.250</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Expired</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(20,071</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(0.250</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td>Outstanding at end of period</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">15,173,398</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">0.328</td> <td style="padding-bottom: 3pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Exerciseable at end of period</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">15,173,398</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right"> </td> <td style="padding-bottom: 3pt"> </td></tr> </table>   A summary of the status of the warrants outstanding as of December 31, 2018 is presented below:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: black 1pt solid; text-align: center">December 31, 2018      </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td colspan="2" style="text-align: center">Number of</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Life (In Years)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exerciseable</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Price</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 19%; text-align: right">13,570,286</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">3.75</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">0.250</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">13,570,286</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">0.250</td> <td style="width: 7%"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: right">714,286</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.58</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.700</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">714,286</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.700</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: right">882,159</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.87</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">882,159</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">6,667</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0.25</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">30.000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">6,667</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">30.000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">15,173,398</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">3.34</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">0.328</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">15,173,398</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">0.328</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   The significant weighted average assumptions relating to the valuation of the Company’s warrants for the three months ended December 31, 2018 were as follows:   Assumptions   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 65%">Dividend yield</td> <td style="width: 35%; text-align: center">0%</td></tr> <tr style="vertical-align: top"> <td>Expected life</td> <td style="text-align: center">1-2 years</td></tr> <tr style="vertical-align: top"> <td>Expected volatility</td> <td style="text-align: center">125%-145%</td></tr> <tr style="vertical-align: top"> <td>Risk free interest rate</td> <td style="text-align: center">.0202-.0214%</td></tr> </table>   There were vested warrants of 14,284,572 as of December 31, 2018 with an aggregate intrinsic value of $9,249,235.

On March 21, 2013, an amendment to the Stock Option Plan was approved by the stockholders of the Company, increasing the number of shares reserved for issuance under the Plan to 93,333 shares. On April 10, 2018, the Board approved an amendment to its 2011 Stock Incentive Plan increasing the number of shares of common stock reserved under the Incentive Plan from 93,333 to 1,200,000. On August 7, 2018, the Board approved an amendment to its 2011 Stock Incentive Plan increasing the number of shares of common stock reserved under the Incentive Plan from 1,200,000 to 2,000,000 to common shares.    Determining Fair Value under ASC 505   The Company records compensation expense associated with stock options and other equity-based compensation using the Black-Scholes-Merton option valuation model for estimating fair value of stock options granted under our plan. The Company amortizes the fair value of stock options on a ratable basis over the requisite service periods, which are generally the vesting periods. The expected life of awards granted represents the period of time that they are expected to be outstanding.  The Company estimates the volatility of our common stock based on the historical volatility of its own common stock over the most recent period corresponding with the estimated expected life of the award. The Company bases the risk-free interest rate used in the Black Scholes-Merton option valuation model on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent remaining term equal to the expected life of the award. The Company has not paid any cash dividends on our common stock and does not anticipate paying any cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield of zero in the Black-Scholes-Merton option valuation model and adjusts share-based compensation for changes to the estimate of expected equity award forfeitures based on actual forfeiture experience. The effect of adjusting the forfeiture rate is recognized in the period the forfeiture estimate is changed.   Stock Option Activity   The Company had the following stock option transactions during the three months ended December 31, 2018:   On October 31, 2018, the Board awarded stock option grants to two directors to acquire 50,000 shares each of the Company’s common stock. The grants were valued at $3.03 per share and expire on October 31, 2013. The grants vested immediately.   On October 31, 2018, the Board awarded Phillip A. Bosua a stock option grant to acquire 100,000 shares of the Company’s Common stock for each $1,000,000 raised by the Company in revenue generated in a planned Kickstarter campaign. In addition, Mr. Bosua was granted a stock option grant to acquire 1,000,000 shares of the Company’s common which vests upon approval of the Company’s blood glucose measurement technology by the U.S. Food and Drug Administration. The grants were valued at $3.03 per share and expire on October 31, 2023.   On October 31, 2018, the Board awarded Ronald P Erickson a stock option grant to acquire 1,000,000 shares of the Company’s common which vests upon the Company’s successful listing of its Common Stock on Nasdaq or the New York Stock Exchange (including the NYSE American Market). The grant was valued at $3.03 per share and expires on October 31, 2023.   There are currently 2,282,668 options to purchase common stock at an average exercise price of $1.757 per share outstanding as of December 31, 2018 under the 2011 Stock Incentive Plan. The Company recorded $171,498 and $2,147 of compensation expense, net of related tax effects, relative to stock options for the three months ended December 31, 2018 and December 31, 2017and in accordance with ASC 505. Net loss per share (basic and diluted) associated with this expense was approximately ($0.010) and ($0.00) per share, respectively. As of December 31, 2018, there is approximately $1,697,737, net of forfeitures, of total unrecognized costs related to employee granted stock options that are not vested. These costs are expected to be recognized over a period of approximately 4.94 years.    Stock option activity for the three months ended December 31, 2018 and the years ended September 30, 2018 and 2017 was as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">Weighted Average     </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Options </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">$ </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 45%">Outstanding as of September 30, 2016</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">50,908</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">18.04</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">918,627</td> <td style="width: 5%"> </td></tr> <tr style="vertical-align: bottom"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeitures</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(35,504</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(19.507</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(692,568</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td>Outstanding as of September 30, 2017</td> <td> </td> <td> </td> <td style="text-align: right">15,404</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">14.675</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">226,059</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">2,180,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.683</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,668,500</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeitures</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(12,736</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">14.764</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(188,040</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td>Outstanding as of September 30, 2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,182,668</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1.698</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,706,519</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">100,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.030</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">303,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeitures</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Outstanding as of December 31, 2018</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">2,282,668</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">1.757</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">4,009,519</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   The following table summarizes information about stock options outstanding and exercisable as of December 31, 2018:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td colspan="2" style="text-align: center">Range of</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining Life</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Prices</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Outstanding</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">In Years</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exerciseable</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exerciseable</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exerciseable</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 17%; text-align: right">0.25</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">530,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">4.86</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.250</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">66,250</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.25</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: right">1.28</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,150,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.96</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.28</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">71,875</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.28</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: right">3.03</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">100,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.96</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.03</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">100,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.03</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: right">4.08-4.20</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.98</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.08-4.20</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: right">13.500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,334</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.44</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">13.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,334</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">13.50</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">15.000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,334</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">15.00</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">15.00</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right"> </td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">2,282,668</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">4.94</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">1.757</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">239,459</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">1.00</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   There were stock option grants of 530,000 shares as of December 31, 2018 with an aggregate intrinsic value of $355,100.

Related Party Transactions with Ronald P. Erickson   See Notes 1, 10, 13 and 15 for related party transactions with Ronald P. Erickson.   Mr. Erickson and/or entities with which he is affiliated also have accrued compensation, travel and interest of approximately $530,102 as of December 31, 2018.   Related Party Transaction with Phillip A. Bosua   See Notes 1, 13 and 15 for related party transactions with Phillip A. Bosua.   Stock Option Grants to Directors   See Note 13 for related party transactions with Directors.

Legal Proceedings   The Company may from time to time become a party to various legal proceedings arising in the ordinary course of our business. The Company is currently not a party to any pending legal proceeding that is not ordinary routine litigation incidental to our business.   Employment Agreement with Phillip A. Bosua, Chief Executive Officer   On April 10, 2018, the Company appointed Mr. Bosua as Chief Executive Officer of the Company, replacing Ronald P. Erickson, who remains Chairman of the Company. Mr. Erickson has been a director and officer of Know Labs since April 2003. He was appointed as our CEO and President in November 2009 and as Chairman of the Board in February 2015. Previously, Mr. Erickson was our President and Chief Executive Officer from September 2003 through August 2003 and was Chairman of the Board from August 2004 until May 2011.   Phillip A. Bosua was appointed the Company’s CEO on April 10, 2018. Previously, Mr. Bosua served as the Company’s Chief Product Officer since August 2017. The Company entered into a Consulting Agreement with Mr. Bosua’s company, Blaze Clinical on July 7, 2017. From September 2012 to February 2015, Mr. Bosua was the founder and Chief Executive Officer of LIFX Inc. (where he developed and marketed an innovative “smart” light bulb) and from August 2015 until February 2016 was Vice President Consumer Products at Soraa (which markets specialty LED light bulbs). From February 2016 to July 2017, Mr. Bosua was the founder and CEO of RAAI, Inc. (where he continued the development of his smart lighting technology). From May 2008 to February 2013 he was the Founder and CEO of LimeMouse Apps, a leading developer of applications for the Apple App Store.   On April 10, 2018, the Company entered into an Employment Agreement with Mr. Bosua reflecting his appointment as Chief Executive Officer. The Employment Agreement is for an initial term of 12 months (subject to earlier termination) and will be automatically extended for additional 12-month terms unless either party notifies the other party of its intention to terminate the Employment Agreement. Mr. Bosua will be paid a base salary of $225,000 per year, received 500,000 shares of common stock valued at $0.33 per share and may be entitled to bonuses and equity awards at the discretion of the Board or a committee of the Board. The Employment Agreement provides for severance pay equal to 12 months of base salary if Mr. Bosua is terminated without “cause” or voluntarily terminates his employment for “good reason.”   Employment Agreement with Ronald P. Erickson, Chairman of the Board and Interim Chief Financial Officer   On August 4, 2017, the Board of Directors approved an Employment Agreement with Ronald P. Erickson pursuant to which the Company engaged Mr. Erickson as our Chief Executive Officer through September 30, 2018.   Mr. Erickson’s annual compensation is $180,000. Mr. Erickson is also entitled to receive an annual bonus and equity awards compensation as approved by the Board. The bonus should be paid no later than 30 days following earning of the bonus.   Mr. Erickson will be entitled to participate in all group employment benefits that are offered by the Company to our senior executives and management employees from time to time, subject to the terms and conditions of such benefit plans, including any eligibility requirements.   If the Company terminates Mr. Erickson’s employment at any time prior to the expiration of the Term without Cause, as defined in the Employment Agreement, or if Mr. Erickson terminates his employment at any time for “Good Reason” or due to a “Disability”, Mr. Erickson will be entitled to receive (i) his Base Salary amount for one year; and (ii) medical benefits for eighteen months.   On April 10, 2018, the Company entered into an Amended Employment Agreement for Ronald P. Erickson which amends the Employment Agreement dated July 1, 2017. The Agreement expires March 21, 2019.   Properties and Operating Leases   The Company is obligated under the following non-cancelable operating leases for its various facilities and certain equipment.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 65%; text-align: center">Years Ended December 31,</td> <td style="width: 35%; border-bottom: black 1pt solid; text-align: center">Total</td></tr> <tr style="vertical-align: top"> <td style="text-align: center">2019</td> <td style="text-align: right"> $ 106,190</td></tr> <tr style="vertical-align: top"> <td style="text-align: center">2020</td> <td style="text-align: right">72,519</td></tr> <tr style="vertical-align: top"> <td style="text-align: center">2021</td> <td style="text-align: right">14,540</td></tr> <tr style="vertical-align: top"> <td style="text-align: center">2022</td> <td style="text-align: right">-</td></tr> <tr style="vertical-align: top"> <td style="text-align: center">2023</td> <td style="text-align: right">-</td></tr> <tr style="vertical-align: top"> <td style="text-align: center">Beyond</td> <td style="border-bottom: black 1pt solid; text-align: right">-</td></tr> <tr style="vertical-align: top"> <td style="text-align: center">Total</td> <td style="border-bottom: black 1.5pt double; text-align: right"> $ 193,249</td></tr> </table>   Corporate Offices   On April 13, 2017, the Company leased its executive office located at 500 Union Street, Suite 810, Seattle, Washington, USA, 98101. The Company leases 943 square feet and the net monthly payment is $2,672. The monthly payment increases approximately 3% each year and the lease expires on May 31, 2022.   Lab Facilities and Executive Offices   On May 1, 2018, the Company leased its lab facilities and executive offices located at 304 Alaskan Way South, Suite 102, Seattle, Washington, USA, 98101. The Company leases 2,800 square feet and the net monthly payment is $4,000. The lease expires on April 30, 2019.   TransTech Facilities   TransTech is located at 12142 NE Sky Lane, Suite 130, Aurora, OR 97002. TransTech leases a total of approximately 6,340 square feet of office and warehouse space for its administrative offices, product inventory and shipping operations. Effective December 1, 2017, TransTech leases this office from December 1, 2017 at $4,465 per month. The monthly payment increases approximately 3% each year and the lease expires on January 31, 2020. Until December 1, 2017, TransTech leased this office on a month to month basis at $6,942 per month.

The Company evaluates subsequent events, for the purpose of adjustment or disclosure, up through the date the financial statements are available. Subsequent to December 31, 2018, there were the following material transactions that require disclosure:   On January 2, 2019, the Company issued 170,000 shares of restricted common stock to a Names Executive Officer and a consultant and for services during 2018.   On January 16, 2019, the Company leased replacement lab facilities and executive offices located at 1517 12th Ave Suite 203 Seattle, WA 98122. The lease commences February 1, 2019 and expires June 30, 2021. The Company leases 2,642 square feet and the net monthly payment is $8,256. The monthly payment increases approximately 3% on June 30, 2019 and 2020.   On January 29, 2019, the Company issued 45,888 shares of common stock and cancelled warrants to purchase 4,112 shares of common stock at $0.25 per share to an investor related to the exercise of warrants.   On January 29, 2019, the Company issued 80,000 shares of common stock and cancelled 20,000 shares of Series A Convertible Preferred Stock at $0.25 per share to an investor related to the conversion of the preferred stock.

Principles of Consolidation – The consolidated financial statements include the accounts of the Company and its wholly owned and majority-owned subsidiaries, TransTech Systems, Inc and RAAI Lighting, Inc. Inter-Company items and transactions have been eliminated in consolidation.

Cash and Cash Equivalents – The Company classifies highly liquid temporary investments with an original maturity of three months or less when purchased as cash equivalents. The Company maintains cash balances at various financial institutions. Balances at US banks are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant risk for cash on deposit.

Accounts Receivable and Allowance for Doubtful Accounts – Accounts receivable consist primarily of amounts due to the Company from normal business activities. The Company maintains an allowance for doubtful accounts to reflect the expected non-collection of accounts receivable based on past collection history and specific risks identified within the portfolio. If the financial condition of the customers were to deteriorate resulting in an impairment of their ability to make payments, or if payments from customers are significantly delayed, additional allowances might be required.

Inventories – Inventories consist primarily of printers and consumable supplies, including ribbons and cards, badge accessories, capture devices, and access control components held for resale and are stated at the lower of cost or market on the first-in, first-out (“FIFO”) method.  Inventories are considered available for resale when drop shipped and invoiced directly to a customer from a vendor, or when physically received by TransTech at a warehouse location.  The Company records a provision for excess and obsolete inventory whenever an impairment has been identified. There is a $35,000 reserve for impaired inventory as of December 31, 2018 and September 30, 2018, respectively.

Equipment – Equipment consists of machinery, leasehold improvements, furniture and fixtures and software, which are stated at cost less accumulated depreciation and amortization. Depreciation is computed by the straight-line method over the estimated useful lives or lease period of the relevant asset, generally 2-10 years, except for leasehold improvements which are depreciated over 2-3 years.

Long-Lived Assets – The Company reviews its long-lived assets for impairment annually or when changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Long-lived assets under certain circumstances are reported at the lower of carrying amount or fair value. Assets to be disposed of and assets not expected to provide any future service potential to the Company are recorded at the lower of carrying amount or fair value (less the projected cost associated with selling the asset). To the extent carrying values exceed fair values, an impairment loss is recognized in operating results.

Intangible Assets – Intangible assets are capitalized and amortized on a straight-line basis over their estimated useful life, if the life is determinable. If the life is not determinable, amortization is not recorded. We regularly perform reviews to determine if facts and circumstances exist which indicate that the useful lives of our intangible assets are shorter than originally estimated or the carrying amount of these assets may not be recoverable. When an indication exists that the carrying amount of intangible assets may not be recoverable, we assess the recoverability of our assets by comparing the projected undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. Such impairment test is based on the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. Impairment, if any, is based on the excess of the carrying amount over the estimated fair value of those assets.

Research, Development and Engineering Expenses – Research, development and engineering expenses consist of the cost of employees, consultants and contractors who design, engineer and develop new products and processes as well as materials, supplies and facilities used in producing prototypes.   The Company’s research and development efforts are primarily focused improving the core foundational ChromaID technology and developing new and unique applications for the technology. As part of this effort, the Company typically conduct testing to ensure that ChromaID application methods are compatible with the customer’s requirements, and that they can be implemented in a cost effective manner. The Company is also actively involved in identifying new application methods. Know Lab’s team has considerable experience working with the application of light-based technologies and their application to various industries. The Company believes that its continued development of new and enhanced technologies relating to our core business is essential to its future success. The Company spent $206,990, $570,514 and $79,405 during the three months ended December 31, 2018 and the years ended September 30, 2018 and 2017, respectively, on research and development activities.

Fair Value Measurements and Financial Instruments – ASC Topic 820, Fair Value Measurement and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.  This topic also establishes a fair value hierarchy, which requires classification based on observable and unobservable inputs when measuring fair value.  The fair value hierarchy distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs).  The hierarchy consists of three levels:   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 100%; font: 12pt Times New Roman, Times, Serif">Level 1 – Quoted prices in active markets for identical assets and liabilities;</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 100%"> Level 2 – Inputs other than level one inputs that are either directly or indirectly observable; and.   Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.  </td></tr> </table> The recorded value of other financial assets and liabilities, which consist primarily of cash and cash equivalents, accounts receivable, other current assets, and accounts payable and accrued expenses approximate the fair value of the respective assets and liabilities as of December 31, 2018 and September 30, 2018 are based upon the short-term nature of the assets and liabilities.

Derivative Financial Instruments -The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.

Revenue Recognition – Know Lab and TransTech revenue are derived from products and services. Revenue is considered realized when the products or services have been provided to the customer, the work has been accepted by the customer and collectability is reasonably assured. Furthermore, if an actual measurement of revenue cannot be determined, the Company defers all revenue recognition until such time that an actual measurement can be determined. If during the course of a contract management determines that losses are expected to be incurred, such costs are charged to operations in the period such losses are determined. Revenues are deferred when cash has been received from the customer but the revenue has not been earned.

Stock Based Compensation – The Company has share-based compensation plans under which employees, consultants, suppliers and directors may be granted restricted stock, as well as options to purchase shares of Company common stock at the fair market value at the time of grant. Stock-based compensation cost is measured by the Company at the grant date, based on the fair value of the award, over the requisite service period. For options issued to employees, the Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit.  Grants of stock options and stock to non-employees and other parties are accounted for in accordance with the ASC 505.

Convertible Securities – Based upon ASC 815-15, we have adopted a sequencing approach regarding the application of ASC 815-40 to convertible securities. We will evaluate our contracts based upon the earliest issuance date. In the event partial reclassification of contracts subject to ASC 815-40-25 is necessary, due to our inability to demonstrate we have sufficient shares authorized and unissued, shares will be allocated on the basis of issuance date, with the earliest issuance date receiving first allocation of shares. If a reclassification of an instrument were required, it would result in the instrument issued latest being reclassified first.

Net Loss per Share – Under the provisions of ASC 260, “Earnings Per Share,” basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of the Company, subject to anti-dilution limitations. As of December 31, 2018, there were options outstanding for the purchase of 2,282,668 common shares, warrants for the purchase of 15,173,398 common shares, and 4,914,071 shares of the Company’s common stock issuable upon the conversion of Series A, Series C and Series D Convertible Preferred Stock. In addition, the Company has an unknown number of shares (9,020,264 common shares at the current price of $0.25 per share) are issuable upon conversion of convertible debentures of $2,255,066. All of which could potentially dilute future earnings per share.   As of December 31, 2017, there were options outstanding for the purchase of 15,404 common shares, warrants for the purchase of 7,767,416 common shares, 2,825,053 shares of the Company’s common stock issuable upon the conversion of Series A, Series C and Series D Convertible Preferred Stock and up to 332,940 shares of the Company’s common stock issuable upon the exercise of placement agent warrants. In addition, the Company has an unknown number of shares issuable upon conversion of convertible debentures of $870,000. All of which could potentially dilute future earnings per share.

Dividend Policy – The Company has never paid any cash dividends and intends, for the foreseeable future, to retain any future earnings for the development of our business. Our future dividend policy will be determined by the board of directors on the basis of various factors, including our results of operations, financial condition, capital requirements and investment opportunities.

Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements   A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, management has not determined whether implementation of such proposed standards would be material to the Company’s consolidated financial statements.

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="text-align: center">Estimated</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">December 31, 2018    </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> Useful Lives</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Purchased</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Capital Leases</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 30%">Machinery and equipment</td> <td style="width: 18%; text-align: center">2-10 years</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">335,154</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">42,681</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">377,835</td> <td style="width: 5%"> </td></tr> <tr style="vertical-align: bottom"> <td>Leasehold improvements</td> <td style="text-align: center">2-3 years</td> <td> </td> <td> </td> <td style="text-align: right">276,112</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">276,112</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Furniture and fixtures</td> <td style="text-align: center">2-3 years</td> <td> </td> <td> </td> <td style="text-align: right">58,050</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">95,020</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">153,070</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Software and websites</td> <td style="text-align: center">3- 7 years</td> <td> </td> <td> </td> <td style="text-align: right">35,830</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">35,830</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Less: accumulated depreciation</td> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(551,456</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(137,701</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(689,157</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">153,690</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">153,690</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="text-align: center">Estimated</td> <td> </td> <td colspan="2" style="text-align: center">December 31,</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">September 30,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> Useful Lives</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 44%">Technology</td> <td style="width: 20%; text-align: center">3 years</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">520,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">520,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Less: accumulated amortization</td> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(115,555</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(72,222</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td>    Intangible assets, net</td> <td> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">404,445</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">447,778</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">December 31,</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">September 30,</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 64%">Capital Source Business Finance Group</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: black 1pt solid">$</td> <td style="width: 15%; border-bottom: black 1pt solid; text-align: right">46,576</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: black 1pt solid">$</td> <td style="width: 15%; border-bottom: black 1pt solid; text-align: right">145,186</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Total debt</td> <td> </td> <td> </td> <td style="text-align: right">46,576</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">145,186</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Less current portion of long term debt</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(46,576</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(145,186</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td>Long term debt</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">-</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: black 1pt solid; text-align: center">December 31, 2018      </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td colspan="2" style="text-align: center">Number of</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Shares</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Life (In Years)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exerciseable</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Price</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 19%; text-align: right">13,570,286</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">3.75</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">0.250</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">13,570,286</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">0.250</td> <td style="width: 7%"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: right">714,286</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.58</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.700</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">714,286</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.700</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: right">882,159</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2.87</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">882,159</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">6,667</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0.25</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">30.000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">6,667</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">30.000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">15,173,398</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">3.34</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">0.328</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">15,173,398</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">0.328</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

Assumptions   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 65%">Dividend yield</td> <td style="width: 35%; text-align: center">0%</td></tr> <tr style="vertical-align: top"> <td>Expected life</td> <td style="text-align: center">1-2 years</td></tr> <tr style="vertical-align: top"> <td>Expected volatility</td> <td style="text-align: center">125%-145%</td></tr> <tr style="vertical-align: top"> <td>Risk free interest rate</td> <td style="text-align: center">.0202-.0214%</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1pt solid; text-align: center">Weighted Average     </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Options </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Price </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">$ </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 45%">Outstanding as of September 30, 2016</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">50,908</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">18.04</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">918,627</td> <td style="width: 5%"> </td></tr> <tr style="vertical-align: bottom"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeitures</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(35,504</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(19.507</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(692,568</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td>Outstanding as of September 30, 2017</td> <td> </td> <td> </td> <td style="text-align: right">15,404</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">14.675</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">226,059</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">2,180,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.683</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,668,500</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeitures</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(12,736</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">14.764</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(188,040</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td>Outstanding as of September 30, 2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,182,668</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1.698</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">3,706,519</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">100,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.030</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">303,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeitures</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Outstanding as of December 31, 2018</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">2,282,668</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">1.757</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">4,009,519</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Weighted</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Average</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td colspan="2" style="text-align: center">Range of</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Remaining Life</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Number</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exercise Prices</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Outstanding</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">In Years</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exerciseable</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exerciseable</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Exerciseable</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 17%; text-align: right">0.25</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">530,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">4.86</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.250</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">66,250</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.25</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: right">1.28</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,150,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.96</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.28</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">71,875</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1.28</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: right">3.03</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">100,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.96</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.03</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">100,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.03</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: right">4.08-4.20</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.98</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4.08-4.20</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: right">13.500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,334</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">0.44</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">13.50</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,334</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">13.50</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">15.000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,334</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">15.00</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">15.00</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right"> </td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">2,282,668</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">4.94</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">1.757</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">239,459</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">1.00</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 65%; text-align: center">Years Ended December 31,</td> <td style="width: 35%; border-bottom: black 1pt solid; text-align: center">Total</td></tr> <tr style="vertical-align: top"> <td style="text-align: center">2019</td> <td style="text-align: right"> $ 106,190</td></tr> <tr style="vertical-align: top"> <td style="text-align: center">2020</td> <td style="text-align: right">72,519</td></tr> <tr style="vertical-align: top"> <td style="text-align: center">2021</td> <td style="text-align: right">14,540</td></tr> <tr style="vertical-align: top"> <td style="text-align: center">2022</td> <td style="text-align: right">-</td></tr> <tr style="vertical-align: top"> <td style="text-align: center">2023</td> <td style="text-align: right">-</td></tr> <tr style="vertical-align: top"> <td style="text-align: center">Beyond</td> <td style="border-bottom: black 1pt solid; text-align: right">-</td></tr> <tr style="vertical-align: top"> <td style="text-align: center">Total</td> <td style="border-bottom: black 1.5pt double; text-align: right"> $ 193,249</td></tr> </table>

-769203

-3257597

-3901232

35000

60000

689157

670666

551456

137701

35830

153070

58050

95020

276112

377835

335154

42681

18491

13828

520000

115555

72222

404445

447778

-217828

63493

32602

46576

145186

46576

145186

15173398

15473398

2182668

2282668

15404

50908

100000

2180000

279929

12736

35504

20071

15173398

.328

.326

1.698

1.757

14.675

18.040

.000

3.030

1.683

.000

.250

.000

-14.764

19.507

0.250

15173398

2282668

13570286

714286

882159

6667

530000

1150000

100000

500000

1334

15173398

239459

13570286

714286

882159

6667

66250

71875

100000

1334

0.328

1.757

0.250

0.700

1.000

30.000

.25

1.28

3.03

13.50

15.00

4.08

4.20

0.328

1.757

0.250

0.700

1.000

30.000

P3Y4M2D

P3Y9M

P2Y6M29D

P2Y10M13D

P3M

P4Y11M8D

P4Y10M10D

P5M8D

P4Y11M16D

P4Y11M23D

0.000000

P1Y

P2Y

1.250000

1.450000

0.000202

0.000214

14284572

9249235

3706519

4009519

226059

918627

303000

3668500

188040

692568

0.25

13.500

15.000

1.28

3.03

4.08

4.20

1.00 .25 1.28 3.03 0.00 13.50 15.00

355100

530102

106190

72519

14540

193249

171498

1697737

P4Y11M8D

EX-101.SCH 8 knwn-20181231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - 1. ORGANIZATION link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 2. GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 4. ACCOUNTS RECEIVABLE/CUSTOMER CONCENTRATION link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 5. INVENTORIES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 6. FIXED ASSETS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 7. INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 8. ACCOUNTS PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 9. DERIVATIVE INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 10. CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 11. NOTES PAYABLE, CAPITALIZED LEASES AND LONG TERM DEBT link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 12. EQUITY link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 13. STOCK OPTIONS link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 14. OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 15. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 16. SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS (Policies) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 6. FIXED ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 7. INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 11. NOTES PAYABLE, CAPITALIZED LEASES AND LONG TERM DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 12. EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 13. STOCK OPTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - 15. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - 2. GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - 3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - 4. ACCOUNTS RECEIVABLE/CUSTOMER CONCENTRATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - 5. INVENTORIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - 6. FIXED ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - 6. FIXED ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - 7. INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - 8. ACCOUNTS PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - 9. DERIVATIVE INSTRUMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - 10. CONVERTIBLE NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - 11. NOTES PAYABLE, CAPITALIZED LEASES AND LONG TERM DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - 12. EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - 12. EQUITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - 12. EQUITY (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - 12. EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - 13. STOCK OPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - 13. STOCK OPTIONS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - 13. STOCK OPTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - 14. OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES (Details narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - 15. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 knwn-20181231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 knwn-20181231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 knwn-20181231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Series A Convertible Preferred stock [Member] Series C Convertible Preferred stock [Member] Series D Convertible Preferred stock [Member] Property, Plant and Equipment, Type [Axis] Purchased [Member] Capital Leases [Member] Range [Axis] Minimum [Member] Maximum [Member] Leasehold Improvements [Member] Award Type [Axis] Stock Options 2011 Stock Incentive Plan Exercise Price Range [Axis] Exercise Price Total Warrant One [Member] Warrant Two [Member] Warrant Three [Member] Related Party [Axis] Chief Executive Officer Warrant Four [Member] Finite-Lived Intangible Assets by Major Class [Axis] Technology Short-term Debt, Type [Axis] Convertible Promissory Note [Member] Convertible Redeemable Promissory Note [Member] Exercise Price 0.25 Exercise Price 13.500 Exercise Price 15.000 Exercise Price 1.28 Exercise Price 3.03 Exercise Price 4.08-4.20 Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity's Reporting Status Current? Entity Filer Category Entity Emerging Growth Company Entity Small Business Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] ASSETS CURRENT ASSETS: Cash and cash equivalents Accounts receivable, net of allowance of $60,000 and $60,000, respectively Prepaid expenses Inventories, net Total current assets EQUIPMENT, NET OTHER ASSETS Intangible assets Other assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' (DEFICIT) CURRENT LIABILITIES: Accounts payable - trade Accounts payable - related parties Accrued expenses Accrued expenses - related parties Deferred revenue Convertible notes payable Notes payable - current portion of long term debt Total current liabilities COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' DEFICIT Preferred stock - $0.001 par value, 5,000,000 shares authorized, 0 shares issued and outstanding at 12/31/2018 and 9/30/2018, respectively Common stock - $0.001 par value, 100,000,000 shares authorized, 17,811,431 and 17,531,502 shares issued and outstanding at 12/31/2018 and 9/30/2018, respectively Additional paid in capital Accumulated deficit Total stockholders' deficit TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Allowance for accounts receivable EQUITY (DEFICIT) Preferred stock par value Preferred stock shares authorized Preferred stock shares issued Preferred stock shares outstanding Common stock par value Common stock shares authorized Common stock shares issued Common stock shares outstanding Income Statement [Abstract] REVENUE COST OF SALES GROSS PROFIT RESEARCH AND DEVELOPMENT EXPENSES SELLING, GENERAL AND ADMINISTRATIVE EXPENSES OPERATING LOSS OTHER INCOME (EXPENSE): Interest expense Other income Total other income (expense) (LOSS) BEFORE INCOME TAXES Income taxes - current provision NET (LOSS) Basic and diluted loss per common share attributable to Know Labs,, Inc. and subsidiaries common shareholders Basic and diluted loss per share Weighted average shares of common stock outstanding- basic and diluted Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash (used in) operating activities Depreciation and amortization Stock based compensation- stock option grants (Loss) on sale of assets Amortization of debt discount Provision on loss on accounts receivable Changes in operating assets and liabilities: Accounts receivable Prepaid expenses Inventory Other assets Accounts payable - trade and accrued expenses Deferred revenue NET CASH (USED IN) OPERATING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES: Investment in equipment Proceeds from sale of equipment NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES: CASH FLOWS FROM FINANCING ACTIVITIES: (Repayments) proceeds from line of credit Proceeds from convertible notes payable NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES NET (DECREASE) IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS, beginning of period CASH AND CASH EQUIVALENTS, end of period Supplemental disclosures of cash flow information: Interest paid Taxes paid Non-cash investing and financing activities: Benificial conversion feature Notes to Financial Statements ORGANIZATION GOING CONCERN SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS ACCOUNTS RECEIVABLE/CUSTOMER CONCENTRATION INVENTORIES FIXED ASSETS Finite-Lived Intangible Assets, Net [Abstract] INTANGIBLE ASSETS Accounts Payable [Abstract] ACCOUNTS PAYABLE Derivative Instruments and Hedging Activities Disclosure [Abstract] DERIVATIVE INSTRUMENTS Convertible Notes Payable CONVERTIBLE NOTES PAYABLE NOTES PAYABLE, CAPITALIZED LEASES AND LONG TERM DEBT EQUITY STOCK OPTIONS OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Principles of Consolidation Cash and Cash Equivalents Accounts Receivable and Allowance for Doubtful Accounts Inventories Equipment Long-Lived Assets Intangible Assets Research, Development and Engineering Expenses Fair Value Measurements and Financial Instruments Derivative Financial Instruments Revenue Recognition Stock Based Compensation Convertible Securities Net Loss per Share Dividend Policy Use of Estimates Recent Accounting Pronouncements Schedule of property and equipment Schedule of intangible assets Notes payable, capitalized leases and long term debt Summary of the warrants issued Summary of the status of the warrants outstanding Weighted average assumptions relating to the valuation of the Companys warrants Stock option activity Stock options outstanding and exercisable Commitments Contingencies And Legal Proceedings Properties and operating leases Net loss Net cash used in operating activities Accumulated Deficit Reserve for impaired inventory Estimated useful lives of assets EX-101.PRE 12 knwn-20181231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Dec. 31, 2018	Feb. 12, 2019
Document And Entity Information
Entity Registrant Name	KNOW LABS, INC.
Entity Central Index Key	0001074828
Document Type	10-Q
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding		18,107,319
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2019

XML 14 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2018	Sep. 30, 2018
CURRENT ASSETS:
Cash and cash equivalents	$ 310,779	$ 934,407
Accounts receivable, net of allowance of $60,000 and $60,000, respectively	206,084	320,538
Prepaid expenses	14,691	20,140
Inventories, net	159,223	203,582
Total current assets	690,777	1,478,667
EQUIPMENT, NET	153,690	169,333
OTHER ASSETS
Intangible assets	404,445	447,778
Other assets	7,170	7,170
TOTAL ASSETS	1,256,082	2,102,948
CURRENT LIABILITIES:
Accounts payable - trade	1,412,018	1,512,617
Accounts payable - related parties	0	12,019
Accrued expenses	71,036	72,140
Accrued expenses - related parties	676,681	657,551
Deferred revenue	0	55,959
Convertible notes payable	2,255,066	2,255,066
Notes payable - current portion of long term debt	46,576	145,186
Total current liabilities	4,461,377	4,710,538
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Preferred stock - $0.001 par value, 5,000,000 shares authorized, 0 shares issued and outstanding at 12/31/2018 and 9/30/2018, respectively	0	0
Common stock - $0.001 par value, 100,000,000 shares authorized, 17,811,431 and 17,531,502 shares issued and outstanding at 12/31/2018 and 9/30/2018, respectively	17,811	17,532
Additional paid in capital	32,334,605	32,163,386
Accumulated deficit	(35,560,527)	(34,791,324)
Total stockholders' deficit	(3,205,295)	(2,607,590)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	1,256,082	2,102,948
Series A Convertible Preferred stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock - $0.001 par value, 5,000,000 shares authorized, 0 shares issued and outstanding at 12/31/2018 and 9/30/2018, respectively	11	11
Series C Convertible Preferred stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock - $0.001 par value, 5,000,000 shares authorized, 0 shares issued and outstanding at 12/31/2018 and 9/30/2018, respectively	1,790	1,790
Series D Convertible Preferred stock [Member]
STOCKHOLDERS' DEFICIT
Preferred stock - $0.001 par value, 5,000,000 shares authorized, 0 shares issued and outstanding at 12/31/2018 and 9/30/2018, respectively	$ 1,015	$ 1,015

XML 15 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2018	Sep. 30, 2018
CURRENT ASSETS:
Allowance for accounts receivable	$ 60,000	$ 60,000
EQUITY (DEFICIT)
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized	5,000,000	5,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock par value	$ 0.001	$ 0.001
Common stock shares authorized	100,000,000	100,000,000
Common stock shares issued	17,811,431	17,531,502
Common stock shares outstanding	17,811,431	17,531,502
Series A Convertible Preferred stock [Member]
EQUITY (DEFICIT)
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized	23,334	23,334
Preferred stock shares issued	20,000	20,000
Preferred stock shares outstanding	20,000	20,000
Series C Convertible Preferred stock [Member]
EQUITY (DEFICIT)
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized	1,785,715	1,785,715
Preferred stock shares issued	1,785,715	1,785,715
Preferred stock shares outstanding	1,785,715	1,785,715
Series D Convertible Preferred stock [Member]
EQUITY (DEFICIT)
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized	1,016,014	1,016,014
Preferred stock shares issued	1,016,014	1,016,014
Preferred stock shares outstanding	1,016,014	1,016,014

XML 16 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
REVENUE	$ 602,209	$ 1,232,857
COST OF SALES	472,286	985,023
GROSS PROFIT	129,923	247,834
RESEARCH AND DEVELOPMENT EXPENSES	206,990	87,720
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	689,446	414,365
OPERATING LOSS	(766,513)	(254,251)
OTHER INCOME (EXPENSE):
Interest expense	(9,126)	(293,202)
Other income	6,436	19,188
Total other income (expense)	(2,690)	(274,014)
(LOSS) BEFORE INCOME TAXES	(769,203)	(528,265)
Income taxes - current provision	0	0
NET (LOSS)	$ (769,203)	$ (528,265)
Basic and diluted loss per common share attributable to Know Labs,, Inc. and subsidiaries common shareholders
Basic and diluted loss per share	$ (0.04)	$ (0.11)
Weighted average shares of common stock outstanding- basic and diluted	17,571,057	4,655,486

XML 17 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (769,203)	$ (528,265)
Adjustments to reconcile net loss to net cash (used in) operating activities
Depreciation and amortization	61,824	13,898
Stock based compensation- stock option grants	171,499	5,187
(Loss) on sale of assets	0	(1,710)
Amortization of debt discount	0	216,774
Provision on loss on accounts receivable	1,371	0
Changes in operating assets and liabilities:
Accounts receivable	113,083	(40,117)
Prepaid expenses	5,449	(9,499)
Inventory	44,359	64,597
Other assets	0	(2,100)
Accounts payable - trade and accrued expenses	(94,593)	(90,162)
Deferred revenue	(55,959)	0
NET CASH (USED IN) OPERATING ACTIVITIES	(522,170)	(371,397)
CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in equipment	(2,848)	0
Proceeds from sale of equipment	0	1,710
NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES:	(2,848)	1,710
CASH FLOWS FROM FINANCING ACTIVITIES:
(Repayments) proceeds from line of credit	(98,610)	58,764
Proceeds from convertible notes payable	0	300,000
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(98,610)	358,764
NET (DECREASE) IN CASH AND CASH EQUIVALENTS	(623,628)	(10,923)
CASH AND CASH EQUIVALENTS, beginning of period	934,407	103,181
CASH AND CASH EQUIVALENTS, end of period	310,779	92,258
Supplemental disclosures of cash flow information:
Interest paid	9,126	11,723
Taxes paid	0	0
Non-cash investing and financing activities:
Benificial conversion feature	$ 0	$ 216,774

XML 18 R6.htm IDEA: XBRL DOCUMENT

1. ORGANIZATION

3 Months Ended

Dec. 31, 2018

Notes to Financial Statements

ORGANIZATION

Overview

Merger with RAAI Lighting, Inc.

Appointment of Director

Appointment of Officer

On April 10, 2018, the Company entered into an Amended Employment Agreement for Ronald P. Erickson which amends the Employment Agreement dated July 1, 2017. The Agreement expires March 21, 2019.

Merger with Know Labs, Inc.

Corporate Name Change and Symbol Change

Closing of Financing on June 25, 2018

The initial exercise price of the warrants described above is $0.25 per share, subject to certain adjustments, and the warrants expire five years after their issuance.

XML 19 R7.htm IDEA: XBRL DOCUMENT

2. GOING CONCERN

3 Months Ended

Dec. 31, 2018

Notes to Financial Statements

GOING CONCERN

XML 20 R8.htm IDEA: XBRL DOCUMENT

3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS

3 Months Ended

Dec. 31, 2018

Notes to Financial Statements

SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS

Basis of Presentation – The accompanying unaudited consolidated financial statements include the accounts of the Company. Intercompany accounts and transactions have been eliminated. The preparation of these unaudited condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (“GAAP”).

Principles of Consolidation – The consolidated financial statements include the accounts of the Company and its wholly owned and majority-owned subsidiaries, TransTech Systems, Inc and RAAI Lighting, Inc. Inter-Company items and transactions have been eliminated in consolidation.

Cash and Cash Equivalents – The Company classifies highly liquid temporary investments with an original maturity of three months or less when purchased as cash equivalents. The Company maintains cash balances at various financial institutions. Balances at US banks are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant risk for cash on deposit.

Accounts Receivable and Allowance for Doubtful Accounts – Accounts receivable consist primarily of amounts due to the Company from normal business activities. The Company maintains an allowance for doubtful accounts to reflect the expected non-collection of accounts receivable based on past collection history and specific risks identified within the portfolio. If the financial condition of the customers were to deteriorate resulting in an impairment of their ability to make payments, or if payments from customers are significantly delayed, additional allowances might be required.

Inventories – Inventories consist primarily of printers and consumable supplies, including ribbons and cards, badge accessories, capture devices, and access control components held for resale and are stated at the lower of cost or market on the first-in, first-out (“FIFO”) method. Inventories are considered available for resale when drop shipped and invoiced directly to a customer from a vendor, or when physically received by TransTech at a warehouse location. The Company records a provision for excess and obsolete inventory whenever an impairment has been identified. There is a $35,000 reserve for impaired inventory as of December 31, 2018 and September 30, 2018, respectively.

Equipment – Equipment consists of machinery, leasehold improvements, furniture and fixtures and software, which are stated at cost less accumulated depreciation and amortization. Depreciation is computed by the straight-line method over the estimated useful lives or lease period of the relevant asset, generally 2-10 years, except for leasehold improvements which are depreciated over 2-3 years.

Long-Lived Assets – The Company reviews its long-lived assets for impairment annually or when changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Long-lived assets under certain circumstances are reported at the lower of carrying amount or fair value. Assets to be disposed of and assets not expected to provide any future service potential to the Company are recorded at the lower of carrying amount or fair value (less the projected cost associated with selling the asset). To the extent carrying values exceed fair values, an impairment loss is recognized in operating results.

Intangible Assets – Intangible assets are capitalized and amortized on a straight-line basis over their estimated useful life, if the life is determinable. If the life is not determinable, amortization is not recorded. We regularly perform reviews to determine if facts and circumstances exist which indicate that the useful lives of our intangible assets are shorter than originally estimated or the carrying amount of these assets may not be recoverable. When an indication exists that the carrying amount of intangible assets may not be recoverable, we assess the recoverability of our assets by comparing the projected undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. Such impairment test is based on the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. Impairment, if any, is based on the excess of the carrying amount over the estimated fair value of those assets.

Research, Development and Engineering Expenses – Research, development and engineering expenses consist of the cost of employees, consultants and contractors who design, engineer and develop new products and processes as well as materials, supplies and facilities used in producing prototypes.

Fair Value Measurements and Financial Instruments – ASC Topic 820, Fair Value Measurement and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. This topic also establishes a fair value hierarchy, which requires classification based on observable and unobservable inputs when measuring fair value. The fair value hierarchy distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs). The hierarchy consists of three levels:

Level 1 – Quoted prices in active markets for identical assets and liabilities;

Level 2 – Inputs other than level one inputs that are either directly or indirectly observable; and.

Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Derivative Financial Instruments -The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. For stock-based derivative financial instruments, the Company uses a Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.

Revenue Recognition – Know Lab and TransTech revenue are derived from products and services. Revenue is considered realized when the products or services have been provided to the customer, the work has been accepted by the customer and collectability is reasonably assured. Furthermore, if an actual measurement of revenue cannot be determined, the Company defers all revenue recognition until such time that an actual measurement can be determined. If during the course of a contract management determines that losses are expected to be incurred, such costs are charged to operations in the period such losses are determined. Revenues are deferred when cash has been received from the customer but the revenue has not been earned.

Stock Based Compensation – The Company has share-based compensation plans under which employees, consultants, suppliers and directors may be granted restricted stock, as well as options to purchase shares of Company common stock at the fair market value at the time of grant. Stock-based compensation cost is measured by the Company at the grant date, based on the fair value of the award, over the requisite service period. For options issued to employees, the Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit. Grants of stock options and stock to non-employees and other parties are accounted for in accordance with the ASC 505.

Convertible Securities – Based upon ASC 815-15, we have adopted a sequencing approach regarding the application of ASC 815-40 to convertible securities. We will evaluate our contracts based upon the earliest issuance date. In the event partial reclassification of contracts subject to ASC 815-40-25 is necessary, due to our inability to demonstrate we have sufficient shares authorized and unissued, shares will be allocated on the basis of issuance date, with the earliest issuance date receiving first allocation of shares. If a reclassification of an instrument were required, it would result in the instrument issued latest being reclassified first.

Net Loss per Share – Under the provisions of ASC 260, “Earnings Per Share,” basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of the Company, subject to anti-dilution limitations. As of December 31, 2018, there were options outstanding for the purchase of 2,282,668 common shares, warrants for the purchase of 15,173,398 common shares, and 4,914,071 shares of the Company’s common stock issuable upon the conversion of Series A, Series C and Series D Convertible Preferred Stock. In addition, the Company has an unknown number of shares (9,020,264 common shares at the current price of $0.25 per share) are issuable upon conversion of convertible debentures of $2,255,066. All of which could potentially dilute future earnings per share.

Dividend Policy – The Company has never paid any cash dividends and intends, for the foreseeable future, to retain any future earnings for the development of our business. Our future dividend policy will be determined by the board of directors on the basis of various factors, including our results of operations, financial condition, capital requirements and investment opportunities.

Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

XML 21 R9.htm IDEA: XBRL DOCUMENT

4. ACCOUNTS RECEIVABLE/CUSTOMER CONCENTRATION

3 Months Ended

Dec. 31, 2018

Notes to Financial Statements

ACCOUNTS RECEIVABLE/CUSTOMER CONCENTRATION

XML 22 R10.htm IDEA: XBRL DOCUMENT

5. INVENTORIES

3 Months Ended

Dec. 31, 2018

Notes to Financial Statements

INVENTORIES

XML 23 R11.htm IDEA: XBRL DOCUMENT

6. FIXED ASSETS

3 Months Ended

Dec. 31, 2018

Notes to Financial Statements

FIXED ASSETS

Property and equipment as of December 31, 2018 was comprised of the following:

	Estimated	December 31, 2018
	Useful Lives	Purchased			Capital Leases			Total
Machinery and equipment	2-10 years	$	335,154		$	42,681		$	377,835
Leasehold improvements	2-3 years		276,112			-			276,112
Furniture and fixtures	2-3 years		58,050			95,020			153,070
Software and websites	3- 7 years		35,830			-			35,830
Less: accumulated depreciation			(551,456	)		(137,701	)		(689,157	)
		$	153,690		$	-		$	153,690

XML 24 R12.htm IDEA: XBRL DOCUMENT

7. INTANGIBLE ASSETS

3 Months Ended

Dec. 31, 2018

Finite-Lived Intangible Assets, Net [Abstract]

INTANGIBLE ASSETS

Intangible assets as of December 31, 2018 and September 30, 2018 consisted of the following:

	Estimated	December 31,			September 30,
	Useful Lives	2018			2018

Technology	3 years	$	520,000		$	520,000
Less: accumulated amortization			(115,555	)		(72,222	)
Intangible assets, net		$	404,445		$	447,778

Total amortization expense was $43,332 and $72,222 for the three months ended December 31, 2018 and the year ended December 31, 2018, respectively.

Merger with RAAI Lighting, Inc.

Merger with Know Labs, Inc.

XML 25 R13.htm IDEA: XBRL DOCUMENT

8. ACCOUNTS PAYABLE

3 Months Ended

Dec. 31, 2018

Accounts Payable [Abstract]

ACCOUNTS PAYABLE

XML 26 R14.htm IDEA: XBRL DOCUMENT

9. DERIVATIVE INSTRUMENTS

3 Months Ended

Dec. 31, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE INSTRUMENTS

XML 27 R15.htm IDEA: XBRL DOCUMENT

10. CONVERTIBLE NOTES PAYABLE

3 Months Ended

Dec. 31, 2018

Convertible Notes Payable

CONVERTIBLE NOTES PAYABLE

Convertible notes payable as of December 31, 2018 and September 30, 2018 consisted of the following:

Convertible Promissory Note dated September 30, 2016

Securities Purchase Agreement dated August 14, 2017

The initial conversion price of the Debenture is $0.25 per share, subject to certain adjustments. The initial exercise price of the Warrant is $0.25 per share, also subject to certain adjustments.

During the year ended September 30, 2017, $156,941 was recorded as interest expense related to debt discounts, beneficial conversions and warrants associated with Convertible Promissory Notes.

Convertible Redeemable Promissory Notes with Ronald P. Erickson and J3E2A2Z

XML 28 R16.htm IDEA: XBRL DOCUMENT

11. NOTES PAYABLE, CAPITALIZED LEASES AND LONG TERM DEBT

3 Months Ended

Dec. 31, 2018

Notes to Financial Statements

NOTES PAYABLE, CAPITALIZED LEASES AND LONG TERM DEBT

Notes payable, capitalized leases and long-term debt as of December 31, 2018 and September 30, 2018 consisted of the following:

	December 31,			September 30,
	2018			2018

Capital Source Business Finance Group	$	46,576		$	145,186
Total debt		46,576			145,186
Less current portion of long term debt		(46,576	)		(145,186	)
Long term debt	$	-		$	-

Capital Source Business Finance Group

XML 29 R17.htm IDEA: XBRL DOCUMENT

12. EQUITY

3 Months Ended

Dec. 31, 2018

Notes to Financial Statements

EQUITY

Authorized Capital Stock

Voting Preferred Stock

The Company is authorized to issue up to 5,000,000 shares of preferred stock with a par value of $0.001.

Series A Preferred Stock

In July 2015, the Company sold Series A Preferred Stock to two investors for a total of $350,000. As of December 31, 2018, the Company had 20,000 Series A Preferred Stock issued and outstanding.

On August 14, 2017, the price of the Series A Preferred Stock and Series C and D Warrants were adjusted to $0.25 per share pursuant to the documents governing such instruments.

Series C and D Preferred Stock and Warrants

Series F Preferred Stock

Securities Subject to Price Adjustments

Common Stock

The following equity issuances occurred during the three months ended December 31, 2018:

Warrants to Purchase Common Stock

The following warrants were issued during the three months ended December 31, 2018:

A summary of the warrants outstanding as of December 31, 2018 were as follows:

	December 31, 2018
				Weighted
				Average
				Exercise
	Shares			Price
Outstanding at beginning of period		15,473,398		$	0.326
Issued		-			-
Exercised		(279,929	)		(0.250	)
Forfeited		-			-
Expired		(20,071	)		(0.250	)
Outstanding at end of period		15,173,398		$	0.328
Exerciseable at end of period		15,173,398

A summary of the status of the warrants outstanding as of December 31, 2018 is presented below:

		December 31, 2018
		Weighted		Weighted				Weighted
		Average		Average				Average
Number of		Remaining		Exercise		Shares		Exercise
Warrants		Life (In Years)		Price		Exerciseable		Price
	13,570,286		3.75	$	0.250		13,570,286	$	0.250
	714,286		2.58		0.700		714,286		0.700
	882,159		2.87		1.000		882,159		1.000
	6,667		0.25		30.000		6,667		30.000
	15,173,398		3.34	$	0.328		15,173,398	$	0.328

The significant weighted average assumptions relating to the valuation of the Company’s warrants for the three months ended December 31, 2018 were as follows:

Assumptions

Dividend yield	0%
Expected life	1-2 years
Expected volatility	125%-145%
Risk free interest rate	.0202-.0214%

There were vested warrants of 14,284,572 as of December 31, 2018 with an aggregate intrinsic value of $9,249,235.

XML 30 R18.htm IDEA: XBRL DOCUMENT

13. STOCK OPTIONS

3 Months Ended

Dec. 31, 2018

Notes to Financial Statements

STOCK OPTIONS

Determining Fair Value under ASC 505

Stock Option Activity

The Company had the following stock option transactions during the three months ended December 31, 2018:

Stock option activity for the three months ended December 31, 2018 and the years ended September 30, 2018 and 2017 was as follows:

	Weighted Average
	Options			Exercise Price			$
Outstanding as of September 30, 2016		50,908		$	18.04		$	918,627
Granted		-			-			-
Exercised		-			-			-
Forfeitures		(35,504	)		(19.507	)		(692,568	)
Outstanding as of September 30, 2017		15,404			14.675			226,059
Granted		2,180,000			1.683			3,668,500
Exercised		-			-			-
Forfeitures		(12,736	)		14.764			(188,040	)
Outstanding as of September 30, 2018		2,182,668			1.698			3,706,519
Granted		100,000			3.030			303,000
Exercised		-			-			-
Forfeitures		-			-			-
Outstanding as of December 31, 2018		2,282,668		$	1.757		$	4,009,519

The following table summarizes information about stock options outstanding and exercisable as of December 31, 2018:

				Weighted		Weighted				Weighted
				Average		Average				Average
Range of		Number		Remaining Life		Exercise Price		Number		Exercise Price
Exercise Prices		Outstanding		In Years		Exerciseable		Exerciseable		Exerciseable
	0.25		530,000		4.86	$	0.250		66,250	$	0.25
	1.28		1,150,000		4.96		1.28		71,875		1.28
	3.03		100,000		4.96		3.03		100,000		3.03
	4.08-4.20		500,000		4.98		4.08-4.20		-		-
	13.500		1,334		0.44		13.50		1,334		13.50
	15.000		1,334		-		15.00		-		15.00
			2,282,668		4.94	$	1.757		239,459	$	1.00

There were stock option grants of 530,000 shares as of December 31, 2018 with an aggregate intrinsic value of $355,100.

XML 31 R19.htm IDEA: XBRL DOCUMENT

14. OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES

3 Months Ended

Dec. 31, 2018

Notes to Financial Statements

OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES

Related Party Transactions with Ronald P. Erickson

See Notes 1, 10, 13 and 15 for related party transactions with Ronald P. Erickson.

Mr. Erickson and/or entities with which he is affiliated also have accrued compensation, travel and interest of approximately $530,102 as of December 31, 2018.

Related Party Transaction with Phillip A. Bosua

See Notes 1, 13 and 15 for related party transactions with Phillip A. Bosua.

Stock Option Grants to Directors

See Note 13 for related party transactions with Directors.

XML 32 R20.htm IDEA: XBRL DOCUMENT

15. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS

3 Months Ended

Dec. 31, 2018

Notes to Financial Statements

COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS

Legal Proceedings

Employment Agreement with Phillip A. Bosua, Chief Executive Officer

Employment Agreement with Ronald P. Erickson, Chairman of the Board and Interim Chief Financial Officer

On April 10, 2018, the Company entered into an Amended Employment Agreement for Ronald P. Erickson which amends the Employment Agreement dated July 1, 2017. The Agreement expires March 21, 2019.

Properties and Operating Leases

The Company is obligated under the following non-cancelable operating leases for its various facilities and certain equipment.

Years Ended December 31,	Total
2019	$ 106,190
2020	72,519
2021	14,540
2022	-
2023	-
Beyond	-
Total	$ 193,249

Corporate Offices

Lab Facilities and Executive Offices

TransTech Facilities

XML 33 R21.htm IDEA: XBRL DOCUMENT

16. SUBSEQUENT EVENTS

3 Months Ended

Dec. 31, 2018

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

On January 2, 2019, the Company issued 170,000 shares of restricted common stock to a Names Executive Officer and a consultant and for services during 2018.

XML 34 R22.htm IDEA: XBRL DOCUMENT

3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS (Policies)

3 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Basis of Presentation

Principles of Consolidation

Cash and Cash Equivalents

Accounts Receivable and Allowance for Doubtful Accounts

Research, Development and Engineering Expenses

Fair Value Measurements and Financial Instruments

Level 1 – Quoted prices in active markets for identical assets and liabilities;

Level 2 – Inputs other than level one inputs that are either directly or indirectly observable; and.

Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Derivative Financial Instruments

Revenue Recognition

Stock Based Compensation

Convertible Securities

Net Loss per Share

Dividend Policy

Use of Estimates

Recent Accounting Pronouncements

Recent Accounting Pronouncements

XML 35 R23.htm IDEA: XBRL DOCUMENT

6. FIXED ASSETS (Tables)

3 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Schedule of property and equipment

	Estimated	December 31, 2018
	Useful Lives	Purchased			Capital Leases			Total
Machinery and equipment	2-10 years	$	335,154		$	42,681		$	377,835
Leasehold improvements	2-3 years		276,112			-			276,112
Furniture and fixtures	2-3 years		58,050			95,020			153,070
Software and websites	3- 7 years		35,830			-			35,830
Less: accumulated depreciation			(551,456	)		(137,701	)		(689,157	)
		$	153,690		$	-		$	153,690

XML 36 R24.htm IDEA: XBRL DOCUMENT

7. INTANGIBLE ASSETS (Tables)

3 Months Ended

Dec. 31, 2018

Finite-Lived Intangible Assets, Net [Abstract]

Schedule of intangible assets

	Estimated	December 31,			September 30,
	Useful Lives	2018			2018

Technology	3 years	$	520,000		$	520,000
Less: accumulated amortization			(115,555	)		(72,222	)
Intangible assets, net		$	404,445		$	447,778

XML 37 R25.htm IDEA: XBRL DOCUMENT

11. NOTES PAYABLE, CAPITALIZED LEASES AND LONG TERM DEBT (Tables)

3 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Notes payable, capitalized leases and long term debt

	December 31,			September 30,
	2018			2018

Capital Source Business Finance Group	$	46,576		$	145,186
Total debt		46,576			145,186
Less current portion of long term debt		(46,576	)		(145,186	)
Long term debt	$	-		$	-

XML 38 R26.htm IDEA: XBRL DOCUMENT

12. EQUITY (Tables)

3 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Summary of the warrants issued

	December 31, 2018
				Weighted
				Average
				Exercise
	Shares			Price
Outstanding at beginning of period		15,473,398		$	0.326
Issued		-			-
Exercised		(279,929	)		(0.250	)
Forfeited		-			-
Expired		(20,071	)		(0.250	)
Outstanding at end of period		15,173,398		$	0.328
Exerciseable at end of period		15,173,398

Summary of the status of the warrants outstanding

		December 31, 2018
		Weighted		Weighted				Weighted
		Average		Average				Average
Number of		Remaining		Exercise		Shares		Exercise
Warrants		Life (In Years)		Price		Exerciseable		Price
	13,570,286		3.75	$	0.250		13,570,286	$	0.250
	714,286		2.58		0.700		714,286		0.700
	882,159		2.87		1.000		882,159		1.000
	6,667		0.25		30.000		6,667		30.000
	15,173,398		3.34	$	0.328		15,173,398	$	0.328

Weighted average assumptions relating to the valuation of the Companys warrants

Assumptions

Dividend yield	0%
Expected life	1-2 years
Expected volatility	125%-145%
Risk free interest rate	.0202-.0214%

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 39 R27.htm IDEA: XBRL DOCUMENT

13. STOCK OPTIONS (Tables)

3 Months Ended

Dec. 31, 2018

Notes to Financial Statements

Stock option activity

	Weighted Average
	Options			Exercise Price			$
Outstanding as of September 30, 2016		50,908		$	18.04		$	918,627
Granted		-			-			-
Exercised		-			-			-
Forfeitures		(35,504	)		(19.507	)		(692,568	)
Outstanding as of September 30, 2017		15,404			14.675			226,059
Granted		2,180,000			1.683			3,668,500
Exercised		-			-			-
Forfeitures		(12,736	)		14.764			(188,040	)
Outstanding as of September 30, 2018		2,182,668			1.698			3,706,519
Granted		100,000			3.030			303,000
Exercised		-			-			-
Forfeitures		-			-			-
Outstanding as of December 31, 2018		2,282,668		$	1.757		$	4,009,519

Stock options outstanding and exercisable

				Weighted		Weighted				Weighted
				Average		Average				Average
Range of		Number		Remaining Life		Exercise Price		Number		Exercise Price
Exercise Prices		Outstanding		In Years		Exerciseable		Exerciseable		Exerciseable
	0.25		530,000		4.86	$	0.250		66,250	$	0.25
	1.28		1,150,000		4.96		1.28		71,875		1.28
	3.03		100,000		4.96		3.03		100,000		3.03
	4.08-4.20		500,000		4.98		4.08-4.20		-		-
	13.500		1,334		0.44		13.50		1,334		13.50
	15.000		1,334		-		15.00		-		15.00
			2,282,668		4.94	$	1.757		239,459	$	1.00

XML 40 R28.htm IDEA: XBRL DOCUMENT

15. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS (Tables)

3 Months Ended

Dec. 31, 2018

Commitments Contingencies And Legal Proceedings

Properties and operating leases

Years Ended December 31,	Total
2019	$ 106,190
2020	72,519
2021	14,540
2022	-
2023	-
Beyond	-
Total	$ 193,249

XML 41 R29.htm IDEA: XBRL DOCUMENT

2. GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
2. GOING CONCERN (Details Narrative) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2018	Sep. 30, 2017
Notes to Financial Statements
Net loss	$ (769,203)		$ (3,257,597)	$ (3,901,232)
Net cash used in operating activities	(522,170)	$ (371,397)	(1,117,131)	$ (1,264,324)
Accumulated Deficit	$ (35,560,527)		$ (34,791,324)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 42 R30.htm IDEA: XBRL DOCUMENT

3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2018	Sep. 30, 2018
Reserve for impaired inventory	$ 35,000	$ 35,000
Minimum [Member]
Estimated useful lives of assets	2 years
Maximum [Member]
Estimated useful lives of assets	10 years
Leasehold Improvements [Member] \| Minimum [Member]
Estimated useful lives of assets	5 years
Leasehold Improvements [Member] \| Maximum [Member]
Estimated useful lives of assets	20 years

XML 43 R31.htm IDEA: XBRL DOCUMENT

4. ACCOUNTS RECEIVABLE/CUSTOMER CONCENTRATION (Details Narrative) - USD ($)	Dec. 31, 2018	Sep. 30, 2018
Notes to Financial Statements
Accounts receivable, net of allowance	$ 206,084	$ 320,538
Allowance for bad debt	$ 60,000

XML 44 R32.htm IDEA: XBRL DOCUMENT

5. INVENTORIES (Details Narrative) - USD ($)	Dec. 31, 2018	Sep. 30, 2018
Notes to Financial Statements
Inventories	$ 159,223	$ 203,582
Reserve for impaired inventory	$ 35,000	$ 35,000

XML 45 R33.htm IDEA: XBRL DOCUMENT

6. FIXED ASSETS (Details) - USD ($)	Dec. 31, 2018	Sep. 30, 2018
Machinery and equipment (2-10 years)	$ 377,835
Leasehold improvements (5-20 years)	276,112
Furniture and fixtures (3-10 years)	153,070
Software and websites (3- 7 years)	35,830
Less: accumulated depreciation	(689,157)	$ (670,666)
Property and equipment, net	153,690	$ 169,333
Purchased [Member]
Machinery and equipment (2-10 years)	335,154
Leasehold improvements (5-20 years)	276,112
Furniture and fixtures (3-10 years)	58,050
Software and websites (3- 7 years)	35,830
Less: accumulated depreciation	(551,456)
Property and equipment, net	153,690
Capital Leases [Member]
Machinery and equipment (2-10 years)	42,681
Leasehold improvements (5-20 years)	0
Furniture and fixtures (3-10 years)	95,020
Software and websites (3- 7 years)	0
Less: accumulated depreciation	(137,701)
Property and equipment, net	$ 0

XML 46 R34.htm IDEA: XBRL DOCUMENT

6. FIXED ASSETS (Details Narrative) - USD ($)	3 Months Ended
6. FIXED ASSETS (Details Narrative) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2018
Notes to Financial Statements
Property and equipment, net	$ 153,690		$ 169,333
Property and equipment, accumulated depreciation	689,157		$ 670,666
Depreciation expense	$ 18,491	$ 13,828

XML 47 R35.htm IDEA: XBRL DOCUMENT

7. INTANGIBLE ASSETS (Details) - Technology - USD ($)	Dec. 31, 2018	Sep. 30, 2018
Intangible assets, gross	$ 520,000	$ 520,000
Less: accumulated amortization	(115,555)	(72,222)
Intangible assets, net	$ 404,445	$ 447,778

XML 48 R36.htm IDEA: XBRL DOCUMENT

8. ACCOUNTS PAYABLE (Details Narrative) - USD ($)	Dec. 31, 2018	Sep. 30, 2018
Accounts Payable [Abstract]
Accounts payable - trade	$ 1,412,018	$ 1,512,617

XML 49 R37.htm IDEA: XBRL DOCUMENT

9. DERIVATIVE INSTRUMENTS (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
9. DERIVATIVE INSTRUMENTS (Details Narrative) - USD ($)	Dec. 31, 2018	Sep. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Change in the fair value of the liability	$ (217,828)	$ (217,828)

XML 50 R38.htm IDEA: XBRL DOCUMENT

10. CONVERTIBLE NOTES PAYABLE (Details Narrative)	Dec. 31, 2018 USD ($)
Convertible Promissory Note [Member]
Accrued interest	$ 63,493
Convertible Redeemable Promissory Note [Member]
Accrued interest	$ 32,602

XML 51 R39.htm IDEA: XBRL DOCUMENT

11. NOTES PAYABLE, CAPITALIZED LEASES AND LONG TERM DEBT (Details) - USD ($)	Dec. 31, 2018	Sep. 30, 2018
Notes Payable Capitalized Leases And Long Term Debt Details
Capital Source Business Finance Group	$ 46,576	$ 145,186
Total debt	46,576	145,186
Less current portion of long term debt	(46,576)	(145,186)
Long term debt	$ 0	$ 0

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

XML 52 R40.htm IDEA: XBRL DOCUMENT

12. EQUITY (Details)	3 Months Ended
12. EQUITY (Details)	Dec. 31, 2018 $ / shares shares
Shares
Outstanding at beginning of period	15,473,398
Issued	0
Exercised	(279,929)
Forfeited	0
Expired	(20,071)
Outstanding at end of period	15,173,398
Exercisable at end of period	15,173,398
Weighted Average Exercise Price:
Outstanding at beginning of period \| $ / shares	$ .326
Issued \| $ / shares	.000
Exercised \| $ / shares	(.250)
Forfeited \| $ / shares	.000
Expired \| $ / shares	(0.250)
Outstanding at end of period \| $ / shares	$ .328

XML 53 R41.htm IDEA: XBRL DOCUMENT

12. EQUITY (Details 1)	3 Months Ended
12. EQUITY (Details 1)	Dec. 31, 2018 $ / shares shares
Number of Warrants \| shares	15,173,398
Weighted Average Remaining Life (years)	3 years 4 months 2 days
Weighted Average Exercise Price, outstanding \| $ / shares	$ 0.328
Shares Exercisable \| shares	15,173,398
Weighted Average Exercise Price, exerciseable \| $ / shares	$ 0.328
Warrant One [Member]
Number of Warrants \| shares	13,570,286
Weighted Average Remaining Life (years)	3 years 9 months
Weighted Average Exercise Price, outstanding \| $ / shares	$ 0.250
Shares Exercisable \| shares	13,570,286
Weighted Average Exercise Price, exerciseable \| $ / shares	$ 0.250
Warrant Two [Member]
Number of Warrants \| shares	714,286
Weighted Average Remaining Life (years)	2 years 6 months 29 days
Weighted Average Exercise Price, outstanding \| $ / shares	$ 0.700
Shares Exercisable \| shares	714,286
Weighted Average Exercise Price, exerciseable \| $ / shares	$ 0.700
Warrant Three [Member]
Number of Warrants \| shares	882,159
Weighted Average Remaining Life (years)	2 years 10 months 13 days
Weighted Average Exercise Price, outstanding \| $ / shares	$ 1.000
Shares Exercisable \| shares	882,159
Weighted Average Exercise Price, exerciseable \| $ / shares	$ 1.000
Warrant Four [Member]
Number of Warrants \| shares	6,667
Weighted Average Remaining Life (years)	3 months
Weighted Average Exercise Price, outstanding \| $ / shares	$ 30.000
Shares Exercisable \| shares	6,667
Weighted Average Exercise Price, exerciseable \| $ / shares	$ 30.000

XML 54 R42.htm IDEA: XBRL DOCUMENT

12. EQUITY (Details 2)	3 Months Ended
12. EQUITY (Details 2)	Dec. 31, 2018
Dividend yield	0.00%
Minimum [Member]
Expected life	1 year
Expected volatility	125.00%
Risk free interest rate	0.0202%
Maximum [Member]
Expected life	2 years
Expected volatility	145.00%
Risk free interest rate	0.0214%

XML 55 R43.htm IDEA: XBRL DOCUMENT

12. EQUITY (Details Narrative)	Dec. 31, 2018 USD ($) shares
Notes to Financial Statements
Warrants Vested \| shares	14,284,572
Intrinsic value \| $	$ 9,249,235

XML 56 R44.htm IDEA: XBRL DOCUMENT

13. STOCK OPTIONS (Details) - USD ($)	3 Months Ended	12 Months Ended
13. STOCK OPTIONS (Details) - USD ($)	Dec. 31, 2018	Sep. 30, 2018	Sep. 30, 2017
Shares:
Outstanding at beginning of period	15,473,398
Shares granted	0
Shares exercised	279,929
Shares forfeitures	0
Outstanding at end of period	15,173,398	15,473,398
Weighted Average Exercise Price:
Outstanding at beginning of period	$ .326
Shares granted	.000
Shares exercised	.250
Shares forfeitures	(.000)
Outstanding at end of period	$ .328	$ .326
Aggregate Intrinsic Value
Aggregate Intrinsic Value Outstanding, End	$ 9,249,235
Stock Options
Shares:
Outstanding at beginning of period	2,182,668	15,404	50,908
Shares granted	100,000	2,180,000	0
Shares exercised	0	0	0
Shares forfeitures	0	(12,736)	(35,504)
Outstanding at end of period	2,282,668	2,182,668	15,404
Weighted Average Exercise Price:
Outstanding at beginning of period	$ 1.698	$ 14.675	$ 18.040
Shares granted	3.030	1.683	.000
Shares exercised	.000	.000	.000
Shares forfeitures	(.000)	14.764	(19.507)
Outstanding at end of period	$ 1.757	$ 1.698	$ 14.675
Aggregate Intrinsic Value
Aggregate Intrinsic Value Outstanding, Beginning	$ 3,706,519	$ 226,059	$ 918,627
Aggregate Intrinsic Value Outstanding, Granted	$ 303,000	$ 3,668,500	$ 0
Aggregate Intrinsic Value Outstanding, Exercised	$ 0	$ 0	$ 0
Aggregate Intrinsic Value Outstanding, Forefeitures	$ 0	$ (188,040)	$ (692,568)
Aggregate Intrinsic Value Outstanding, End	$ 4,009,519	$ 3,706,519	$ 226,059

XML 57 R45.htm IDEA: XBRL DOCUMENT

13. STOCK OPTIONS (Details 1)	3 Months Ended
13. STOCK OPTIONS (Details 1)	Dec. 31, 2018 $ / shares shares
Number of Outstanding Stock Options \| shares	15,173,398
Weighted Average Remaining Life (years)	3 years 4 months 2 days
Weighted Average Exercise Price Exerciseable	$ 0.328
Number Exercisable \| shares	15,173,398
Exercise Price 0.25
Range of Exercise Prices	$ 0.25
Number of Outstanding Stock Options \| shares	530,000
Weighted Average Remaining Life (years)	4 years 10 months 10 days
Weighted Average Exercise Price Exerciseable	$ .25
Number Exercisable \| shares	66,250
Weighted Average Exercise Price Exerciseable	$ .25
Exercise Price 1.28
Range of Exercise Prices	$ 1.28
Number of Outstanding Stock Options \| shares	1,150,000
Weighted Average Remaining Life (years)	4 years 11 months 16 days
Weighted Average Exercise Price Exerciseable	$ 1.28
Number Exercisable \| shares	71,875
Weighted Average Exercise Price Exerciseable	$ 1.28
Exercise Price 3.03
Range of Exercise Prices	$ 3.03
Number of Outstanding Stock Options \| shares	100,000
Weighted Average Remaining Life (years)	4 years 11 months 16 days
Weighted Average Exercise Price Exerciseable	$ 3.03
Number Exercisable \| shares	100,000
Weighted Average Exercise Price Exerciseable	$ 3.03
Exercise Price 4.08-4.20
Number of Outstanding Stock Options \| shares	500,000
Weighted Average Remaining Life (years)	4 years 11 months 23 days
Number Exercisable \| shares	0
Weighted Average Exercise Price Exerciseable	$ 0.00
Exercise Price 4.08-4.20 \| Minimum [Member]
Range of Exercise Prices	4.08
Weighted Average Exercise Price Exerciseable	4.08
Exercise Price 4.08-4.20 \| Maximum [Member]
Range of Exercise Prices	4.20
Weighted Average Exercise Price Exerciseable	4.20
Exercise Price 13.500
Range of Exercise Prices	$ 13.500
Number of Outstanding Stock Options \| shares	1,334
Weighted Average Remaining Life (years)	5 months 8 days
Weighted Average Exercise Price Exerciseable	$ 13.50
Number Exercisable \| shares	1,334
Weighted Average Exercise Price Exerciseable	$ 13.50
Exercise Price 15.000
Range of Exercise Prices	$ 15.000
Number of Outstanding Stock Options \| shares	1,334
Weighted Average Exercise Price Exerciseable	$ 15.00
Number Exercisable \| shares	0
Weighted Average Exercise Price Exerciseable	$ 15.00
Exercise Price Total
Number of Outstanding Stock Options \| shares	2,282,668
Weighted Average Remaining Life (years)	4 years 11 months 8 days
Weighted Average Exercise Price Exerciseable	$ 1.757
Number Exercisable \| shares	239,459
Weighted Average Exercise Price Exerciseable	$ 1.00

XML 58 R46.htm IDEA: XBRL DOCUMENT

13. STOCK OPTIONS (Details Narrative)	3 Months Ended
13. STOCK OPTIONS (Details Narrative)	Dec. 31, 2018 USD ($) $ / shares shares
Options to purchase common stock under 2011 Stock Incentive Plan	15,173,398
Average exercise price under 2011 Stock Incentive Plan \| $ / shares	$ 0.328
Compensation expense \| $	$ 171,498
Unrecognized compensation costs \| $	$ 1,697,737
Period for recognition	4 years 11 months 8 days
Exercisable at end of period	15,173,398
Stock options granted	0
Aggregate intrinsic value \| $	$ 355,100
2011 Stock Incentive Plan
Options to purchase common stock under 2011 Stock Incentive Plan	2,282,668
Average exercise price under 2011 Stock Incentive Plan \| $ / shares	$ 1.757

XML 59 R47.htm IDEA: XBRL DOCUMENT

14. OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES (Details narrative)	3 Months Ended
	Dec. 31, 2018 USD ($)
Chief Executive Officer
Accrued liabilities related parties from advances	$ 530,102

XML 60 R48.htm IDEA: XBRL DOCUMENT

15. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS (Details)	Dec. 31, 2018 USD ($)
Commitments Contingencies And Legal Proceedings Details Abstract
2019	$ 106,190
2020	72,519
2021	14,540
2022	0
2023	0
Beyond	0
Total	$ 193,249

XML 61 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 60 182 1 false 25 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://knowlabs.co/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://knowlabs.co/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://knowlabs.co/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://knowlabs.co/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://knowlabs.co/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 00000006 - Disclosure - 1. ORGANIZATION Sheet http://knowlabs.co/role/Organization 1. ORGANIZATION Notes 6 false false R7.htm 00000007 - Disclosure - 2. GOING CONCERN Sheet http://knowlabs.co/role/GoingConcern 2. GOING CONCERN Notes 7 false false R8.htm 00000008 - Disclosure - 3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS Sheet http://knowlabs.co/role/SignificantAccountingPoliciesAdoptionOfAccountingStandards 3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS Notes 8 false false R9.htm 00000009 - Disclosure - 4. ACCOUNTS RECEIVABLE/CUSTOMER CONCENTRATION Sheet http://knowlabs.co/role/AccountsReceivablecustomerConcentration 4. ACCOUNTS RECEIVABLE/CUSTOMER CONCENTRATION Notes 9 false false R10.htm 00000010 - Disclosure - 5. INVENTORIES Sheet http://knowlabs.co/role/Inventories 5. INVENTORIES Notes 10 false false R11.htm 00000011 - Disclosure - 6. FIXED ASSETS Sheet http://knowlabs.co/role/FixedAssets 6. FIXED ASSETS Notes 11 false false R12.htm 00000012 - Disclosure - 7. INTANGIBLE ASSETS Sheet http://knowlabs.co/role/IntangibleAssets 7. INTANGIBLE ASSETS Notes 12 false false R13.htm 00000013 - Disclosure - 8. ACCOUNTS PAYABLE Sheet http://knowlabs.co/role/AccountsPayable 8. ACCOUNTS PAYABLE Notes 13 false false R14.htm 00000014 - Disclosure - 9. DERIVATIVE INSTRUMENTS Sheet http://knowlabs.co/role/DerivativeInstruments 9. DERIVATIVE INSTRUMENTS Notes 14 false false R15.htm 00000015 - Disclosure - 10. CONVERTIBLE NOTES PAYABLE Notes http://knowlabs.co/role/ConvertibleNotesPayable 10. CONVERTIBLE NOTES PAYABLE Notes 15 false false R16.htm 00000016 - Disclosure - 11. NOTES PAYABLE, CAPITALIZED LEASES AND LONG TERM DEBT Notes http://knowlabs.co/role/NotesPayableCapitalizedLeasesAndLongTermDebt 11. NOTES PAYABLE, CAPITALIZED LEASES AND LONG TERM DEBT Notes 16 false false R17.htm 00000017 - Disclosure - 12. EQUITY Sheet http://knowlabs.co/role/Equity 12. EQUITY Notes 17 false false R18.htm 00000018 - Disclosure - 13. STOCK OPTIONS Sheet http://knowlabs.co/role/StockOptions 13. STOCK OPTIONS Notes 18 false false R19.htm 00000019 - Disclosure - 14. OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES Sheet http://knowlabs.co/role/OtherSignificantTransactionsWithRelatedParties 14. OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES Notes 19 false false R20.htm 00000020 - Disclosure - 15. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS Sheet http://knowlabs.co/role/CommitmentsContingenciesAndLegalProceedings 15. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS Notes 20 false false R21.htm 00000021 - Disclosure - 16. SUBSEQUENT EVENTS Sheet http://knowlabs.co/role/SubsequentEvents 16. SUBSEQUENT EVENTS Notes 21 false false R22.htm 00000022 - Disclosure - 3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS (Policies) Sheet http://knowlabs.co/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies 3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS (Policies) Policies 22 false false R23.htm 00000023 - Disclosure - 6. FIXED ASSETS (Tables) Sheet http://knowlabs.co/role/FixedAssetsTables 6. FIXED ASSETS (Tables) Tables http://knowlabs.co/role/FixedAssets 23 false false R24.htm 00000024 - Disclosure - 7. INTANGIBLE ASSETS (Tables) Sheet http://knowlabs.co/role/IntangibleAssetsTables 7. INTANGIBLE ASSETS (Tables) Tables http://knowlabs.co/role/IntangibleAssets 24 false false R25.htm 00000025 - Disclosure - 11. NOTES PAYABLE, CAPITALIZED LEASES AND LONG TERM DEBT (Tables) Notes http://knowlabs.co/role/NotesPayableCapitalizedLeasesAndLongTermDebtTables 11. NOTES PAYABLE, CAPITALIZED LEASES AND LONG TERM DEBT (Tables) Tables http://knowlabs.co/role/NotesPayableCapitalizedLeasesAndLongTermDebt 25 false false R26.htm 00000026 - Disclosure - 12. EQUITY (Tables) Sheet http://knowlabs.co/role/EquityTables 12. EQUITY (Tables) Tables http://knowlabs.co/role/Equity 26 false false R27.htm 00000027 - Disclosure - 13. STOCK OPTIONS (Tables) Sheet http://knowlabs.co/role/StockOptionsTables 13. STOCK OPTIONS (Tables) Tables http://knowlabs.co/role/StockOptions 27 false false R28.htm 00000028 - Disclosure - 15. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS (Tables) Sheet http://knowlabs.co/role/CommitmentsContingenciesAndLegalProceedingsTables 15. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS (Tables) Tables http://knowlabs.co/role/CommitmentsContingenciesAndLegalProceedings 28 false false R29.htm 00000029 - Disclosure - 2. GOING CONCERN (Details Narrative) Sheet http://knowlabs.co/role/GoingConcernDetailsNarrative 2. GOING CONCERN (Details Narrative) Details http://knowlabs.co/role/GoingConcern 29 false false R30.htm 00000030 - Disclosure - 3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS (Details Narrative) Sheet http://knowlabs.co/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsDetailsNarrative 3. SIGNIFICANT ACCOUNTING POLICIES: ADOPTION OF ACCOUNTING STANDARDS (Details Narrative) Details http://knowlabs.co/role/SignificantAccountingPoliciesAdoptionOfAccountingStandardsPolicies 30 false false R31.htm 00000031 - Disclosure - 4. ACCOUNTS RECEIVABLE/CUSTOMER CONCENTRATION (Details Narrative) Sheet http://knowlabs.co/role/AccountsReceivablecustomerConcentrationDetailsNarrative 4. ACCOUNTS RECEIVABLE/CUSTOMER CONCENTRATION (Details Narrative) Details http://knowlabs.co/role/AccountsReceivablecustomerConcentration 31 false false R32.htm 00000032 - Disclosure - 5. INVENTORIES (Details Narrative) Sheet http://knowlabs.co/role/InventoriesDetailsNarrative 5. INVENTORIES (Details Narrative) Details http://knowlabs.co/role/Inventories 32 false false R33.htm 00000033 - Disclosure - 6. FIXED ASSETS (Details) Sheet http://knowlabs.co/role/FixedAssetsDetails 6. FIXED ASSETS (Details) Details http://knowlabs.co/role/FixedAssetsTables 33 false false R34.htm 00000034 - Disclosure - 6. FIXED ASSETS (Details Narrative) Sheet http://knowlabs.co/role/FixedAssetsDetailsNarrative 6. FIXED ASSETS (Details Narrative) Details http://knowlabs.co/role/FixedAssetsTables 34 false false R35.htm 00000035 - Disclosure - 7. INTANGIBLE ASSETS (Details) Sheet http://knowlabs.co/role/IntangibleAssetsDetails 7. INTANGIBLE ASSETS (Details) Details http://knowlabs.co/role/IntangibleAssetsTables 35 false false R36.htm 00000036 - Disclosure - 8. ACCOUNTS PAYABLE (Details Narrative) Sheet http://knowlabs.co/role/AccountsPayableDetailsNarrative 8. ACCOUNTS PAYABLE (Details Narrative) Details http://knowlabs.co/role/AccountsPayable 36 false false R37.htm 00000037 - Disclosure - 9. DERIVATIVE INSTRUMENTS (Details Narrative) Sheet http://knowlabs.co/role/DerivativeInstrumentsDetailsNarrative 9. DERIVATIVE INSTRUMENTS (Details Narrative) Details http://knowlabs.co/role/DerivativeInstruments 37 false false R38.htm 00000038 - Disclosure - 10. CONVERTIBLE NOTES PAYABLE (Details Narrative) Notes http://knowlabs.co/role/ConvertibleNotesPayableDetailsNarrative 10. CONVERTIBLE NOTES PAYABLE (Details Narrative) Details http://knowlabs.co/role/ConvertibleNotesPayable 38 false false R39.htm 00000039 - Disclosure - 11. NOTES PAYABLE, CAPITALIZED LEASES AND LONG TERM DEBT (Details) Notes http://knowlabs.co/role/NotesPayableCapitalizedLeasesAndLongTermDebtDetails 11. NOTES PAYABLE, CAPITALIZED LEASES AND LONG TERM DEBT (Details) Details http://knowlabs.co/role/NotesPayableCapitalizedLeasesAndLongTermDebtTables 39 false false R40.htm 00000040 - Disclosure - 12. EQUITY (Details) Sheet http://knowlabs.co/role/EquityDetails 12. EQUITY (Details) Details http://knowlabs.co/role/EquityTables 40 false false R41.htm 00000041 - Disclosure - 12. EQUITY (Details 1) Sheet http://knowlabs.co/role/EquityDetails1 12. EQUITY (Details 1) Details http://knowlabs.co/role/EquityTables 41 false false R42.htm 00000042 - Disclosure - 12. EQUITY (Details 2) Sheet http://knowlabs.co/role/EquityDetails2 12. EQUITY (Details 2) Details http://knowlabs.co/role/EquityTables 42 false false R43.htm 00000043 - Disclosure - 12. EQUITY (Details Narrative) Sheet http://knowlabs.co/role/EquityDetailsNarrative 12. EQUITY (Details Narrative) Details http://knowlabs.co/role/EquityTables 43 false false R44.htm 00000044 - Disclosure - 13. STOCK OPTIONS (Details) Sheet http://knowlabs.co/role/StockOptionsDetails 13. STOCK OPTIONS (Details) Details http://knowlabs.co/role/StockOptionsTables 44 false false R45.htm 00000045 - Disclosure - 13. STOCK OPTIONS (Details 1) Sheet http://knowlabs.co/role/StockOptionsDetails1 13. STOCK OPTIONS (Details 1) Details http://knowlabs.co/role/StockOptionsTables 45 false false R46.htm 00000046 - Disclosure - 13. STOCK OPTIONS (Details Narrative) Sheet http://knowlabs.co/role/StockOptionsDetailsNarrative 13. STOCK OPTIONS (Details Narrative) Details http://knowlabs.co/role/StockOptionsTables 46 false false R47.htm 00000047 - Disclosure - 14. OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES (Details narrative) Sheet http://knowlabs.co/role/OtherSignificantTransactionsWithRelatedPartiesDetailsNarrative 14. OTHER SIGNIFICANT TRANSACTIONS WITH RELATED PARTIES (Details narrative) Details http://knowlabs.co/role/OtherSignificantTransactionsWithRelatedParties 47 false false R48.htm 00000048 - Disclosure - 15. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS (Details) Sheet http://knowlabs.co/role/CommitmentsContingenciesAndLegalProceedingsDetails 15. COMMITMENTS, CONTINGENCIES AND LEGAL PROCEEDINGS (Details) Details http://knowlabs.co/role/CommitmentsContingenciesAndLegalProceedingsTables 48 false false All Reports Book All Reports knwn-20181231.xml knwn-20181231.xsd knwn-20181231_cal.xml knwn-20181231_def.xml knwn-20181231_lab.xml knwn-20181231_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 67 0001654954-19-001367-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-19-001367-xbrl.zip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ⅅ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end